[go: up one dir, main page]

US20120040990A1 - Indol-3-y-carbonyl-piperidin and piperazin-derivatives - Google Patents

Indol-3-y-carbonyl-piperidin and piperazin-derivatives Download PDF

Info

Publication number
US20120040990A1
US20120040990A1 US13/282,520 US201113282520A US2012040990A1 US 20120040990 A1 US20120040990 A1 US 20120040990A1 US 201113282520 A US201113282520 A US 201113282520A US 2012040990 A1 US2012040990 A1 US 2012040990A1
Authority
US
United States
Prior art keywords
chloro
indol
phenyl
alkyl
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/282,520
Inventor
Caterina Bissantz
Christophe Grundschober
Hasane Ratni
Mark Rogers-Evans
Patrick Schnider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37442112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20120040990(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to US13/282,520 priority Critical patent/US20120040990A1/en
Publication of US20120040990A1 publication Critical patent/US20120040990A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Definitions

  • Vasopressin is a 9 amino acid peptide mainly produced by the paraventricular nucleus of the hypothalamus. Three vasopressin receptors, all belonging to the class I G-protein coupled receptors, are known.
  • the V1a receptor is expressed in the brain, liver, vascular smooth muscle, lung, uterus and testis, the V1b or V3 receptor is expressed in the brain and pituitary gland, the V2 receptor is expressed in the kidney where it regulates water excretion and mediates the antidiuretic effects of vasopressin.
  • vasopressin acts as a neurohormone and stimulates vasoconstriction, glycogenolysis and antidiuresis.
  • vasopressin acts as a neuromodulator and is elevated in the amygdala during stress (Ebner, K., C. T. Wotjak, et al. (2002). “Forced swimming triggers vasopressin release within the amygdala to modulate stress-coping strategies in rats.” Eur J Neurosci 15(2): 384-8).
  • the V1a receptor is extensively expressed in the brain and particularly in limbic areas like the amygdala, lateral septum and hippocampus which are playing an important role in the regulation of anxiety.
  • V1a knock-out mouse show a reduction in anxiety behavior in the plus-maze, open field and light-dark box (Bielsky, I. F., S. B. Hu, et al. (2003). “Profound Impairment in Social Recognition and Reduction in Anxiety-Like Behavior in Vasopressin V1a Receptor Knockout Mice.” Neuropsychopharmacology ).
  • the downregulation of the V1a receptor using antisense oligonucleotide injection in the septum also causes a reduction in anxiety behavior (Landgraf, R., R. Gerstberger, et al. (1995). “V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats.” Regul Pept 59(2): 229-39).
  • the V1a receptor is also mediating the cardiovascular effects of vasopressin in the brain by centrally regulating blood pressure and heart rate in the solitary tract nucleus (Michelini, L. C. and M. Morris (1999). “Endogenous vasopressin modulates the cardiovascular responses to exercise.” Ann NY Acad Sci 897: 198-211). In the periphery it induces the contraction of vascular smooth muscles and chronic inhibition of the V1a receptor improves hemodynamic parameters in myocardial infarcted rats (Van Kerckhoven, R., I. Lankhuizen, et al. (2002). “Chronic vasopressin V(1A) but not V(2) receptor antagonism prevents heart failure in chronically infarcted rats.” Eur J Pharmacol 449(1-2): 135-41).
  • vasopressin receptor antagonists are useful as therapeutics in the conditions of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders.
  • the present invention provides compounds of formula (I)
  • R 1 is H
  • R 3 is H
  • R 4 is —NH(CO)R e , wherein R e is
  • R 5 is H, OH, CN, COOR iii or CONR iii R iv ;
  • R 6 is C 2-6 -alkyl
  • the compounds of formula (I) can contain asymmetric carbon atoms. Accordingly, the present invention includes all stereioisomeric forms of the compounds of formula I, including each of the individual enantiomers and mixtures thereof.
  • the invention provides pharmaceutical compositions comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the invention further provides a method fortreatiing dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders by administering a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the preferred indications with regard to the present invention are the treatment of anxiety and depressive disorders.
  • aryl means a monovalent cyclic aromatic hydrocarbon moiety consisting of a mono-, bi- or tricyclic aromatic ring.
  • aryl moieties include, but are not limited to, optionally substituted phenyl, naphthyl, phenanthryl, fluorenyl, indenyl, pentalenyl, azulenyl, oxydiphenyl, biphenyl, methylenediphenyl, aminodiphenyl, diphenylsulfidyl, diphenylsulfonyl, diphenylisopropylidenyl, benzodioxanyl, benzofuranyl, benzodioxylyl, benzopyranyl, benzoxazinyl, benzoxazinonyl, benzopiperadinyl, benzopiperazinyl, benzopyrrolidinyl, benzomorpholinyl, methylenedioxyphenyl, ethylene
  • aryl include, but are not limited to, halogen, C 1-6 -alkyl, and C 1-6 -alkoxy.
  • Preferred aryl are phenyl and naphthyl, and still more preferably phenyl.
  • aryloxy denotes a group wherein the aryl residue is as defined hereinabove, which is attached via an oxygen atom.
  • the preferred aryloxy group is phenyloxy, optionally substituted by halo, e.g. F, as well as those specifically illustrated by the examples herein below.
  • C 1-6 -alkyl denotes a saturated straight- or branched-chain hydrocarbon group containing from 1 to 6 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n-butyl, i-butyl, 2-butyl, t-butyl as well as those specifically illustrated by the examples herein below.
  • Preferred C 1-6 -alkyl groups are C 1-4 -groups, i.e. with 1-4 carbon atoms.
  • C 1-6 -alkoxy denotes a group wherein the alkyl residues are as defined above, which is attached via an oxygen atom.
  • Preferred C 1-6 -alkoxy groups are methoxy and ethoxy as well as those specifically illustrated by the examples herein below.
  • C 2-6 -alkenyl denotes a carbon chain of 2 to 6 carbon atoms comprising a double bond in its chain.
  • C 2-6 -alkenyl groups include ethenyl, propen-1-yl, propen-2-yl, buten-1-yl, buten-3-yl, penten-1-yl, penten-2-yl, penten-3-yl, penten-4-yl, hexen-1-yl, hexen-2-yl, hexen-3-yl, hexen-4-yl and hexen-5-yl, as well as those specifically illustrated by the examples herein below.
  • benzyloxy denotes a benzyl group attached via an oxygen atom.
  • halogen or “halo” denotes chlorine (Cl), iodine (I), fluorine (F) and bromine (Br).
  • C 1-6 -haloalkyl denotes a C 1-6 -alkyl group as defined above which is substituted by one or more halogen atom.
  • Examples of C 1-6 -haloalkyl include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl, tert-butyl, pentyl or n-hexyl substituted by one or more Cl, F, Br or I atom(s) as well as those groups specifically illustrated by the examples herein below.
  • Preferred C 1-6 -haloalkyl are difluoro- or trifluoro-methyl or ethyl.
  • C 1-6 -haloalkoxy denotes a C 1-6 -alkoxy group as defined above which is substituted by one or more halogen atoms.
  • Examples of C 1-6 -haloalkoxy include, but are not limited to, methoxy or ethoxy, substituted by one or more Cl, F, Br or I atom(s) as well as those groups specifically illustrated by the examples herein below.
  • Preferred C 1-6 -haloalkoxy are difluoro- or trifluoro-methoxy or ethoxy.
  • C 3-6 -cycloalkyl denotes a monovalent or divalent saturated carbocyclic moiety consisting of a monocyclic ring.
  • Cycloalkyl can optionally be substituted with one, two, three or four substituents, wherein each substituent is independently hydroxy, C 1-6 -alkyl, C 1-6 -alkoxy, halogen, or amino, unless otherwise specifically indicated.
  • Examples of cycloalkyl moieties include optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl and optionally substituted cyclohexyl as well as those specifically illustrated by the examples herein below.
  • 4 to 7 membered heterocycloalkyl means a monovalent saturated moiety, consisting of one ring of 4 to 7 atoms as ring members, including one, two, or three heteroatoms chosen from nitrogen, oxygen or sulfur, the rest being carbon atoms.
  • 4 to 7 membered heterocycloalkyl can optionally be substituted with one, two, three or four substituents, wherein each substituent is independently hydroxy, C 1-6 -alkyl, C 1-6 -alkoxy, C 1-6 -thioalkyl, halo, C 1-6 -haloalkyl, C 1-6 -hydroxyalkyl, alkoxycarbonyl, amino, C 1-6 -alkylamino, di(C 1-6 )alkylamino, aminocarbonyl, or carbonylamino, unless otherwise specifically indicated.
  • heterocyclic moieties include, but are not limited to, optionally substituted oxetane, optionally substituted tetrahydro-furanyl, optionally substituted piperidinyl, optionally substituted pyrrolidinyl, optionally substituted morpholinyl, optionally substituted piperazinyl, and the like or those which are specifically exemplified herein.
  • Substituents can be selected from C 1-6 -alkyl, C 1-6 -alkoxy, C 1-6 -haloalkyl, halo, CN, OH, and NH 2 , as well as those substituents which are specifically illustrated in the examples hereinafter.
  • Preferred 4 to 7 membered heterocycloalkyl are 5 to 6 membered heterocycloalkyl.
  • 5 or 6 membered heteroaryl means an aromatic ring of 5 or 6 ring atoms as ring members containing one, two, or three ring heteroatoms selected from N, O, or S, the rest being carbon atoms.
  • 5 or 6 heteroaryl can optionally be substituted with one, two, three or four substituents, wherein each substituent is independently hydroxy, C 1-6 -alkyl, C 1-6 -alkoxy, C 1-6 -thioalkyl, halo, C 1-6 -haloalkyl, C 1-6 -hydroxyalkyl, alkoxycarbonyl, amino, C 1-6 -alkylamino, di(C 1-6 )alkylamino, aminocarbonyl, or carbonylamino, unless otherwise specifically indicated.
  • heteroaryl moieties include, but are not limited to, optionally substituted imidazolyl, optionally substituted oxazolyl, optionally substituted thiazolyl, optionally substituted pyrazinyl, optionally substituted pyrrolyl, optionally substituted pyrazinyl, optionally substituted pyridinyl, optionally substituted pyrimidinyl, optionally substituted furanyl, and those which are specifically exemplified herein.
  • sulfonylaryl denotes an aryl group as defined hereinabove which is attached via a sulfonyl group.
  • 9 or 10 membered bicyclic heteroaryl means an aromatic bicyclic ring of 9 or 10 ring atoms as ring members containing one, two, or three ring heteroatoms selected from N, O, or S, the rest being carbon atoms.
  • 9 or 10 membered bicyclic heteroaryl can optionally be substituted with one, two, three or four substituents, wherein each substituent is independently hydroxy, —C(O), C 1-6 -alkyl, C 1-6 -alkoxy, C 1-6 -thioalkyl, halo, C 1-6 -haloalkyl, C 1-6 -hydroxyalkyl, alkoxycarbonyl, amino, C 1-6 -alkylamino, di(C 1-6 )alkylamino, aminocarbonyl, or carbonylamino, unless otherwise specifically indicated.
  • substituent is independently hydroxy, —C(O), C 1-6 -alkyl, C 1-6 -alkoxy, C 1-6 -thioalkyl, halo, C 1-6 -haloalkyl, C 1-6 -hydroxyalkyl, alkoxycarbonyl, amino, C 1-6 -alkylamino, di(C 1-6 )alkylamino, amino
  • 9 membered bicyclic heteroaryl moieties include, but are not limited to, optionally substituted indolyl, optionally substituted thieno[2,3-c]pyridinyl, thieno[3,2-c]pyridinyl, benzoxazolyl, benzisoxazolyl as well as those 9 membered bicyclic heteroaryl which are specifically exemplified herein.
  • oxo or dioxo bridge denotes an oxo or dioxo bridge of the following formulae:
  • “Pharmaceutically acceptable,” such as pharmaceutically acceptable carrier, excipient, etc., means pharmacologically acceptable and substantially non-toxic to the subject to which the particular compound is administered.
  • pharmaceutically acceptable acid addition salts embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane-sulfonic acid, p-toluenesulfonic acid, as well as those specifically illustrated by the examples herein below.
  • “Therapeutically effective amount” means an amount that is effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated.
  • the present invention provides compounds of formula (I)
  • R 1 is H
  • R 3 is H
  • R 4 is —NH(CO)R e , wherein R e is
  • R 5 is H, OH, CN, COOR iii or CONR iii R iv ;
  • R 6 is C 2-6 -alkyl
  • the compounds of formula (I) are those compounds wherein:
  • R 1 is H
  • R 3 is H
  • R 4 is —NH(CO)R e , wherein R e is C 1-6 -alkoxy or aryl optionally substituted by halo,
  • R 5 is H, OH, CN, COOR iii or CONR iii R iv ;
  • R 6 is C 1-6 -alkyl
  • the compounds of formula (I) are those compounds wherein:
  • R 1 is H
  • R 3 is H
  • R 4 is —NH(CO)R e , wherein R e is C 1-6 -alkoxy, or aryl optionally substituted by halo,
  • R 5 is H, OH or CN
  • R 6 is C 1-6 -alkyl
  • the compounds of formula (I) are those compounds wherein:
  • R 1 is H
  • R 4 is —NH(CO)R e , wherein R e is C 1-6 -alkoxy, or aryl optionally substituted by halo,
  • R 5 is H, OH, or CN
  • R 6 is aryl, 5 or 6 membered heteroaryl, or a 9 or 10-membered bicyclic heteroaryl ring each of which is optionally substituted by halo, C 1-6 -alkyl, C 1-6 -alkoxy, C 1-6 -haloalkyl, CN, nitro, NR i R ii , NR iii R iv , C 1-6 -alkoxy-C 1-6 -alkylene, COOH, or S(O) 2 —C 1-6 -alkyl, or by an oxo or dioxo bridge;
  • B is halo, C 1-6 -alkyl optionally substituted by CN, halo or C 1-6 -alkoxy, or C 1-6 -alkoxy;
  • R i and R ii are each independently H, C 1-6 -alkyl, C 1-6 -alkyl-NR ii R iv , —C(O)—C
  • the invention encompasses compounds according to the general formula (I) as described herein, with the proviso that R 1 , R 2 and R 3 are not simultaneously H, as well as pharmaceutical acceptable salts thereof.
  • the invention encompasses compounds according to the general formula (I) as described herein, with the proviso that R 4 is not a 1H-benzimidazole derivative:
  • CN optionally substituted by CN, halo, C 1-6 -alkyl, C 1-6 -alkoxy, C 1-6 -haloalkyl, nitro, hydroxyl, NR i R ii , NR iii R iv , C 1-6 -alkoxy-C 1-6 -alkylene, S(O) 2 —C 1-6 -alkyl, or C 1-6 -haloalkoxy, or by an oxo or dioxo bridge.
  • R 1 to R 4 are as defined hereinabove for formula (I).
  • Preferred compounds of formula (I-a) are those compounds wherein,
  • R 1 is H or —(CH 2 ) m —R a wherein R a is aryl and m is 1 to 6; there is one or more R 2 , wherein each R 2 is the same or different, R 2 is one or more H or halo; R 3 is H or C 1-6 -alkyl; R 4 is aryl which is optionally substituted by halo or C 1-6 -alkoxy; and pharmaceutically acceptable salts thereof.
  • R 1 , R 2 and R 3 are not simultaneously H.
  • R 1 to R 5 are as defined hereinabove for formula (I).
  • Preferred compounds of formula (I-b) are those compounds wherein,
  • R 1 is H
  • R 5 is H, OH or CN
  • R i and R ii are each independently H, C 1-6 -alkyl, or C 1-6 -alkyl-NR iii R iv ; R iii and R iv are each independently H or C 1-6 -alkyl; m is 1 to 6; and n is 0 to 4; and pharmaceutically acceptable salts thereof.
  • R 1 , R 2 and R 3 are not simultaneously H.
  • R 4 is not an 1H-benzimidazole derivative as described hereinabove.
  • Preferred examples of compounds of formula (I-b) according to the invention are:
  • R 1 to R 3 and R 6 are as defined hereinabove for formula (I).
  • Preferred compounds of formula (I-c) are those compounds wherein,
  • R 1 is H or
  • R 1 , R 2 and R 3 are not simultaneously H.
  • Preferred examples of compounds of formula (I-c) according to the invention are:
  • R 1 to R 3 and R 6 are as defined hereinabove for formula (I).
  • R 1 , R 2 and R 3 are not simultaneously H.
  • Preferred compounds of formula (I-d) are those compounds wherein the substitution pattern is analogous to that of the preferred compounds of formula (I-c), and further preferred are those compounds wherein
  • R 1 is H
  • R 2 is one or more halo
  • R 3 is H
  • R 6 is aryl substituted by C 1-6 -alkoxy; and pharmaceutically acceptable salts thereof.
  • the invention also encompasses methods for the treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety or depressive disorders which comprise administering a compound of formulae (I), (I-a), (I-a′), (I-b), (I-c) or (I-d).
  • the invention also encompasses a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I), (I-a), (I-a′), (I-b), (I-c) or (I-d) and a pharmaceutically acceptable carrier.
  • Such pharmaceutical compositions are useful for treating dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders.
  • the compounds of formula (I) of the invention can be manufactured according to a process comprising reacting a compound of formula (II):
  • the compounds of formula (I) of the invention can be manufactured according to a process comprising reacting a compound of formula (I-1), wherein R 1 is H:
  • the compounds of formula (I) of the invention can be manufactured according to a process comprising hydrolyzing a compound of formula (V):
  • Compounds of formula (I) can be prepared via an amide coupling between an indole 3-carboxylic acid (II) and a compound of formula (A-H), wherein A is defined as hereinabove.
  • Indole 3-carboxylic acids (II) are either commercially available or readily prepared using a procedure described in J. Med. Chem. 1991, 34, 140. Alternatively, they can be prepared following the general scheme C as described hereinafter.
  • the compounds of formula (A-H) are either commercially available or prepared using methods known in the art starting from commercially available materials.
  • General scheme A is hereinafter further illustrated with general procedure I.
  • Compounds of formula (I) with R 1 different from H can be prepared using methods known in the art, e.g. by N-deprotonation of a compound of formula (I-1) (compounds of formula (I) wherein R 1 is H) followed by treatment with an electrophilic reactant R 1 —X (wherein X is a leaving group, e.g. halo) which is either commercially available or easily prepared according to methods well known in the art and commercially available starting materials.
  • R 1 —X wherein X is a leaving group, e.g. halo
  • intermediate (IV) which can be hydrolyzed with an aqueous sodium hydroxide solution to give the 3-carboxylic acid indole derivative (II-1).
  • (IV) could react with an electrophilic reactant R 1 —X to give (V), which is then converted to the corresponding carboxylic acid derivative (II) with NaH/H 2 O in DMF (see J. Org. Chem., 1993, 10, 2862).
  • Intermediate (V) can alternatively be obtained by treatment of an indole derivative (III-2) with trifluoroacetic anhydride in a suitable solvent, e.g. DMF, dichloromethane or 1,2-dichloroethane. Addition of a suitable base may be advantageous.
  • the human V1a receptor was cloned by RT-PCR from total human liver RNA.
  • the coding sequence was subcloned in an expression vector after sequencing to confirm the identity of the amplified sequence.
  • Cell membranes were prepared from HEK293 cells transiently transfected with the expression vector and grown in 20 liter fermenters with the following protocol.
  • the pellet is resuspended in 12.5 ml Lysis buffer+12.5 ml Sucrose 20% and homogenized using a Polytron for 1-2 min.
  • the protein concentration is determined by the Bradford method, and aliquots are stored at ⁇ 80° C. until use.
  • 60 mg Yttrium silicate SPA beads (Amersham) are mixed with an aliquot of membrane in binding buffer (50 mM Tris, 120 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 10 mM MgCl 2 ) for 15 minutes with mixing.
  • the present invention also provides pharmaceutical compositions containing compounds of the invention or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier.
  • Such pharmaceutical compositions can be in the form of tablets, coated tablets, dragées, hard and soft gelatin capsules, solutions, emulsions or suspensions.
  • the pharmaceutical compositions also can be in the form of suppositories or injectable solutions.
  • compositions of the invention in addition to one or more compounds of the invention, contain a pharmaceutically acceptable carrier.
  • suitable pharmaceutically acceptable carriers include pharmaceutically inert, inorganic or organic excipients for the production of tablets, coated tablets, dragées, and hard gelatin capsules. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts etc can be used as such excipients e.g. for tablets, dragées and hard gelatin capsules.
  • Suitable excipients for soft gelatin capsules are e.g. vegetable oils, waxes, fats, semi-solid and liquid polyols etc.
  • Suitable excipients for the manufacture of solutions and syrups are e.g.
  • Suitable excipients for injection solutions are e.g. water, alcohols, polyols, glycerol, vegetable oils etc.
  • Suitable excipients for suppositories are e.g. natural or hardened oils, waxes, fats, semi-liquid or liquid polyols etc.
  • compositions can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
  • the present invention also provides a method for the manufacture of pharmaceutical compositions. Such process comprises bringing one or more compounds of formula I and/or pharmaceutically acceptable acid addition salts thereof and, if desired, one or more other therapeutically valuable substances into a galenical administration form together with one or more therapeutically inert carriers.
  • Compounds of formula (I) have good activity on the V1a receptor.
  • the invention provides methods for treating dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders by administering a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the preferred indications with regard to the present invention are the treatment of anxiety and depressive disorders.
  • the compounds and compositions of the invention can be administered in a conventional manner, for example, orally rectally, or parenterally.
  • the pharmaceutical compositions of the invention can be administered orally, for example, in the form of tablets, coated tablets, dragees, hard and soft gelatin capsules, solutions, emulsions, or suspensions.
  • the pharmaceutical compositions also can be administered rectally, for example, in the form of suppositories, or parenterally, for example, in the form of injectable solutions.
  • a daily dosage of about 10 to 1000 mg per person of a compound of general formula (I), (I-a), (I-b); (I-c) or (I-d) should be appropriate, although the above upper limit can also be exceeded when necessary.
  • the active substance, lactose and corn starch are firstly mixed in a mixer and then in a comminuting machine.
  • the mixture is returned to the mixer, the talc is added thereto and mixed thoroughly.
  • the mixture is filled by machine into hard gelatin capsules.
  • the suppository mass is melted in a glass or steel vessel, mixed thoroughly and cooled to 45° C.
  • the finely powdered active substance is added thereto and stirred until it has dispersed completely.
  • the mixture is poured into suppository moulds of suitable size, left to cool; the suppositories are then removed from the moulds and packed individually in wax paper or metal foil.
  • journal references are cited in the examples, the example was performed using the starting material listed with the reactants and conditions cited in the reference. All procedures in such references are well known to those of ordinary skill in the art. All journal references cited herein are incorporated by reference.
  • reaction mixture was diluted with saturated aqueous ammonium chloride solution and extracted with tert-butyl methyl ether (2 ⁇ 50 ml). The combined organic layers were washed with 1 M sodium hydroxide solution (1 ⁇ 30 ml) and water (1 ⁇ 30 ml), dried over sodium sulfate, concentrated in vacuo and purified by flash-chromatography (aminopropyl-modified silica gel, n-heptane/ethyl acetate) to give the title compound (0.087 g, 56%) as a light yellow solid.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention relates to indol-3-yl-carbonyl-piperidin and piperazin derivatives which act as V1a receptor antagonists and which are represented by Formula I:
Figure US20120040990A1-20120216-C00001
wherein the residues R1 to R3 are as defined herein. The invention also relates to pharmaceutical compositions containing such compounds, and methods for preparation of the compounds and compositions. The invention further relates to methods for treating dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders.

Description

    PRIORITY TO RELATED APPLICATIONS
  • This application is a continuation of U.S. application Ser. No. 12/779,099, filed May 13, 2010, now pending; which is a division of U.S. application Ser. No. 11/492,312, filed Jul. 25, 2006, now U.S. Pat. No. 7,781,436, issued Aug. 24, 2010; which claims the benefit of European Application Nos. 05107044.9, filed Jul. 29, 2005, and 05111072.4, filed Nov. 22, 2005. The entire contents of the above-identified applications are hereby incorporated by reference.
    • BACKGROUND OF THE INVENTION
  • Vasopressin is a 9 amino acid peptide mainly produced by the paraventricular nucleus of the hypothalamus. Three vasopressin receptors, all belonging to the class I G-protein coupled receptors, are known. The V1a receptor is expressed in the brain, liver, vascular smooth muscle, lung, uterus and testis, the V1b or V3 receptor is expressed in the brain and pituitary gland, the V2 receptor is expressed in the kidney where it regulates water excretion and mediates the antidiuretic effects of vasopressin.
  • In the periphery vasopressin acts as a neurohormone and stimulates vasoconstriction, glycogenolysis and antidiuresis. In the brain vasopressin acts as a neuromodulator and is elevated in the amygdala during stress (Ebner, K., C. T. Wotjak, et al. (2002). “Forced swimming triggers vasopressin release within the amygdala to modulate stress-coping strategies in rats.” Eur J Neurosci 15(2): 384-8). The V1a receptor is extensively expressed in the brain and particularly in limbic areas like the amygdala, lateral septum and hippocampus which are playing an important role in the regulation of anxiety. Indeed V1a knock-out mouse show a reduction in anxiety behavior in the plus-maze, open field and light-dark box (Bielsky, I. F., S. B. Hu, et al. (2003). “Profound Impairment in Social Recognition and Reduction in Anxiety-Like Behavior in Vasopressin V1a Receptor Knockout Mice.” Neuropsychopharmacology). The downregulation of the V1a receptor using antisense oligonucleotide injection in the septum also causes a reduction in anxiety behavior (Landgraf, R., R. Gerstberger, et al. (1995). “V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats.” Regul Pept 59(2): 229-39).
  • The V1a receptor is also mediating the cardiovascular effects of vasopressin in the brain by centrally regulating blood pressure and heart rate in the solitary tract nucleus (Michelini, L. C. and M. Morris (1999). “Endogenous vasopressin modulates the cardiovascular responses to exercise.” Ann NY Acad Sci 897: 198-211). In the periphery it induces the contraction of vascular smooth muscles and chronic inhibition of the V1a receptor improves hemodynamic parameters in myocardial infarcted rats (Van Kerckhoven, R., I. Lankhuizen, et al. (2002). “Chronic vasopressin V(1A) but not V(2) receptor antagonism prevents heart failure in chronically infarcted rats.” Eur J Pharmacol 449(1-2): 135-41).
  • Thus, vasopressin receptor antagonists are useful as therapeutics in the conditions of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders.
    • SUMMARY OF THE INVENTION
  • The present invention provides compounds of formula (I)
  • Figure US20120040990A1-20120216-C00002
  • wherein
    • R1 is H,
      • C1-6-alkyl substituted by CN, C1-6-alkoxy, OH, halo, or NRiRii,
      • C2-6-alkyl,
      • aryl, 5 or 6 membered heteroaryl or sulfonylaryl each of which is optionally substituted by one or more B,
      • —(CH2)m—Ra wherein Ra is:
        • CN,
        • ORi,
        • NRiRii, or
        • C3-6-cycloalkyl, 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl each of which is optionally substituted by one or more B,
      • or —(CH2)n—(CO)—Rb or —(CH2)n—(SO2)—Rb, wherein Rb is:
        • C1-6-alkyl,
        • C1-6-alkoxy,
        • C3-6-cycloalkyl,
        • —(CH2)m—NRiiiRiv,
        • NRiRii, or
        • C3-6-cycloalkyl, 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl each of which is optionally substituted by one or more B,
          or R1 and R3 together with the indole ring to which they are attached form a 5 or 6 membered heterocycloalkyl which is optionally substituted by ═O, C(O)O—C1-6-alkyl or C1-6-alkyl;
          there is one or more R2, wherein each R2 is the same or different,
          R2 is one or more H, OH, halo, CN, nitro, C1-6-alkoxy, —O—CH2—C2-6-alkenyl, benzyloxy, C1-6-haloalkoxy, or C1-6-alkyl optionally substituted by —NRiiiRiv or halo,
      • or two R2 together with the indole ring to which they are attached form an oxo or dioxo bridge;
    R3 is H,
      • F,
      • —(CO)—Rc, wherein Rc is:
        • C1-6 alkyl,
        • —(CH2)n—NRiRii,
        • —(CH2)n—NRiiiRiv, or
        • 5 or 6 membered heterocycloalkyl optionally substituted by C1-6-alkyl,
      • or C1-6-alkyl which is optionally substituted by
        • halo,
        • NRiRii,
        • NRiiiRiv,
        • —O(CO)—C1-6-alkyl, or
        • —NH(CO)Rd, wherein Rd is C1-6-alkyl optionally substituted by halo or nitro, or Rd is aryl or a 5 or 6 membered heteroaryl, each of which is optionally substituted by halo, nitro, C1-6-alkyl or C1-6-haloalkyl;
          A is selected from the group consisting of (a), (a′), (b), (c) and (d):
  • Figure US20120040990A1-20120216-C00003
  • wherein
    R4 is —NH(CO)Re, wherein Re is
      • C1-6-alkoxy or aryl each of which is optionally substituted by halo,
      • C1-6-alkoxy, or
      • CN,
      • oraryl, 5 or 6 membered heteroaryl, benzyl, aryloxy or a 9 or 10-membered bicyclic heteroaryl ring, each of which is optionally substituted by CN, halo, C1-6-alkyl, C1-6-alkoxy, C1-6-haloalkyl, nitro, hydroxyl, NRiRii, NRiiiRiv, C1-6-alkoxy-C1-6-alkylene, S(O)2—C1-6-alkyl, or C1-6-haloalkoxy, or by an oxo or dioxo bridge;
    R5 is H, OH, CN, COORiii or CONRiiiRiv;
  • R6 is C2-6-alkyl,
      • —C(O)—Rf wherein Rf is an aryl group substituted by halo, C1-6-alkoxy, or CN, aryl, 5 or 6 membered heteroaryl, or a 9 or 10-membered bicyclic heteroaryl ring each of which is optionally substituted by halo, C1-6-alkyl, C1-6-alkoxy, C1-6-haloalkyl, CN, nitro, NRiRii, NRiiiRiv, C1-6-alkoxy-C1-6-alkylene, COOH, S(O)2—C1-6-alkyl, hydroxyl, or C1-6-haloalkoxy, or by an oxo or dioxo bridge,
      • or benzyl substituted by halo, C1-6-alkyl, or C1-6-haloalkyl or by an oxo- or dioxo bridge;
        B is halo,
      • CN,
      • NRiRii,
      • C1-6-alkyl optionally substituted by CN, halo or C1-6-alkoxy,
      • C1-6-haloalkyl,
      • C1-6-alkoxy,
      • C1-6-haloalkoxy,
      • C3-6-cycloalkyl,
      • —C(O)O—C1-6-alkyl,
      • —C(O)NRiRii,
      • —C(O)—C1-6-alkyl,
      • —S(O)2—C1-6-alkyl,
      • —S(O)2—NRiRii, or
      • (CRiiiRiv)n-phenyl or (CRiiiRiv)n-5 or 6 membered heteroaryl wherein the phenyl or 5 or 6 membered heteroaryl moiety is optionally substituted by one or more substituent(s) selected from the group consisting of:
        • halo, CN, NRiRii, C1-6-alkyl optionally substituted by CN or C1-6-alkoxy, C1-6-alkoxy, C1-6-haloalkoxy, C3-6-cycloalkyl, —C(O)O—C1-6-alkyl, —C(O)—NRiRii, —C(O)—C1-6-alkyl, —S(O)2—C1-6-alkyl, and —S(O)2—NRiRii;
          Ri and Rii are each independently H, C1-6-alkyl, C1-6-alkyl-NRiiiRiv, —(CO)O—C1-6-alkyl, —C(O)—NRiiiRiv, —C(O)—C1-6-alkyl, —S(O)2—C1-6-alkyl or —S(O)2—NRiiiRiv;
          Riii and Riv are each independently H or C1-6-alkyl;
          m is 1 to 6; and
          n is 0 to 4;
          and pharmaceutically acceptable salts thereof.
  • The compounds of formula (I) can contain asymmetric carbon atoms. Accordingly, the present invention includes all stereioisomeric forms of the compounds of formula I, including each of the individual enantiomers and mixtures thereof.
  • Compounds of formula (I) have good activity on the Via receptor. Therefore, the invention provides pharmaceutical compositions comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. The invention further provides a method fortreatiing dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders by administering a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • The preferred indications with regard to the present invention are the treatment of anxiety and depressive disorders.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The following definitions of general terms used in the present description apply irrespective of whether the terms in question appear alone or in combination. It must be noted that, as used in the specification and the appended claims, the singular forms “a”, “an,” and “the” include plural forms unless the context clearly dictates otherwise.
  • As used herein, the term “aryl” means a monovalent cyclic aromatic hydrocarbon moiety consisting of a mono-, bi- or tricyclic aromatic ring. Examples of aryl moieties include, but are not limited to, optionally substituted phenyl, naphthyl, phenanthryl, fluorenyl, indenyl, pentalenyl, azulenyl, oxydiphenyl, biphenyl, methylenediphenyl, aminodiphenyl, diphenylsulfidyl, diphenylsulfonyl, diphenylisopropylidenyl, benzodioxanyl, benzofuranyl, benzodioxylyl, benzopyranyl, benzoxazinyl, benzoxazinonyl, benzopiperadinyl, benzopiperazinyl, benzopyrrolidinyl, benzomorpholinyl, methylenedioxyphenyl, ethylenedioxyphenyl, as well as those specifically illustrated by the examples herein below. Substituents for aryl include, but are not limited to, halogen, C1-6-alkyl, and C1-6-alkoxy. Preferred aryl are phenyl and naphthyl, and still more preferably phenyl.
  • The term “aryloxy” denotes a group wherein the aryl residue is as defined hereinabove, which is attached via an oxygen atom. The preferred aryloxy group is phenyloxy, optionally substituted by halo, e.g. F, as well as those specifically illustrated by the examples herein below.
  • The term “C1-6-alkyl” denotes a saturated straight- or branched-chain hydrocarbon group containing from 1 to 6 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n-butyl, i-butyl, 2-butyl, t-butyl as well as those specifically illustrated by the examples herein below. Preferred C1-6-alkyl groups are C1-4-groups, i.e. with 1-4 carbon atoms.
  • The term “C1-6-alkoxy” denotes a group wherein the alkyl residues are as defined above, which is attached via an oxygen atom. Preferred C1-6-alkoxy groups are methoxy and ethoxy as well as those specifically illustrated by the examples herein below.
  • The term “C2-6-alkenyl” denotes a carbon chain of 2 to 6 carbon atoms comprising a double bond in its chain. C2-6-alkenyl groups include ethenyl, propen-1-yl, propen-2-yl, buten-1-yl, buten-3-yl, penten-1-yl, penten-2-yl, penten-3-yl, penten-4-yl, hexen-1-yl, hexen-2-yl, hexen-3-yl, hexen-4-yl and hexen-5-yl, as well as those specifically illustrated by the examples herein below.
  • The term “benzyloxy” denotes a benzyl group attached via an oxygen atom.
  • The term “halogen” or “halo” denotes chlorine (Cl), iodine (I), fluorine (F) and bromine (Br).
  • The term “C1-6-haloalkyl” denotes a C1-6-alkyl group as defined above which is substituted by one or more halogen atom. Examples of C1-6-haloalkyl include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl, tert-butyl, pentyl or n-hexyl substituted by one or more Cl, F, Br or I atom(s) as well as those groups specifically illustrated by the examples herein below. Preferred C1-6-haloalkyl are difluoro- or trifluoro-methyl or ethyl.
  • “C1-6-haloalkoxy” denotes a C1-6-alkoxy group as defined above which is substituted by one or more halogen atoms. Examples of C1-6-haloalkoxy include, but are not limited to, methoxy or ethoxy, substituted by one or more Cl, F, Br or I atom(s) as well as those groups specifically illustrated by the examples herein below. Preferred C1-6-haloalkoxy are difluoro- or trifluoro-methoxy or ethoxy.
  • The term “C3-6-cycloalkyl” denotes a monovalent or divalent saturated carbocyclic moiety consisting of a monocyclic ring. Cycloalkyl can optionally be substituted with one, two, three or four substituents, wherein each substituent is independently hydroxy, C1-6-alkyl, C1-6-alkoxy, halogen, or amino, unless otherwise specifically indicated. Examples of cycloalkyl moieties include optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl and optionally substituted cyclohexyl as well as those specifically illustrated by the examples herein below.
  • The term “4 to 7 membered heterocycloalkyl” means a monovalent saturated moiety, consisting of one ring of 4 to 7 atoms as ring members, including one, two, or three heteroatoms chosen from nitrogen, oxygen or sulfur, the rest being carbon atoms. 4 to 7 membered heterocycloalkyl can optionally be substituted with one, two, three or four substituents, wherein each substituent is independently hydroxy, C1-6-alkyl, C1-6-alkoxy, C1-6-thioalkyl, halo, C1-6-haloalkyl, C1-6-hydroxyalkyl, alkoxycarbonyl, amino, C1-6-alkylamino, di(C1-6)alkylamino, aminocarbonyl, or carbonylamino, unless otherwise specifically indicated. Examples of heterocyclic moieties include, but are not limited to, optionally substituted oxetane, optionally substituted tetrahydro-furanyl, optionally substituted piperidinyl, optionally substituted pyrrolidinyl, optionally substituted morpholinyl, optionally substituted piperazinyl, and the like or those which are specifically exemplified herein. Substituents can be selected from C1-6-alkyl, C1-6-alkoxy, C1-6-haloalkyl, halo, CN, OH, and NH2, as well as those substituents which are specifically illustrated in the examples hereinafter. Preferred 4 to 7 membered heterocycloalkyl are 5 to 6 membered heterocycloalkyl.
  • The term “5 or 6 membered heteroaryl” means an aromatic ring of 5 or 6 ring atoms as ring members containing one, two, or three ring heteroatoms selected from N, O, or S, the rest being carbon atoms. 5 or 6 heteroaryl can optionally be substituted with one, two, three or four substituents, wherein each substituent is independently hydroxy, C1-6-alkyl, C1-6-alkoxy, C1-6-thioalkyl, halo, C1-6-haloalkyl, C1-6-hydroxyalkyl, alkoxycarbonyl, amino, C1-6-alkylamino, di(C1-6)alkylamino, aminocarbonyl, or carbonylamino, unless otherwise specifically indicated. Examples of heteroaryl moieties include, but are not limited to, optionally substituted imidazolyl, optionally substituted oxazolyl, optionally substituted thiazolyl, optionally substituted pyrazinyl, optionally substituted pyrrolyl, optionally substituted pyrazinyl, optionally substituted pyridinyl, optionally substituted pyrimidinyl, optionally substituted furanyl, and those which are specifically exemplified herein.
  • The term “sulfonylaryl” denotes an aryl group as defined hereinabove which is attached via a sulfonyl group.
  • The term “9 or 10 membered bicyclic heteroaryl” means an aromatic bicyclic ring of 9 or 10 ring atoms as ring members containing one, two, or three ring heteroatoms selected from N, O, or S, the rest being carbon atoms. 9 or 10 membered bicyclic heteroaryl can optionally be substituted with one, two, three or four substituents, wherein each substituent is independently hydroxy, —C(O), C1-6-alkyl, C1-6-alkoxy, C1-6-thioalkyl, halo, C1-6-haloalkyl, C1-6-hydroxyalkyl, alkoxycarbonyl, amino, C1-6-alkylamino, di(C1-6)alkylamino, aminocarbonyl, or carbonylamino, unless otherwise specifically indicated. Examples of 9 membered bicyclic heteroaryl moieties include, but are not limited to, optionally substituted indolyl, optionally substituted thieno[2,3-c]pyridinyl, thieno[3,2-c]pyridinyl, benzoxazolyl, benzisoxazolyl as well as those 9 membered bicyclic heteroaryl which are specifically exemplified herein.
  • The expression “two R2 together with the indole ring to which they are attached form an oxo or dioxo bridge” denotes an oxo or dioxo bridge of the following formulae:
  • Figure US20120040990A1-20120216-C00004
  • which bind two adjacent carbon atoms of the phenyl or indole ring of the compound of formula (I) to which R2 is binding.
  • Analogously, the expression “oxo or dioxo bridge” denotes an oxo or dioxo bridge of the following formulae:
  • Figure US20120040990A1-20120216-C00005
  • Examples of group illustrating the expression “R1 and R3 together with the indole ring to which they are attached form a 5 or 6 membered heterocycloalkyl which is optionally substituted by ═O” are:
  • Figure US20120040990A1-20120216-C00006
  • as well as those specifically illustrated by the examples.
  • “Pharmaceutically acceptable,” such as pharmaceutically acceptable carrier, excipient, etc., means pharmacologically acceptable and substantially non-toxic to the subject to which the particular compound is administered.
  • The term “pharmaceutically acceptable acid addition salts” embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane-sulfonic acid, p-toluenesulfonic acid, as well as those specifically illustrated by the examples herein below.
  • “Therapeutically effective amount” means an amount that is effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated.
  • The present invention provides compounds of formula (I)
  • Figure US20120040990A1-20120216-C00007
  • wherein
    • R1 is H,
      • C1-6-alkyl substituted by CN, C1-6-alkoxy, OH, halo, or NRiRii,
      • C2-6-alkyl,
      • aryl, 5 or 6 membered heteroaryl or sulfonylaryl each of which is optionally substituted by one or more B,
      • —(CH2)m—Ra wherein Ra is:
        • CN,
        • ORi,
        • NRiRii, or
        • C3-6-cycloalkyl, 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl each of which is optionally substituted by one or more B,
      • or —(CH2)n—(CO)—Rb or —(CH2)n—(SO2)—Rb, wherein Rb is:
        • C1-6-alkyl,
        • C1-6-alkoxy,
        • C3-6-cycloalkyl,
        • —(CH2)m—NRiiRiv,
        • NRiRii, or
        • C3-6-cycloalkyl, 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl each of which is optionally substituted by one or more B,
          or R1 and R3 together with the indole ring to which they are attached form a 5 or 6 membered heterocycloalkyl which is optionally substituted by ═O, C(O)O—C1-6-alkyl or C1-6-alkyl;
          there is one or more R2, wherein each R2 is the same or different,
          R2 is one or more H, OH, halo, CN, nitro, C1-6-alkoxy, —O—CH2—C2-6-alkenyl, benzyloxy, C1-6-haloalkoxy, or C1-6-alkyl optionally substituted by —NRiiiRiv or halo,
      • or two R2 together with the indole ring to which they are attached form an oxo or dioxo bridge;
    R3 is H,
      • F,
      • —(CO)—Rc, wherein Rc is:
        • C1-6 alkyl,
        • —(CH2)n—NRiRii,
        • —(CH2)n—NRiiiRiv, or
        • 5 or 6 membered heterocycloalkyl optionally substituted by C1-6-alkyl,
      • or C1-6-alkyl which is optionally substituted by
        • halo,
        • NRiRii,
        • NRiiiRiv,
        • —O(CO)—C1-6-alkyl, or
        • —NH(CO)Rd, wherein Rd is C1-6-alkyl optionally substituted by halo or nitro, or Rd is aryl or a 5 or 6 membered heteroaryl, each of which is optionally substituted by halo, nitro, C1-6-alkyl or C1-6-haloalkyl;
          A is selected from the group consisting of (a), (a′), (b), (c) and (d):
  • Figure US20120040990A1-20120216-C00008
  • wherein
    R4 is —NH(CO)Re, wherein Re is
      • C1-6-alkoxy or aryl each of which is optionally substituted by halo,
      • C1-6-alkoxy, or
      • CN,
      • oraryl, 5 or 6 membered heteroaryl, benzyl, aryloxy or a 9 or 10-membered bicyclic heteroaryl ring, each of which is optionally substituted by CN, halo, C1-6-alkyl, C1-6-alkoxy, C1-6-haloalkyl, nitro, hydroxyl, NRiRii, NRiiiRiv, C1-6-alkoxy-C1-6-alkylene, S(O)2—C1-6-alkyl, or C1-6-haloalkoxy, or by an oxo or dioxo bridge;
    R5 is H, OH, CN, COORiii or CONRiiiRiv;
  • R6 is C2-6-alkyl,
      • —C(O)—Rf wherein Rf is an aryl group substituted by halo, C1-6-alkoxy, or CN, aryl, 5 or 6 membered heteroaryl, or a 9 or 10-membered bicyclic heteroaryl ring each of which is optionally substituted by halo, C1-6-alkyl, C1-6-alkoxy, C1-6-haloalkyl, CN, nitro, NRiRii, NRiiiRiv, C1-6-alkoxy-C1-6-alkylene, COOH, S(O)2—C1-6-alkyl, hydroxyl, or C1-6-haloalkoxy, or by an oxo or dioxo bridge,
      • or benzyl substituted by halo, C1-6-alkyl, or C1-6-haloalkyl or by an oxo- or dioxo bridge;
        B is halo,
      • CN,
      • NRiRii,
      • C1-6-alkyl optionally substituted by CN, halo or C1-6-alkoxy,
      • C1-6-haloalkyl,
      • C1-6-alkoxy,
      • C1-6-haloalkoxy,
      • C3-6-cycloalkyl,
      • —C(O)O—C1-6-alkyl,
      • —C(O)NRiRii,
      • —C(O)—C1-6-alkyl,
      • —S(O)2—C1-6-alkyl,
      • —S(O)2—NRiRii, or
      • (CRiiiRiv)n-phenyl or (CRiiiRiv)n-5 or 6 membered heteroaryl wherein the phenyl or 5 or 6 membered heteroaryl moiety is optionally substituted by one or more substituent(s) selected from the group consisting of:
        • halo, CN, C1-6-alkyl optionally substituted by CN or C1-6-alkoxy, C1-6-alkoxy, C1-6-haloalkoxy, C3-6-cycloalkyl, —C(O)O—C1-6-alkyl, —C(O)—NRiRii, —C(O)—C1-6-alkyl, —S(O)2—C1-6-alkyl, and —S(O)2—NRiRii;
          Ri and Rii are each independently H, C1-6-alkyl, C1-6-alkyl-NRiiiRiv, —(CO)O—C1-6-alkyl, —C(O)—NRiiiRiv, —C(O)—C1-6-alkyl, —S(O)2—C1-6-alkyl or —S(O)2—NRiiiRiv;
          Riii and Riv are each independently H or C1-6-alkyl;
          m is 1 to 6; and
          n is 0 to 4;
          and pharmaceutically acceptable salts thereof.
  • In certain embodiments of the invention, the compounds of formula (I) are those compounds wherein:
    • R1 is H,
      • C1-6-alkyl optionally substituted by CN or C1-6-alkoxy,
      • aryl, 5 or 6 membered heteroaryl or sulfonylaryl each of which is optionally substituted by one or more B,
      • —(CH2)m—Ra wherein Ra is:
        • CN,
        • ORi,
        • NRiRii, or
        • C3-6-cycloalkyl, 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl each of which is optionally substituted by one or more B,
      • or —(CH2)n—(CO)—Rb or —(CH2)n—(SO2)—Rb, wherein Rb is:
        • C1-6-alkyl,
        • C1-6-alkoxy,
        • C3-6-cycloalkyl,
        • —(CH2)m—NRiiRiv,
        • NRiRii, or
        • C3-6-cycloalkyl, 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl each of which is optionally substituted by one or more B,
          or R1 and R3 together with the indole ring to which they are attached form a 5 or 6 membered heterocycloalkyl which is optionally substituted by (CO);
          there is one or more R2, wherein each R2 is the same or different,
          R2 is one or more H, OH, halo, CN, nitro, C1-6-alkyl optionally substituted by —NRiiiRiv, C1-6-alkoxy, —O—CH2—C2-6-alkenyl, or benzyloxy,
      • or two R2 together with the indole ring to which they are attached form an oxo or dioxo bridge;
    R3 is H,
      • halo,
      • —(CO)—Rc, wherein Rc is:
        • C1-6-alkyl,
        • —(CH2)n—NRiRii,
        • —(CH2)n—NRiiiRiv, or
        • 5 or 6 membered heterocycloalkyl optionally substituted by C1-6-alkyl,
      • or C1-6-alkyl or aryl, each of which is optionally substituted by
        • halo,
        • —O(CO)—C1-6-alkyl, or
        • —NH(CO)Rd, wherein Rd is C1-6-alkyl optionally substituted by halo or nitro, or Rd is aryl or a 5 or 6 membered heteroaryl, each of which is optionally substituted by halo, nitro, C1-6-alkyl or C1-6-haloalkyl;
          A is selected from the group consisting of (a), (b), (c) and (d):
  • Figure US20120040990A1-20120216-C00009
  • wherein
    R4 is —NH(CO)Re, wherein Re is C1-6-alkoxy or aryl optionally substituted by halo,
      • C1-6-alkoxy, or
      • CN,
      • or aryl, 5 or 6 membered heteroaryl, benzyl, aryloxy or a 9 or 10-membered bicyclic heteroaryl ring each of which is optionally substituted by CN, halo, C1-6-alkyl, C1-6-alkoxy, or C1-6-haloalkyl, or by a dioxo bridge;
    R5 is H, OH, CN, COORiii or CONRiiiRiv;
  • R6 is C1-6-alkyl,
      • —C(O)—Rf wherein Rf is an aryl group optionally substituted by halo, C1-6-alkoxy, or CN,
      • or aryl, 5 or 6 membered heteroaryl, benzyl, or a 9 or 10-membered bicyclic heteroaryl ring each of which is optionally substituted by halo, C1-6-alkyl, C1-6-alkoxy, C1-6-haloalkyl, or CN or by a dioxo bridge;
        B is halo,
      • CN,
      • NRiRii,
      • C1-6-alkyl optionally substituted by CN, halo or C1-6-alkoxy,
      • C1-6-alkoxy,
      • C1-6-haloalkoxy,
      • C3-6-cycloalkyl,
      • —C(O)O—C1-6-alkyl,
      • —C(O)NRiRii,
      • —C(O)—C1-6-alkyl,
      • —S(O)2—C1-6-alkyl,
      • —S(O)2—NRiRii,
      • (CRiiiRiv)n-phenyl, or (CRiiiRiv)n-5 or 6 membered heteroaryl wherein the phenyl or 5 or 6 membered heteroaryl moiety is optionally substituted by one or more substituent(s) selected from the group consisting of:
        • halo, CN, NRiRii, C1-6-alkyl optionally substituted by CN or C1-6-alkoxy, C1-6-alkoxy, C1-6-haloalkoxy, C3-6-cycloalkyl, —C(O)O—C1-6-alkyl, —C(O)—NRiRii, —C(O)—C1-6-alkyl, —S(O)2—C1-6-alkyl, and —S(O)2—NRiRii;
          Ri and Rii are each independently H, C1-6-alkyl, C1-6-alkyl-NRiiiRiv, —(CO)O—C1-6-alkyl, —C(O)—NRiiiRiv, —C(O)—C1-6-alkyl, —S(O)2—C1-6-alkyl or —S(O)2—NRiiiRiv;
          Riii and Riv are each independently H or C1-6-alkyl;
          m is 1 to 6; and
          n is 0 to 4;
          and pharmaceutically acceptable salts thereof.
  • In certain embodiments of the invention, the compounds of formula (I) are those compounds wherein:
    • R1 is H,
      • C1-6-alkyl optionally substituted by CN or C1-6-alkoxy,
      • aryl,
      • 5 or 6 membered heteroaryl,
      • sulfonylaryl,
      • —(CH2)m—Ra wherein Ra is C3-6-cycloalkyl, 5 or 6 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl each of which is optionally substituted by one or more substituents selected from the group consisting of:
        • halo, CN, C1-6-alkyl, C1-6-alkoxy, C1-6-haloalkoxy, —C(O)O—C1-6-alkyl and phenyl optionally substituted by halo, C1-6-alkyl, C1-6-haloalkyl or C1-6-alkoxy,
      • —(CH2)m—NRiRii,
      • or —(CH2)n—(CO)—Rb, wherein Rb is aryl or 5 or 6 membered-heterocycloalkyl; there is one or more R2, wherein each R2 is the same or different,
        R2 is one or more H, halo, CN, nitro, C1-6-alkyl, C1-6-alkoxy, —O—CH2—C2-6-alkenyl, or benzyloxy, or two R2 together with the indole ring to which they are attached form an oxo or dioxo bridge;
    R3 is H,
      • halo,
      • —(CO)—Rc, wherein Rc is C1-6-alkyl, 5 or 6 membered heterocycloalkyl optionally substituted by C1-6-alkyl, or Rc is —(CH2)n—NRiRii,
      • or C1-6-alkyl or aryl, each of which is optionally substituted by
        • —O(CO)—C1-6-alkyl or —NH(CO)Rd, wherein Rd is C1-6-alkyl optionally substituted by halo or nitro, or Rd is aryl or a 5 or 6 membered heteroaryl, each of which is optionally substituted by halo, nitro, C1-6-alkyl or C1-6-haloalkyl;
          Ri and Rii are each independently selected from H, C1-6-alkyl and —(CO)O—C1-6-alkyl;
          m is 1 to 6; and
          n is 0 to 4;
          A is selected from the group consisting of (a), (b), (c) and (d):
  • Figure US20120040990A1-20120216-C00010
  • wherein
    R4 is —NH(CO)Re, wherein Re is C1-6-alkoxy, or aryl optionally substituted by halo,
      • or is aryl, benzyl, aryloxy or a 9 or 10-membered bicyclic heteroaryl ring each of which is optionally substituted by halo, C1-6-alkyl, C1-6-alkoxy, or C1-6-haloalkyl, or by a dioxo bridge;
    R5 is H, OH or CN;
  • R6 is C1-6-alkyl,
      • —C(O)—Rf wherein Rf is an aryl group optionally substituted by halo,
      • or aryl, benzyl, or a 9 or 10-membered bicyclic heteroaryl ring each of which is optionally substituted by halo, C1-6-alkyl, C1-6-alkoxy, or C1-6-haloalkyl, or by a dioxo bridge;
        and pharmaceutically acceptable salts thereof.
  • In certain embodiments of the invention, the compounds of formula (I) are those compounds wherein:
    • R1 is H,
      • C1-6-alkyl substituted by NRiRii,
      • —(CH2)m—Ra wherein Ra is:
        • NRiRii, or
        • 5 to 6 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl each of which is optionally substituted by one or more B,
      • or —(CH2)n—(CO)—Rb or —(CH2)n—(SO2)—Rb, wherein Rb is:
        • C1-6-alkyl,
        • C1-6-alkoxy,
        • NRiRii, or
        • 5 to 6 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B,
          or R1 and R3 together with the indole ring to which they are attached form a 5 or 6 membered heterocycloalkyl which is optionally substituted by ═O, C(O)O—C1-6-alkyl or C1-6-alkyl;
          there is one or more R2, wherein each R2 is the same or different,
          R2 is one or more H, halo, or C1-6-alkyl;
          R3 is H or C1-6-alkyl;
          A is selected from the group consisting of (a), (a′), (b), (c) and (d):
  • Figure US20120040990A1-20120216-C00011
  • wherein
    R4 is —NH(CO)Re, wherein Re is C1-6-alkoxy, or aryl optionally substituted by halo,
      • or is aryl, 5 or 6 membered heteroaryl, benzyl, aryloxy or a 9 or 10-membered bicyclic heteroaryl ring, each of which is optionally substituted by halo, C1-6-alkyl, C1-6-alkoxy, C1-6-haloalkyl, nitro, hydroxyl, or C1-6-haloalkoxy, or by an oxo or dioxo bridge; and
    R5 is H, OH, or CN;
  • R6 is aryl, 5 or 6 membered heteroaryl, or a 9 or 10-membered bicyclic heteroaryl ring each of which is optionally substituted by halo, C1-6-alkyl, C1-6-alkoxy, C1-6-haloalkyl, CN, nitro, NRiRii, NRiiiRiv, C1-6-alkoxy-C1-6-alkylene, COOH, or S(O)2—C1-6-alkyl, or by an oxo or dioxo bridge;
    B is halo, C1-6-alkyl optionally substituted by CN, halo or C1-6-alkoxy, or C1-6-alkoxy; Ri and Rii are each independently H, C1-6-alkyl, C1-6-alkyl-NRiiiRiv, —C(O)—C1-6-alkyl or —S(O)2—C1-6-alkyl;
    Riii and Riv are each independently H or C1-6-alkyl;
    m is 1 to 6; and
    n is 0 to 4;
    and pharmaceutically acceptable salts thereof.
  • Preferably, the invention encompasses compounds according to the general formula (I) as described herein, with the proviso that R1, R2 and R3 are not simultaneously H, as well as pharmaceutical acceptable salts thereof.
  • Preferably, the invention encompasses compounds according to the general formula (I) as described herein, with the proviso that R4 is not a 1H-benzimidazole derivative:
  • Figure US20120040990A1-20120216-C00012
  • optionally substituted by CN, halo, C1-6-alkyl, C1-6-alkoxy, C1-6-haloalkyl, nitro, hydroxyl, NRiRii, NRiiiRiv, C1-6-alkoxy-C1-6-alkylene, S(O)2—C1-6-alkyl, or C1-6-haloalkoxy, or by an oxo or dioxo bridge.
  • Also encompassed by the compounds of formula (I) are the following compounds of formula (I-a) or (1-a′) according to the invention:
  • Figure US20120040990A1-20120216-C00013
  • wherein R1 to R4 are as defined hereinabove for formula (I).
  • Preferred compounds of formula (I-a) are those compounds wherein,
  • R1 is H or —(CH2)m—Ra wherein Ra is aryl and m is 1 to 6;
    there is one or more R2, wherein each R2 is the same or different,
    R2 is one or more H or halo;
    R3 is H or C1-6-alkyl;
    R4 is aryl which is optionally substituted by halo or C1-6-alkoxy;
    and pharmaceutically acceptable salts thereof.
  • Again, it is preferred that R1, R2 and R3 are not simultaneously H.
  • Examples of compounds according to the invention are:
    • Benzyl-2-methyl-1H-indol-3-yl)-[4-(4-fluoro-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-methanone;
    • Benzyl-2-methyl-1H-indol-3-yl)-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)-methanone;
    • Benzyl-2-methyl-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-methanone;
    • (6-Chloro-1H-indol-3-yl)-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)-methanone;
    • (6-Chloro-1H-indol-3-yl)-[4-(4-fluoro-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-methanone;
    • (6-Chloro-1H-indol-3-yl)-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)-methanone;
    • (6-Chloro-1H-indol-3-yl)-[4-(4-fluoro-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-methanone;
    • (6-Chloro-1H-indol-3-yl)-[4-(4-chloro-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-methanone; and
    • Benzyl-2-methyl-1H-indol-3-yl)-(3-methyl-4-phenyl-3,6-dihydro-2H-pyridin-1-yl)-methanone.
  • Also encompassed by the compounds of formula (I) are the following compounds of formula (I-b) according to the invention:
  • Figure US20120040990A1-20120216-C00014
  • wherein R1 to R5 are as defined hereinabove for formula (I).
  • Preferred compounds of formula (I-b) are those compounds wherein,
    • R1 is H,
      • —(CH2)m—Ra wherein Ra is:
        • NRiRii, or
        • aryl, or 5 or 6 membered heteroaryl each of which is optionally substituted by one or more halo, C1-6-alkyl, C1-6-alkoxy,
      • or —(CH2)n—(CO)—Rb or —(CH2)n—(SO2)—Rb, wherein Rb is:
        • C1-6-alkyl,
        • C1-6-alkoxy,
        • NRiRii, or
        • 5 to 6 membered-heterocycloalkyl, or 5 or 6 membered heteroaryl each of which is optionally substituted by one or more halo, C1-6-alkyl, or C1-6-alkoxy,
          or R1 and R3 together with the indole ring to which they are attached form a 5 or 6 membered heterocycloalkyl which is optionally substituted by C(O)O—C1-6-alkyl or C1-6-alkyl;
          there is one or more R2, wherein each R2 is the same or different,
          R2 is one or more H, halo or C1-6-alkyl;
          R3 is H or C1-6-alkyl;
          R4 is —NH(CO)Re, wherein Re is C1-6-alkoxy or aryl which is optionally substituted by halo, or is aryl, benzyl, aryloxy or a 9 or 10-membered bicyclic heteroaryl ring each of which is optionally substituted by halo, C1-6-alkyl, C1-6-alkoxy, C1-6-haloalkyl, nitro, hydroxyl, or C1-6-haloalkoxy or by an oxo or dioxo bridge; and
    R5 is H, OH or CN;
  • Ri and Rii are each independently H, C1-6-alkyl, or C1-6-alkyl-NRiiiRiv;
    Riii and Riv are each independently H or C1-6-alkyl;
    m is 1 to 6; and
    n is 0 to 4;
    and pharmaceutically acceptable salts thereof.
  • Again, it is preferred that R1, R2 and R3 are not simultaneously H.
  • Moreover, it is preferred that R4 is not an 1H-benzimidazole derivative as described hereinabove.
  • Examples of compounds of formula (I-b) according to the invention are:
    • (4-Benzyl-4-hydroxy-piperidin-1-yl)-(1-benzyl-2-methyl-1H-indol-3-yl)-methanone;
    • (4-Benzyl-4-hydroxy-piperidin-1-yl)-[1-(2-chloro-benzyl)-2-methyl-1H-indol-3-yl]-methanone;
    • Benzyl-5-chloro-2-methyl-1H-indol-3-yl)-(4-benzyl-4-hydroxy-piperidin-1-yl)-methanone;
    • (4-Benzyl-4-hydroxy-piperidin-1-yl)-[5-chloro-1-(3-methoxy-benzyl)-2-methyl-1H-indol-3-yl]-methanone;
    • (4-Benzyl-4-hydroxy-piperidin-1-yl)-[1-(2-methoxy-benzyl)-2-methyl-1H-indol-3-yl]-methanone;
    • Benzyl-2-methyl-1H-indol-3-yl)-[4-(3-fluoro-phenoxy)-piperidin-1-yl]-methanone;
    • Benzyl-2-methyl-1-indol-3-yl)-(4-hydroxy-4-phenyl-piperidin-1-yl)-methanone;
    • Benzyl-2-methyl-1-indol-3-yl)-[4-(4-fluoro-phenyl)-4-hydroxy-piperidin-1-yl]-methanone;
    • Benzyl-2-methyl-1-indol-3-yl)-[4-(4-chloro-3-trifluoromethyl-phenyl)-4-hydroxy-piperidin-1-yl]-methanone;
    • (4-Benzo[1,3]dioxol-5-yl-4-hydroxy-piperidin-1-yl)-(1-benzyl-2-methyl-1H-indol-3-yl)-methanone;
    • Benzyl-2-methyl-1-indol-3-yl)-(4-hydroxy-4-p-tolyl-piperidin-1-yl)-methanone;
    • Benzyl-2-methyl-1-indol-3-yl)-[4-hydroxy-4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-methanone;
    • (6-Chloro-1H-indol-3-yl)-[4-hydroxy-4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-methanone;
    • 1-(6-Chloro-1H-indole-3-carbonyl)-4-phenyl-piperidine-4-carbonitrile;
    • (6-Chloro-1H-indol-3-yl)-(4-hydroxy-4-p-tolyl-piperidin-1-yl)-methanone;
    • (6-Chloro-1H-indol-3-yl)-[4-(4-chloro-phenyl)-4-hydroxy-piperidin-1-yl]-methanone;
    • (6-Chloro-1H-indol-3-yl)-[4-(4-chloro-3-trifluoromethyl-phenyl)-4-hydroxy-piperidin-1-yl]-methanone;
    • [4-(4-Bromo-phenyl)-4-hydroxy-piperidin-1-yl]-(6-chloro-1H-indol-3-yl)-methanone;
    • [1-(6-Chloro-1H-indole-3-carbonyl)-piperidin-4-yl]-carbamic acid tert-butyl ester;
    • N-[1-(6-Chloro-1H-indole-3-carbonyl)-piperidin-4-yl]-2-fluoro-benzamide;
    • (6-Chloro-1H-indol-3-yl)-[4-(4-chloro-phenyl)-4-hydroxy-piperidin-1-yl]-methanone;
    • (6-Chloro-1H-indol-3-yl)-[4-(4-nitro-phenyl)-piperidin-1-yl]-methanone;
    • (6-Chloro-1H-indol-3-yl)-(4-methoxy-4-phenyl-piperidin-1-yl)-methanone;
    • (6-Chloro-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-piperidin-1-yl]-methanone;
    • (6-Chloro-1H-indol-3-yl)-[4-(2,3-dihydro-benzofuran-7-yl)-piperidin-1-yl]-methanone;
    • N-(2-Amino-ethyl)-2-{6-chloro-3-[4-(2,3-dihydro-benzofuran-7-yl)-piperidine-1-carbonyl]-indol-1-yl}-acetamide;
    • 2-{6-Chloro-3-[4-(2,3-dihydro-benzofuran-7-yl)-piperidine-1-carbonyl]-indol-1-yl}-N-(2-methylamino-ethyl)-acetamide;
    • (6-Chloro-1H-indol-3-yl)-[4-(2-trifluoromethoxy-phenyl)-piperidin-1-yl]-methanone;
    • (6-Chloro-1H-indol-3-yl)-[4-(2-trifluoromethyl-phenyl)-piperidin-1-yl]-methanone;
    • 2-{6-Chloro-3-[4-(2-trifluoromethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N-(2-dimethylamino-ethyl)-acetamide;
    • 2-{6-Chloro-3-[4-(2-trifluoromethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetamide;
    • 2-{6-Chloro-3-[4-(2-trifluoromethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N-(2-methylamino-ethyl)-acetamide;
    • N-(2-Amino-ethyl)-2-{6-chloro-3-[4-(2-trifluoromethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetamide;
    • 2-{6-Chloro-3-[4-(2-trifluoromethyl-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetamide;
    • 2-{6-Chloro-3-[4-(2-trifluoromethyl-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N-(2-methylamino-ethyl)-acetamide or hydrochloride salt thereof;
    • N-(2-Amino-ethyl)-2-[6-chloro-3-[4-(2-trifluoromethyl-phenyl)-piperidine-1-carbonyl]-indol-1-yl]-acetamide or hydrochloride salt thereof;
    • 2-{6-Chloro-3-[4-(2-trifluoromethyl-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N-(2-dimethylamino-ethyl)-acetamide;
    • [1-(2-Amino-ethyl)-6-chloro-1H-indol-3-yl]-[4-(2,3-dihydro-benzofuran-7-yl)-piperidin-1-yl]-methanone;
    • [1-(2-Amino-ethyl)-6-chloro-1H-indol-3-yl]-[4-(2-trifluoromethoxy-phenyl)-piperidin-1-yl]-methanone;
    • [1-(2-Amino-ethyl)-6-chloro-1H-indol-3-yl]-[4-(2-methoxy-phenyl)-piperidin-1-yl]-methanone;
    • [1-(2-Amino-ethyl)-6-chloro-1H-indol-3-yl]-[4-(2-fluoro-phenyl)-piperidin-1-yl]-methanone;
    • 2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetamide;
    • (6-Chloro-1H-indol-3-yl)-(3,4,5,6-tetrahydro-2H-[4,4′]bipyridinyl-1-yl)-methanone;
    • (6-Chloro-2-methyl-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-piperidin-1-yl]-methanone;
    • (6-Chloro-1-methanesulfonyl-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-piperidin-1-yl]-methanone;
    • 10-[4-(2-Methoxy-phenyl)-piperidine-1-carbonyl]-3,4-dihydro-1H-pyrazino[1,2-a]indole-2-carboxylic acid tert-butyl ester;
    • [4-(2-Methoxy-phenyl)-piperidin-1-yl]-(1,2,3,4-tetrahydro-pyrazino[1,2-a]indol-10-yl)-methanone or hydrochloride salt thereof; and
    • [4-(2-Methoxy-phenyl)-piperidin-1-yl]-(2-methyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indol-10-yl)-methanone.
  • Preferred examples of compounds of formula (I-b) according to the invention are:
    • Benzyl-2-methyl-1H-indol-3-yl)-[4-(4-chloro-phenyl)-4-hydroxy-piperidin-1-yl]-methanone;
    • Benzyl-2-methyl-1H-indol-3-yl)-[4-(4-bromo-phenyl)-4-hydroxy-piperidin-1-yl]-methanone;
    • (6-Chloro-1H-indol-3-yl)-(4-phenyl-piperidin-1-yl)-methanone;
    • (4-Benzo[1,3]dioxol-5-yl-4-hydroxy-piperidin-1-yl)-(6-chloro-1H-indol-3-yl)-methanone;
    • Benzyl-2-methyl-1H-indol-3-yl)-[4-(4-fluoro-phenyl)-piperidin-1-yl]-methanone;
    • (6-Chloro-1H-indol-3-yl)-[4-(3-chloro-phenyl)-piperidin-1-yl]-methanone;
    • (6-Chloro-1H-indol-3-yl)-[4-(2-hydroxy-phenyl)-piperidin-1-yl]-methanone;
    • (6-Chloro-1H-indol-3-yl)-[4-(4-fluoro-phenyl)-piperidin-1-yl]-methanone;
    • (6-Chloro-1H-indol-3-yl)-[4-(2-isopropoxy-phenyl)-piperidin-1-yl]-methanone;
    • 2-{3-[4-(2,6-Dimethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-1-(4-methyl-piperazin-1-yl)-ethanone;
    • 2-{6-Chloro-3-[4-(2,6-dimethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N-(2-dimethylamino-ethyl)-acetamide;
    • 2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-1-piperazin-1-yl-ethanone;
    • 2-{6-Chloro-3-[4-(2,3-dihydro-benzofuran-7-yl)-piperidine-1-carbonyl]-indol-1-yl}-N-(2-dimethylamino-ethyl)-acetamide;
    • 2-{6-Chloro-3-[4-(2,3-dihydro-benzofuran-7-yl)-piperidine-1-carbonyl]-indol-1-yl}-1-piperazin-1-yl-ethanone;
    • 2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperidine-1-carbonyl]-5-methyl-indol-1-yl}-N,N-dimethyl-acetamide;
    • 2-{6-Chloro-3-[4-(2,3-dihydro-benzofuran-7-yl)-piperidine-1-carbonyl]-indol-1-yl}-acetamide;
    • 2-{6-Chloro-3-[4-(2,6-dimethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N-(2-methylamino-ethyl)-acetamide;
    • 2-{6-Chloro-3-[4-(2-trifluoromethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-1-piperazin-1-yl-ethanone;
    • 2-{6-Chloro-3-[4-(2-trifluoromethyl-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-1-piperazin-1-yl-ethanone or hydrochloride salt thereof;
    • [6-Chloro-1-(2-methylamino-ethyl)-1H-indol-3-yl]-[4-(2-methoxy-phenyl)-piperidin-1-yl]-methanone;
    • 2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N-(2-dimethylamino-ethyl)-acetamide;
    • 2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N-(2-methylamino-ethyl)-acetamide or hydrochloride salt thereof;
    • N-(2-Amino-ethyl)-2-{6-chloro-3-[4-(2-fluoro-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetamide or hydrochloride salt thereof;
    • 2-{6-Chloro-3-[4-(5-fluoro-benzo[d] isoxazol-3-yl)-piperidine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide;
    • 2-{6-Chloro-3-[4-(2-fluoro-phenyl)-4-hydroxy-piperidine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide; and
    • 2-[6-Chloro-3-(3,4,5,6-tetrahydro-2H-[4,4′]bipyridinyl-1-carbonyl)-indol-1-yl]-N-methyl-acetamide.
  • Particularly preferred examples of compounds of formula (I-b) according to the invention are:
    • Benzyl-2-methyl-1H-indol-3-yl)-(4-phenyl-piperidin-1-yl)-methanone;
    • (6-Chloro-1H-indol-3-yl)-[4-(2,6-dimethoxy-phenyl)-piperidin-1-yl]-methanone;
    • 2-{6-Chloro-3-[4-(2,6-dimethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide;
    • 2-{6-Chloro-3-[4-(2,6-dimethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-1-pyridin-2-yl-ethanone;
    • (6-Chloro-1-pyridin-4-ylmethyl-1H-indol-3-yl)-[4-(2,6-dimethoxy-phenyl)-piperidin-1-yl]-methanone;
    • (6-Chloro-1-pyridin-3-ylmethyl-1H-indol-3-yl)-[4-(2,6-dimethoxy-phenyl)-piperidin-1-yl]-methanone;
    • (6-Chloro-1-pyridin-2-ylmethyl-1H-indol-3-yl)-[4-(2,6-dimethoxy-phenyl)-piperidin-1-yl]-methanone;
    • [6-Chloro-1-(6-chloro-pyridin-3-ylmethyl)-1H-indol-3-yl]-[4-(2,6-dimethoxy-phenyl)-piperidin-1-yl]-methanone;
    • {6-Chloro-3-[4-(2,6-dimethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid tert-butyl ester;
    • (6-Chloro-1-pyrazin-2-ylmethyl-1H-indol-3-yl)-[4-(2,6-dimethoxy-phenyl)-piperidin-1-yl]-methanone;
    • [6-Chloro-1-(3,5-difluoro-benzyl)-1H-indol-3-yl]-[4-(2,6-dimethoxy-phenyl)-piperidin-1-yl]-methanone;
    • [6-Chloro-1-(2-dimethylamino-ethyl)-1H-indol-3-yl]-[4-(2,6-dimethoxy-phenyl)-piperidin-1-yl]-methanone;
    • 2-{6-Chloro-3-[4-(2,6-dimethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-1-(4-methyl-piperazin-1-yl)-ethanone;
    • [6-Chloro-1-(3,5-difluoro-benzyl)-1H-indol-3-yl]-[4-(2-methoxy-phenyl)-piperidin-1-yl]-methanone;
    • 2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide;
    • 2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-1-(4-methyl-piperazin-1-yl)-ethanone;
    • {6-Chloro-3-[4-(2-methoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid tert-butyl ester;
    • 2-{6-Chloro-3-[4-cyano-4-(2-methoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide;
    • 2-{6-Chloro-3-[4-cyano-4-(2-fluoro-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide;
    • 2-{3-[4-(2,6-Dimethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide;
    • [6-Chloro-1-(2-methyl-pyridin-4-ylmethyl)-1H-indol-3-yl]-[4-(2,6-dimethoxy-phenyl)-piperidin-1-yl]-methanone;
    • 2-{6-Chloro-3-[4-(2-isopropoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide;
    • 2-{6-Chloro-3-[4-(2-isopropoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-1-(4-methyl-piperazin-1-yl)-ethanone;
    • 2-{6-Chloro-3-[4-(2,6-dimethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-1-piperazin-1-yl-ethanone;
    • 2-{6-Chloro-3-[4-(2,3-dihydro-benzofuran-7-yl)-piperidine-1-carbonyl]-indol-1-yl}-1-(4-methyl-piperazin-1-yl)-ethanone;
    • 2-{6-Chloro-3-[4-(2,3-dihydro-benzofuran-7-yl)-piperidine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide;
    • 2-{6-Chloro-3-[4-(2,3-dihydro-benzofuran-7-yl)-piperidine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide;
    • 2-{5,6-Dichloro-3-[4-(2-methoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide;
    • 2-{6-Chloro-3-[4-(2,6-dimethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetamide;
    • 2-{6-Chloro-3-[4-(2,6-dimethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide;
    • N-(2-Amino-ethyl)-2-{6-chloro-3-[4-(2,6-dimethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetamide;
    • [6-Chloro-1-(2-dimethylamino-ethyl)-1H-indol-3-yl]-[4-(2,3-dihydro-benzofuran-7-yl)-piperidin-1-yl]-methanone;
    • 2-{6-Chloro-3-[4-(2-trifluoromethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-1-(4-methyl-piperazin-1-yl)-ethanone;
    • 2-{6-Chloro-3-[4-(2-trifluoromethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide;
    • 2-{6-Chloro-3-[4-(2-trifluoromethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide;
    • 2-{6-Chloro-3-[4-(2-trifluoromethyl-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide;
    • 2-{6-Chloro-3-[4-(2-trifluoromethyl-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-1-(4-methyl-piperazin-1-yl)-ethanone;
    • 2-{6-Chloro-3-[4-(2-trifluoromethyl-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide;
    • 2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide;
    • [6-Chloro-1-(2-methylamino-ethyl)-1H-indol-3-yl]-[4-(2,3-dihydro-benzofuran-7-yl)-piperidin-1-yl]-methanone;
    • [6-Chloro-1-(2-dimethylamino-ethyl)-1H-indol-3-yl]-[4-(2-methoxy-phenyl)-piperidin-1-yl]-methanone;
    • 2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide;
    • 2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide;
    • [6-Chloro-1-(2-dimethylamino-ethyl)-1H-indol-3-yl]-[4-(2-fluoro-phenyl)-piperidin-1-yl]-methanone;
    • 2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-1-(4-methyl-piperazin-1-yl)-ethanone;
    • 2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-1-piperazin-1-yl-ethanone or hydrochloride salt thereof; and
    • 2-[6-Chloro-3-(3,4,5,6-tetrahydro-2H-[4,4]bipyridinyl-1-carbonyl)-indol-1-yl]-N,N-dimethyl-acetamide.
  • Also encompassed by the compounds of formula (I) are the following compounds of formula (I-c) according to the invention:
  • Figure US20120040990A1-20120216-C00015
  • wherein R1 to R3 and R6 are as defined hereinabove for formula (I).
  • Preferred compounds of formula (I-c) are those compounds wherein,
    • R1 is H or
      • or is C1-6-alkyl substituted by NRiRii,
      • or is —(CH2)m—Ra wherein Ra is:
        • NRiRii,
        • 5 to 6 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more C1-6-alkyl,
      • or is —(CH2)n—(CO)—Rb, wherein Rb is:
        • NRiRii,
        • 5 to 7 membered-heterocycloalkyl which is optionally substituted by one or more C1m-alkyl;
          R2 is one or more of H, halo or C1-6-alkyl;
          R3 is H or C1-6-alkyl;
          R6 is aryl, 5 or 6 membered heteroaryl, or a 9 or 10-membered bicyclic heteroaryl ring which are optionally substituted by halo, C1-6-alkyl, C1-6-alkoxy, C1-6-haloalkyl, CN, nitro, NRiRii, NRiiiRiv, C1-6-alkoxy-C1-6-alkylene, COOH, S(O)2—C1-6-alkyl, or by an oxo or dioxo bridge;
          Ri and Rii are each independently H, C1-6-alkyl, C1-6-alkyl-NRiiiRiv, —C(O)—C1-6-alkyl, or —S(O)2—C1-6-alkyl;
          Riii and Riv are each independently H or C1-6-alkyl;
          m is 1 to 6; and
          n is 0 to 4;
          and pharmaceutically acceptable salts thereof.
  • It is preferred that R1, R2 and R3 are not simultaneously H.
  • Examples of compounds of formula (I-c) according to the invention are:
    • Benzyl-2-methyl-1H-indol-3-yl)-(4-phenyl-piperazin-1-yl)-methanone;
    • Benzyl-2-methyl-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-piperazin-1-yl]-methanone;
    • Benzyl-2-methyl-1H-indol-3-yl)-[4-(4-methoxy-phenyl)-piperazin-1-yl]-methanone;
    • Benzyl-2-methyl-1H-indol-3-yl)-[4-(2-chloro-phenyl)-piperazin-1-yl]-methanone;
    • Benzyl-2-methyl-1H-indol-3-yl)-[4-(4-chloro-phenyl)-piperazin-1-yl]-methanone;
    • (6-Chloro-1H-indol-3-yl)-(4-phenyl-piperazin-1-yl)-methanone;
    • (6-Chloro-1H-indol-3-yl)-[4-(2-chloro-6-nitro-phenyl)-piperazin-1-yl]-methanone;
    • (6-Chloro-1H-indol-3-yl)-[4-(2,6-dichloro-phenyl)-piperazin-1-yl]-methanone;
    • (6-Chloro-1H-indol-3-yl)-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin-1-yl]-methanone;
    • (6-Chloro-1H-indol-3-yl)-[4-(2-nitro-4-trifluoromethyl-phenyl)-piperazin-1-yl]-methanone;
    • (6-Chloro-1H-indol-3-yl)-[4-(2-chloro-phenyl)-piperazin-1-yl]-methanone;
    • [4-(2-Amino-6-chloro-phenyl)-piperazin-1-yl]-(6-chloro-1H-indol-3-yl)-methanone;
    • (6-Chloro-1H-indol-3-yl)-[4-(4-methoxy-phenyl)-piperazin-1-yl]-methanone;
    • (6-Chloro-1H-indol-3-yl)-[4-(3-methoxy-phenyl)-piperazin-1-yl]-methanone;
    • (6-Chloro-1H-indol-3-yl)-[4-(2-nitro-phenyl)-piperazin-1-yl]-methanone;
    • (6-Chloro-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-piperazin-1-yl]-methanone;
    • (6-Chloro-1H-indol-3-yl)-[4-(4-fluoro-phenyl)-piperazin-1-yl]-methanone;
    • (6-Chloro-1H-indol-3-yl)-[4-(3-fluoro-phenyl)-piperazin-1-yl]-methanone;
    • 3-Chloro-4-[4-(6-chloro-1H-indole-3-carbonyl)-piperazin-1-yl]-benzonitrile;
    • (6-Chloro-1H-indol-3-yl)-[4-(2-ethoxy-phenyl)-piperazin-1-yl]-methanone;
    • 2-{6-Chloro-3-[4-(2-ethoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-1-(4-methyl-piperazin-1-yl)-ethanone;
    • 2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-(2-dimethylamino-ethyl)-acetamide;
    • 2-{6-Chloro-3-[4-(2-ethoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-(2-dimethylamino-ethyl)-acetamide;
    • 2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-acetamide;
    • 2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperazine-1-carbonyl]-5-methyl-indol-1-yl}-N,N-dimethyl-acetamide;
    • 2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-1-piperazin-1-yl-ethanone or hydrochloride salt thereof;
    • 2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-(2-methylamino-ethyl)-acetamide or hydrochloride salt thereof;
    • N-(2-Amino-ethyl)-2-{6-chloro-3-[4-(2-methoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-acetamide or hydrochloride salt thereof;
    • [1-(2-Amino-ethyl)-6-chloro-1H-indol-3-yl]-[4-(2-methoxy-phenyl)-piperazin-1-yl]-methanone;
    • [6-Chloro-1-(2-methylamino-ethyl)-1H-indol-3-yl]-[4-(2-methoxy-phenyl)-piperazin-1-yl]-methanone;
    • [6-Chloro-1-(2-methylamino-ethyl)-1H-indol-3-yl]-[4-(2-ethoxy-phenyl)-piperazin-1-yl]-methanone;
    • 2-{6-Chloro-3-[4-(2-ethoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-(2-methylamino-ethyl)-acetamide;
    • [6-Chloro-1-(2-dimethylamino-ethyl)-1H-indol-3-yl]-[4-(2-ethoxy-phenyl)-piperazin-1-yl]-methanone;
    • (6-Chloro-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone;
    • [1-(2-Amino-ethyl)-6-chloro-1H-indol-3-yl]-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone;
    • 2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-(2-dimethylamino-ethyl)-acetamide;
    • 2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-(2-methylamino-ethyl)-acetamide;
    • N-(2-Amino-ethyl)-2-{6-chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-acetamide;
    • 2-{6-Chloro-3-[4-(2-methoxymethyl-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-(2-dimethylamino-ethyl)-acetamide;
    • 2-{6-Chloro-3-[4-(2-trifluoromethyl-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-(2-dimethylamino-ethyl)-acetamide;
    • 2-[6-Chloro-3-(4-pyridin-2-yl-piperazine-1-carbonyl)-indol-1-yl]-N-(2-dimethylamino-ethyl)-acetamide;
    • (6-Chloro-1H-indol-3-yl)-[4-(2,4-difluoro-phenyl)-piperazin-1-yl]-methanone;
    • (6-Chloro-1H-indol-3-yl)-[4-(3-methyl-pyridin-2-yl)-piperazin-1-yl]-methanone;
    • (6-Chloro-1H-indol-3-yl)-[4-(3,5-dichloro-pyridin-4-yl)-piperazin-1-yl]-methanone;
    • (6-Chloro-1H-indol-3-yl)-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-methanone;
    • 2-[4-(6-Chloro-1H-indole-3-carbonyl)-piperazin-1-yl]-nicotinonitrile;
    • (6-Chloro-1H-indol-3-yl)-(4-pyridin-2-yl-piperazin-1-yl)-methanone;
    • (6-Chloro-1H-indol-3-yl)-(4-thiazol-2-yl-piperazin-1-yl)-methanone;
    • 2-[6-Chloro-3-(2,3,5,6-tetrahydro-[1,2′]bipyrazinyl-4-carbonyl)-indol-1-yl]-N-methyl-acetamide;
    • 2-{6-Chloro-3-[4-(3-methyl-pyridin-2-yl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide;
    • 2-{6-Chloro-3-[4-(3,5-dichloro-pyridin-4-yl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide;
    • 2-[6-Chloro-3-(4-pyridin-2-yl-piperazine-1-carbonyl)-indol-1-yl]-N-methyl-acetamide;
    • 2-[6-Chloro-3-(4-thiazol-2-yl-piperazine-1-carbonyl)-indol-1-yl]-N-methyl-acetamide;
    • 2-{6-Chloro-3-[4-(3-cyano-pyridin-2-yl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide;
    • (6-Chloro-1-(S)-1-piperidin-3-ylmethyl-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone;
    • (6-Chloro-1-(RS)-1-pyrrolidin-3-ylmethyl-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone;
    • [6-Chloro-1-((S)-1-methyl-piperidin-3-ylmethyl)-1H-indol-3-yl]-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone;
    • [6-Chloro-1-((RS)-1-methyl-pyrrolidin-3-ylmethyl)-1H-indol-3-yl]-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone;
    • 2-[6-Chloro-3-(2,3,5,6-tetrahydro-[1,2′]bipyrazinyl-4-carbonyl)-indol-1-yl]-N,N-dimethyl-acetamide;
    • 2-{6-Chloro-3-[4-(3-methyl-pyridin-2-yl)-piperazine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide;
    • 2-{6-Chloro-3-[4-(3,5-dichloro-pyridin-4-yl)-piperazine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide;
    • 2-[6-Chloro-3-(4-pyridin-2-yl-piperazine-1-carbonyl)-indol-1-yl]-N,N-dimethyl-acetamide;
    • 2-[6-Chloro-3-(4-thiazol-2-yl-piperazine-1-carbonyl)-indol-1-yl]-N,N-dimethyl-acetamide;
    • 2-{6-Chloro-3-[4-(3-cyano-pyridin-2-yl)-piperazine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide;
    • 2-[6-Chloro-3-(4-pyrimidin-2-yl-piperazine-1-carbonyl)-indol-1-yl]-N,N-dimethyl-acetamide;
    • (6-Chloro-2-methyl-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-piperazin-1-yl]-methanone;
    • 2-{6-Chloro-3-[4-(6-chloro-pyridin-2-yl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide;
    • 2-{6-Chloro-3-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide;
    • 2-[6-Chloro-3-(4-thieno[2,3-c]pyridin-7-yl-piperazine-1-carbonyl)-indol-1-yl]-N-methyl-acetamide;
    • 2-{6-Chloro-3-[4-(3-chloro-5-trifluoromethyl-pyridin-2-yl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide;
    • 2-[4-(6-Chloro-1-methylcarbamoylmethyl-1H-indole-3-carbonyl)-piperazin-1-yl]-nicotinic acid;
    • 2-{6-Chloro-3-[4-(2,4-difluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-(2-dimethylamino-ethyl)-acetamide; and
    • 2-{6-Chloro-3-[4-(4-fluoro-2-methanesulfonyl-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide.
  • Preferred examples of compounds of formula (I-c) according to the invention are:
    • 2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide;
    • 2-{6-Chloro-3-[4-(2-ethoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide;
    • 2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-1-(4-methyl-piperazin-1-yl)-ethanone;
    • 2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide;
    • [6-Chloro-1-(2-dimethylamino-ethyl)-1H-indol-3-yl]-[4-(2-methoxy-phenyl)-piperazin-1-yl]-methanone;
    • [6-Chloro-1-(2-dimethylamino-ethyl)-1H-indol-3-yl]-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone;
    • 2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-1-(4-methyl-piperazin-1-yl)-ethanone;
    • 2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide;
    • 2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-acetamide;
    • 2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide;
    • 2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-1-piperazin-1-yl-ethanone;
    • 2-{6-Chloro-3-[4-(2,4-difluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide;
    • 2-{6-Chloro-3-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide;
    • [1-((S)-2-Amino-propyl)-6-chloro-1H-indol-3-yl]-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone;
    • (6-Chloro-1-(S)-1-pyrrolidin-2-ylmethyl-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone;
    • [6-Chloro-1-((S)-1-methyl-pyrrolidin-2-ylmethyl)-1H-indol-3-yl]-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone;
    • 2-{6-Chloro-3-[4-(2,4-difluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide;
    • 2-{6-Chloro-3-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide;
    • (6-Chloro-1-(R)-1-pyrrolidin-2-ylmethyl-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone;
    • [6-Chloro-1-((R)-1-methyl-pyrrolidin-2-ylmethyl)-1H-indol-3-yl]-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone;
    • N-(2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-ethyl)-acetamide;
    • N-(2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-ethyl)-methanesulfonamide;
    • N-(2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-ethyl)-N-methyl-acetamide;
    • N-(2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-ethyl)-N-methyl-methanesulfonamide;
    • 2-[6-Chloro-3-(4-thieno[3,2-c]pyridin-4-yl-piperazine-1-carbonyl)-indol-1-yl]-N-methyl-acetamide; and
    • 2-{6-Chloro-3-[4-(3-iodo-pyridin-2-yl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide.
  • Also encompassed by the compounds of formula (I) are the following compounds of formula (I-d) according to the invention:
  • Figure US20120040990A1-20120216-C00016
  • wherein R1 to R3 and R6 are as defined hereinabove for formula (I).
  • Again, it is preferred that R1, R2 and R3 are not simultaneously H.
  • Preferred compounds of formula (I-d) are those compounds wherein the substitution pattern is analogous to that of the preferred compounds of formula (I-c), and further preferred are those compounds wherein
    • R1 is H;
  • R2 is one or more halo;
    • R3 is H;
  • R6 is aryl substituted by C1-6-alkoxy;
    and pharmaceutically acceptable salts thereof.
  • As an example, (6-chloro-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-4-oxy-piperazin-1-yl]-methanone is mentioned.
  • The combinations of the substitution patterns provided herein for compounds of formula (I), (I-a), (I-a′), (I-b), (I-c) and (I-d) for each of the embodiments provided are also encompassed by the invention.
  • The invention also encompasses methods for the treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety or depressive disorders which comprise administering a compound of formulae (I), (I-a), (I-a′), (I-b), (I-c) or (I-d).
  • The invention also encompasses a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I), (I-a), (I-a′), (I-b), (I-c) or (I-d) and a pharmaceutically acceptable carrier. Such pharmaceutical compositions are useful for treating dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders.
  • In a certain embodiment, the compounds of formula (I) of the invention can be manufactured according to a process comprising reacting a compound of formula (II):
  • Figure US20120040990A1-20120216-C00017
  • with a compound of formula A-H, to obtain a compound of formula (I) wherein A, R1, R2 and R3 are as defined hereinabove for formula (I).
  • In another embodiment, the compounds of formula (I) of the invention can be manufactured according to a process comprising reacting a compound of formula (I-1), wherein R1 is H:
  • Figure US20120040990A1-20120216-C00018
  • with a compound of formula R1—X, to obtain a compound of formula (I) wherein A, R1, R2 and R3 are as defined hereinabove for formula (I) and X is halo.
  • In another embodiment, the compounds of formula (I) of the invention can be manufactured according to a process comprising hydrolyzing a compound of formula (V):
  • Figure US20120040990A1-20120216-C00019
  • to obtain a compound of formula (II):
  • Figure US20120040990A1-20120216-C00020
  • and then reacting the compound of formula (II) with a compound of formula A-H, to obtain a compound of formula (I) wherein R1, R2 and R3 are as defined hereinabove for formula (I).
  • These processes are described more in details with the following general schemes and procedures A to C.
  • Figure US20120040990A1-20120216-C00021
    • General Scheme A
  • Compounds of formula (I) can be prepared via an amide coupling between an indole 3-carboxylic acid (II) and a compound of formula (A-H), wherein A is defined as hereinabove. The usual reagents and protocols known in the art can be used to effect the amide coupling. Indole 3-carboxylic acids (II) are either commercially available or readily prepared using a procedure described in J. Med. Chem. 1991, 34, 140. Alternatively, they can be prepared following the general scheme C as described hereinafter. The compounds of formula (A-H) are either commercially available or prepared using methods known in the art starting from commercially available materials. General scheme A is hereinafter further illustrated with general procedure I.
  • Figure US20120040990A1-20120216-C00022
    • General Procedure B
  • Compounds of formula (I) with R1 different from H can be prepared using methods known in the art, e.g. by N-deprotonation of a compound of formula (I-1) (compounds of formula (I) wherein R1 is H) followed by treatment with an electrophilic reactant R1—X (wherein X is a leaving group, e.g. halo) which is either commercially available or easily prepared according to methods well known in the art and commercially available starting materials. General scheme B is hereinafter further illustrated with general procedure II.
  • Figure US20120040990A1-20120216-C00023
    • General Procedure C
  • The treatment of an indole derivative (III-1) with trifluoroacetic anhydride in DMF affords intermediate (IV) which can be hydrolyzed with an aqueous sodium hydroxide solution to give the 3-carboxylic acid indole derivative (II-1). Alternatively, (IV) could react with an electrophilic reactant R1—X to give (V), which is then converted to the corresponding carboxylic acid derivative (II) with NaH/H2O in DMF (see J. Org. Chem., 1993, 10, 2862). Intermediate (V) can alternatively be obtained by treatment of an indole derivative (III-2) with trifluoroacetic anhydride in a suitable solvent, e.g. DMF, dichloromethane or 1,2-dichloroethane. Addition of a suitable base may be advantageous.
    • V1a Activity Material & Method:
  • The human V1a receptor was cloned by RT-PCR from total human liver RNA. The coding sequence was subcloned in an expression vector after sequencing to confirm the identity of the amplified sequence. To demonstrate the affinity of the compounds from the present invention to the human V1a receptor binding studies were performed. Cell membranes were prepared from HEK293 cells transiently transfected with the expression vector and grown in 20 liter fermenters with the following protocol.
  • 50 g of cells are resuspended in 30 ml freshly prepared ice cold Lysis buffer (50 mM HEPES, 1 mM EDTA, 10 mM MgCl2 adjusted to pH=7.4+complete cocktail of protease inhibitor (Roche Diagnostics)). Homogenized with Polytron for 1 min and sonicated on ice for 2×2 minutes at 80% intensity (Vibracell sonicator). The preparation is centrifuged 20 min at 500 g at 4° C., the pellet is discarded and the supernatant centrifuged 1 hour at 43,000 g at 4° C. (19′000 rpm). The pellet is resuspended in 12.5 ml Lysis buffer+12.5 ml Sucrose 20% and homogenized using a Polytron for 1-2 min. The protein concentration is determined by the Bradford method, and aliquots are stored at −80° C. until use. For binding studies 60 mg Yttrium silicate SPA beads (Amersham) are mixed with an aliquot of membrane in binding buffer (50 mM Tris, 120 mM NaCl, 5 mM KCl, 2 mM CaCl2, 10 mM MgCl2) for 15 minutes with mixing. 50 ul of bead/membrane mixture is then added to each well of a 96 well plate, followed by 50 ul of 4 nM 3H-Vasopressin (American Radiolabeled Chemicals). For total binding measurement 100 ul of binding buffer are added to the respective wells, for non-specific binding 100 ul of 8.4 mM cold vasopressin and for compound testing 100 ul of a serial dilution of each compound in 2% DMSO. The plate is incubated 1 h at room temperature, centrifuged 1 min at 1000 g and counted on a Packard Top-Count. Non-specific binding counts are subtracted from each well, and data is normalized to the maximum specific binding set at 100%. To calculate an IC 50 the curve is fitted using a non-linear regression model (XLfit) and the Ki is calculated using the Cheng-Prussoff equation.
  • Ex. No. Ki (nM)
    3 14
    24 10
    40 8
    43 2
    44 3
    45 7
    46 7
    47 4
    48 7
    49 3
    50 4
    51 0
    52 4
    55 2
    56 2
    57 2
    58 9
    59 2
    60 8
    61 13
    62 11
    63 2
    66 4
    67 5
    69 6
    71 5
    72 3
    76 8
    80 6
    81 13
    82 2
    84 11
    87 4
    88 7
    90 8
    95 13
    96 11
    97 6
    102 7
    106 5
    107 12
    108 8
    111 7
    114 3
    115 11
    117 6
    118 12
    122 10
    151 14
    152 14
    153 23
    162 27
    163 22
    171 7
    172 10
    174 3
    175 32
    176 8
    177 8
    190 19
    196 26
    198 20
    200 21
    203 2
    205 10
    211 13
    214 16
    215 6
    217 21
    218 16
    219 15
    220 17
    224 27
    225 12
  • The present invention also provides pharmaceutical compositions containing compounds of the invention or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier. Such pharmaceutical compositions can be in the form of tablets, coated tablets, dragées, hard and soft gelatin capsules, solutions, emulsions or suspensions. The pharmaceutical compositions also can be in the form of suppositories or injectable solutions.
  • The pharmaceutical compositions of the invention, in addition to one or more compounds of the invention, contain a pharmaceutically acceptable carrier. Suitable pharmaceutically acceptable carriers include pharmaceutically inert, inorganic or organic excipients for the production of tablets, coated tablets, dragées, and hard gelatin capsules. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts etc can be used as such excipients e.g. for tablets, dragées and hard gelatin capsules. Suitable excipients for soft gelatin capsules are e.g. vegetable oils, waxes, fats, semi-solid and liquid polyols etc. Suitable excipients for the manufacture of solutions and syrups are e.g. water, polyols, saccharose, invert sugar, glucose etc. Suitable excipients for injection solutions are e.g. water, alcohols, polyols, glycerol, vegetable oils etc. Suitable excipients for suppositories are e.g. natural or hardened oils, waxes, fats, semi-liquid or liquid polyols etc.
  • Moreover, the pharmaceutical compositions can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
  • The present invention also provides a method for the manufacture of pharmaceutical compositions. Such process comprises bringing one or more compounds of formula I and/or pharmaceutically acceptable acid addition salts thereof and, if desired, one or more other therapeutically valuable substances into a galenical administration form together with one or more therapeutically inert carriers.
  • Compounds of formula (I) have good activity on the V1a receptor. The invention provides methods for treating dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders by administering a compound of formula (I) or a pharmaceutically acceptable salt thereof. The preferred indications with regard to the present invention are the treatment of anxiety and depressive disorders.
  • The compounds and compositions of the invention can be administered in a conventional manner, for example, orally rectally, or parenterally. The pharmaceutical compositions of the invention can be administered orally, for example, in the form of tablets, coated tablets, dragees, hard and soft gelatin capsules, solutions, emulsions, or suspensions. The pharmaceutical compositions also can be administered rectally, for example, in the form of suppositories, or parenterally, for example, in the form of injectable solutions.
  • The dosage at which a compound of the invention can be administered can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case. In general, in the case of oral administration a daily dosage of about 10 to 1000 mg per person of a compound of general formula (I), (I-a), (I-b); (I-c) or (I-d) should be appropriate, although the above upper limit can also be exceeded when necessary.
  • The following Examples illustrate the present invention without limiting it. All temperatures are given in degrees Celsius.
    • Example A
  • Tablets of the following composition are manufactured in the usual manner:
  • mg/tablet
    Active substance 5
    Lactose 45
    Corn starch 15
    Microcrystalline cellulose 34
    Magnesium stearate 1
    Tablet weight 100
    • Example B
  • Capsules of the following composition are manufactured:
  • mg/capsule
    Active substance 10
    Lactose 155
    Corn starch 30
    Talc 5
    Capsule fill weight 200
  • The active substance, lactose and corn starch are firstly mixed in a mixer and then in a comminuting machine. The mixture is returned to the mixer, the talc is added thereto and mixed thoroughly. The mixture is filled by machine into hard gelatin capsules.
    • Example C
  • Suppositories of the following composition are manufactured:
  • mg/supp.
    Active substance 15
    Suppository mass 1285
    Total 1300
  • The suppository mass is melted in a glass or steel vessel, mixed thoroughly and cooled to 45° C.
  • Thereupon, the finely powdered active substance is added thereto and stirred until it has dispersed completely. The mixture is poured into suppository moulds of suitable size, left to cool; the suppositories are then removed from the moulds and packed individually in wax paper or metal foil.
  • Where journal references are cited in the examples, the example was performed using the starting material listed with the reactants and conditions cited in the reference. All procedures in such references are well known to those of ordinary skill in the art. All journal references cited herein are incorporated by reference.
    • EXAMPLES General Procedure I Amide Coupling
  • To a stirred solution of an indole-3-carboxylic acid derivative (1 mmol) in 10 ml CH2Cl2 were added (1.3 mmol) EDC, (1.3 mmol) HOBt, (1.3 mmol) Et3N and (1 mmol) of the amine derivative. The mixture was stirred overnight at RT and then poured onto water and extracted with CH2Cl2. The combined organic phases were dried over Na2SO4 and concentrated in vacuo. Flash chromatography or preparative HPLC afforded the title compound.
    • General procedure II Alkylation
  • To a stirred solution of (6-chloro-1H-indol-3-yl)-(4-phenyl-piperidin-1-yl)-methanone in DMF were added 2.1 eq. NaH (60% in oil). The mixture was stirred at RT for 30 min. and then the electrophilic reagent R1—X (1.1 eq.) was added. The mixture was stirred an additional 14 hours at 60° C. and then poured onto water and extracted with ethyl acetate. The combined organic phases were dried over Na2SO4 and concentrated in vacuo. Purification by preparative HPLC afforded the corresponding derivatives.
    • Acid Intermediates of Formula II and II-1 Acid 1 6-Chloro-1H-indole-3-carboxylic acid
  • Using a procedure described in J. Med. Chem. 1991, 34, 140, from 7.0 g (0.046 mmol) of 6-chloro-1H-indole were prepared 5.80 g (64%) of 6-chloro-1H-indole-3-carboxylic acid as a light brown solid.
  • ES-MS m/e (%): 194 (M−H+).
    • Acid 2 6-Chloro-1-dimethylcarbamoylmethyl-1H-indole-3-carboxylic acid 1-(6-Chloro-1H-indol-3-yl)-2,2,2-trifluoro-ethanone
  • Using a procedure described in J. Med. Chem. 1991, 34, 140, from 0.50 g (0.004 mol) of 6-chloro-1H-indole were prepared 0.76 g (95%) of 1-(6-chloro-1H-indol-3-yl)-2,2,2-trifluoro-ethanone as a white solid.
    • 2-[6-Chloro-3-(2,2,2-trifluoro-acetyl)-indol-1-yl]-N,N-dimethyl-acetamide
  • To a stirred solution of 1-(6-chloro-1H-indol-3-yl)-2,2,2-trifluoro-ethanone (0.75 g) in 20 ml of DMF at 0° C., were added 128 mg (1.1 eq.) of NaH (60% in oil). The mixture was stirred for 30 min. and then 0.32 ml (1.1 eq.) of dimethylamino-acetyl chloride were added. The mixture was stirred an additional hour and then poured onto water and extracted with ethyl acetate. The combined organic phases were dried over Na2SO4 and concentrated in vacuo to afford 598 mg (61%) of 2-[6-chloro-3-(2,2,2-trifluoro-acetyl)-indol-1-yl]-N,N-dimethyl-acetamide as a white solid.
    • 6-Chloro-1-dimethylcarbamoylmethyl-1H-indole-3-carboxylic acid
  • Using a procedure similar to that described in J. Med. Chem. 1991, 34, 140, from 0.50 g of 2-[6-chloro-5-methyl-3-(2,2,2-trifluoro-acetyl)-indol-1-yl]-N,N-dimethyl-acetamide were prepared 0.38 g (76%) of 6-chloro-1-dimethylcarbamoylmethyl-1H-indole-3-carboxylic acid as a white solid
    • Acid 3 6-Chloro-1-methylcarbamoylmethyl-1H-indole-3-carboxylic acid 2-[6-Chloro-3-(2,2,2-trifluoro-acetyl)-indol-1-yl]-N-methyl-acetamide
  • Following general procedure II, the alkylation of 1-(6-chloro-1H-indol-3-yl)-2,2,2-trifluoro-ethanone, with (commercially available) 2-chloro-N-methyl-acetamide gave the title compound.
  • ES-MS m/e (%): 319.3 (M+H+).
    • 6-Chloro-1-methylcarbamoylmethyl-1H-indole-3-carboxylic acid 2-[6-Chloro-3-(2,2,2-trifluoro-acetyl)-indol-1-yl]-N-methyl-acetamide was suspensed in DCE and treated with (2.2 eq.) of sodium trimethylsilanolate. After shaking at room temperature for 20 min, the mixture was concentrated in vacuo and purified by prep. HPLC to give the title compound in 27% yield.
  • ES-MS m/e (%): 265.0 (M−H+).
    • Acid 4 6-Chloro-1-[(2-dimethylamino-ethylcarbamoyl)-methyl]-1H-indole-3-carboxylic acid [6-Chloro-3-(2,2,2-trifluoro-acetyl)-indol-1-yl]-acetic acid methyl ester
  • To a stirred solution of 6.65 g (0.0265 mol, 1 eq.) of 1-(6-chloro-1H-indol-3-yl)-2,2,2-trifluoro-ethanone in 25 ml of DMF at 0° C. were added 1.23 g of NaH (55% in oil, 0.0282 mol, 1.05 eq). After 30 minutes, 4.31 g (0.0282 mol, 1.05 eq.) of bromo-acetic acid methyl ester were added and the temperature raised to RT, and stirring was continued overnight. The reaction was quenched by the addition of aq. HCl 0.1 M, and the product was extracted with EtOAc and the combined organic phases dried over Na2SO4. Recrystallisation in Et2O/Heptane afforded 6.90 g (80%) of [6-chloro-3-(2,2,2-trifluoro-acetyl)-indol-1-yl]-acetic acid methyl ester as white crystals.
    • [6-Chloro-3-(2,2,2-trifluoro-acetyl)-indol-1-yl]-acetic acid
  • To as stirred solution of 2 g (6.3 mmol) of [6-chloro-3-(2,2,2-trifluoro-acetyl)-indol-1-yl]-acetic acid methyl ester in 45 ml of THF/MeOH/H2O 1/1/1, at 40° C., were added 0.79 g (18.9 mmol, 3 eq.) of LiOH.H2O. After 1 hour, the reaction mixture was diluted in EtOAc, acidified with aq. HCl 1M. The organic phase were dried over Na2SO4, and concentrated under vacuo to afford 1.9 g (99%) of [6-chloro-3-(2,2,2-trifluoro-acetyl)-indol-1-yl]-acetic acid as a white solid.
    • 2-[6-Chloro-3-(2,2,2-trifluoro-acetyl)-indol-1-yl]-N-(2-dimethylamino-ethyl)-acetamide
  • An amide coupling between 0.99 g of [6-Chloro-3-(2,2,2-trifluoro-acetyl)-indol-1-yl]-acetic and N1,N1-dimethyl-ethane-1,2-diamine according to the general procedure I, afforded 78 mg (6%) of 2-[6-chloro-3-(2,2,2-trifluoro-acetyl)-indol-1-yl]-N-(2-dimethylamino-ethyl)-acetamide as a white solid.
    • 6-Chloro-1-[(2-dimethylamino-ethylcarbamoyl)-methyl]-1H-indole-3-carboxylic acid
  • Using a similar procedure described in J. Med. Chem. 1991, 34, 140, from 78 mg of 2-[6-chloro-3-(2,2,2-trifluoro-acetyl)-indol-1-yl]-N-(2-dimethylamino-ethyl)-acetamide were prepared 65 mg (96%) of 6-chloro-1-[(2-dimethylamino-ethylcarbamoyl)-methyl]-1H-indole-3-carboxylic acid as a white solid.
    • Acid 5 6-Chloro-1-dimethylcarbamoylmethyl-5-methyl-1H-indole-3-carboxylic acid 1-(6-Chloro-5-methyl-1H-indol-3-yl)-2,2,2-trifluoro-ethanone
  • Using a procedure described in J. Med. Chem. 1991, 34, 140, from 0.250 g (0.002 mol) of 6-chloro-5-methyl-1H-indole were prepared 0.38 g (96%) of 1-(6-chloro-5-methyl-1H-indol-3-yl)-2,2,2-trifluoro-ethanone as a white solid.
    • 2-[6-Chloro-5-methyl-3-(2,2,2-trifluoro-acetyl)-indol-1-yl]-N,N-dimethyl-acetamide
  • To a stirred solution of 1-(6-chloro-5-methyl-1H-indol-3-yl)-2,2,2-trifluoro-ethanone (0.38 g) in 10 ml of DMF at 0° C., were added 64 mg (1.1 eq.) of NaH (60% in oil). The mixture was stirred for 30 min. and then 0.16 ml (1.1 eq.) of dimethylamino-acetyl chloride were added. The mixture was stirred an additional hour and then poured onto water and extracted with ethyl acetate. The combined organic phases were dried over Na2SO4 and concentrated in vacuo to afford 300 mg (60%) of 2-[6-chloro-5-methyl-3-(2,2,2-trifluoro-acetyl)-indol-1-yl]-N,N-dimethyl-acetamide as a white solid.
    • 6-Chloro-1-dimethylcarbamoylmethyl-5-methyl-1H-indole-3-carboxylic acid
  • Using a similar procedure described in J. Med. Chem. 1991, 34, 140, from 0.280 g of 2-[6-chloro-5-methyl-3-(2,2,2-trifluoro-acetyl)-indol-1-yl]-N,N-dimethyl-acetamide were prepared 0.18 g (76%) of 6-chloro-1-dimethylcarbamoylmethyl-5-methyl-1H-indole-3-carboxylic acid as a white solid
    • Acid 6 5,6-Dichloro-1-dimethylcarbamoylmethyl-1H-indole-3-carboxylic acid 1-(5,6-Dichloro-1H-indol-3-yl)-2,2,2-trifluoro-ethanone
  • Using a procedure described in J. Med. Chem. 1991, 34, 140, from 0.120 g (0.64 mmol) of 5,6-dichloro-1H-indole were prepared 0.11 g (59%) of 1-(5,6-dichloro-1H-indol-3-yl)-2,2,2-trifluoro-ethanone as a white solid.
    • 2-[5,6-Dichloro-3-(2,2,2-trifluoro-acetyl)-indol-1-yl]-N,N-dimethyl-acetamide
  • To a stirred solution of 1-(5,6-dichloro-1H-indol-3-yl)-2,2,2-trifluoro-ethanone (0.11 g) in 3 ml of DMF at 0° C., were added 18 mg (1.05 eq.) of NaH (60% in oil). The mixture was stirred for 30 min. and then 0.04 ml (1.0 eq.) of dimethylamino-acetyl chloride were added. The mixture was stirred an additional hour and then poured onto water and extracted with ethyl acetate. The combined organic phases were dried over Na2SO4 and concentrated in vacuo to afford 112 mg (78%) of 2-[5,6-dichloro-3-(2,2,2-trifluoro-acetyl)-indol-1-yl]-N,N-dimethyl-acetamide as a white solid.
    • 5,6-Dichloro-1-dimethylcarbamoylmethyl-1H-indole-3-carboxylic acid
  • Using a similar procedure described in J. Med. Chem. 1991, 34, 140, from 0.112 g of 2-[5,6-dichloro-3-(2,2,2-trifluoro-acetyl)-indol-1-yl]-N,N-dimethyl-acetamide were prepared 0.047 g (49%) of 5,6-dichloro-1-dimethylcarbamoylmethyl-1H-indole-3-carboxylic acid as a white solid.
    • Acid 7 6-Chloro-2-methyl-1H-indole-3-carboxylic acid (6-Chloro-1H-indol-2-yl)-methanol
  • To a solution of 2.00 g (8.94 mmol) 6-chlorindole-2-carboxylic acid ethyl ester in 50 ml diethyl ether were added 0.475 g (12.5 mmol) lithium aluminum hydride at 0° C. The reaction mixture was heated at reflux for 45 min and quenched by consecutive addition of 10 ml water, 10 ml aqueous 2 M sodium hydroxide solution and 10 ml water at 0° C. The aqueous layer was extracted with tert-butyl methyl ether (3×100 ml). The combined organic layers were dried over sodium sulfate and concentrated in vacuo to give the crude title compound (1.64 g; 100%) as a white solid.
  • MS m/e (%): 180 (M−H+, 100).
    • 6-Chloro-2-methyl-1H-indole
  • A solution of 1.60 g (8.81 mmol) (6-chloro-1H-indol-2-yl)-methanol in 5 ml 1,2-dichloroethane was added to a mixture of 80.0 ml trifluoroacetic acid and 32.0 ml triethylsilane at 65° C. After 5 min, the reaction mixture was cooled to room temperature and quenched with water. The pH was adjusted to 14 by the addition of aqueous sodium hydroxide solution (32%). The aqueous layer was extracted with tert-butyl methyl ether (3×200 ml). The combined organic layers were dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash-chromatography (aminopropyl-modified silica gel, n-heptane/ethyl acetate) to give the title compound (0.39 g; 27%) as a white solid.
  • MS m/e (%): 164 (M−H+, 100).
    • 1-(6-Chloro-2-methyl-1H-indol-3-yl)-2,2,2-trifluoro-ethanone
  • To a solution of 0.38 g (2.3 mmol) 6-chloro-2-methyl-1H-indole in 20 ml 1,2-dichloroethane at 0° C. were added 0.35 ml (2.5 mmol) trifluoroacetic anhydride. The reaction mixture was quenched with aqueous 2 M sodium carbonate solution after 30 min and extracted with dichloromethane (3×100 ml). The combined organic layers were dried over sodium sulfate and concentrated in vacuo to give the title compound (0.57 g; 95%) as an off-white solid.
  • MS m/e (%): 260 (M−H+, 100).
    • 6-Chloro-2-methyl-1H-indole-3-carboxylic acid
  • A solution of 0.57 g (2.2 mmol) 1-(6-chloro-2-methyl-1H-indol-3-yl)-2,2,2-trifluoro-ethanone in 21.7 ml (86.8 mmol) aqueous 4 M sodium hydroxide solution was heated at reflux for 45 min. After cooling to room temperature the reaction mixture was diluted with water and extracted with tert-butyl methyl ether (2×50 ml). The aqueous layer was cooled to 0-5° C., acidified (pH 1-2) with concentrated aqueous hydrochloric acid solution and extracted with ethyl acetate (3×100 ml). The combined ethyl acetate layers were dried over sodium sulfate and concentrated in vacuo to give the title compound (0.14 g, 31%) as an off-white solid.
  • MS m/e (%): 208 (M−H+, 100).
    • Acid 8 5-Chloro-2-methyl-1H-indole-3-carboxylic acid
  • Using a procedure described in J. Med. Chem. 1991, 34, 140, from the 5-chloro-2-methyl-1H-indole was prepared 5-chloro-2-methyl-1H-indole-3-carboxylic acid.
    • Acid 9 Benzyl-2-methyl-1H-indole-3-carboxylic acid
  • To a stirred solution of 0.50 g (3.1 mmol) 2-methyl-1H-indole-3-carboxylic acid (described in J. Heterocyclic Chem. 1977, 14, 1123) in 5 ml DMF were added 0.27 g (6.75 mmol) of NaH (60% in oil). The mixture was stirred at RT for 30 min. and then 0.39 ml (3.28 mmol) of benzyl bromid were added. The mixture was stirred an additional hour and then poured onto water and extracted with ethyl acetate. The combined organic phases were dried over Na2SO4 and concentrated in vacuo. Crystallization in Et2O afforded 0.61 g (78%) of 1-benzyl-2-methyl-1H-indole-3-carboxylic acid as a white solid.
    • Acid 10 3,4-Dihydro-1H-pyrazino[1,2-a]indole-2,10-dicarboxylic acid 2-tert-butyl ester 10-(2,2,2-Trifluoro-acetyl)-3,4-dihydro-1H-pyrazino[1,2-a]indole-2-carboxylic acid tert-butyl ester
  • To a stirred solution of 0.21 ml (1.5 mmol) trifluoroacetic anhydride in 7 ml 1,2-dichloroethane was added at 0° C. a solution of 0.37 g (1.4 mmol) 3,4-dihydro-1H-pyrazino[1,2-a]indole-2-carboxylic acid tert-butyl ester and a solution of 0.23 ml (1.63 mmol) triethylamine in 3 ml 1,2-dichloroethane. After stirring for 30 min the reaction mixture was quenched with saturated aqueous sodium hydrogen carbonate solution and extracted with dichloromethane (2×100 ml). The combined organic layers were dried over sodium sulfate, concentrated in vacuo and purified by flash chromatography (n-heptane/ethyl acetate) to give the title compound (0.288 g, 58%) as a light yellow solid.
  • MS m/e (%): 369 (M+H+, 27).
    • 3,4-Dihydro-1H-pyrazino[1,2-a]indole-2,10-dicarboxylic acid 2-tert-butyl ester
  • To a solution of 0.29 g (0.77 mmol) 10-(2,2,2-trifluoro-acetyl)-3,4-dihydro-1H-pyrazino[1,2-a]indole-2-carboxylic acid tert-butyl ester in 7 ml N,N-dimethylformamide were subsequently added 0.22 g (4.6 mmol) sodium hydride (50% in oil) and a solution of 0.070 ml (3.9 mmol) water in 1 ml N,N-dimethylformamide at room temperature. The reaction mixture was diluted with tert-butyl methyl ether after 2 h and extracted with 1 M sodium hydroxide solution (2×30 ml). The combined aqueous layers were acidified (pH 1-2) with 2 M hydrochloric acid at 0° C. and extracted with tert-butyl methyl ether (3×50 ml). The combined organic layers were dried over sodium sulfate and concentrated in vacuo to give the title compound (0.21 g, 86%) as a light brown solid.
  • MS m/e (%): 315 (M−H+, 100).
    • Examples of Compounds of Formula I-a and I-a′ Example 1 Benzyl-2-methyl-1H-indol-3-yl)-[4-(4-fluoro-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00024
  • Amide coupling according to general procedure I:
  • Amine: 4-(4-Fluoro-phenyl)-1,2,3,6-tetrahydro-pyridine (commercially available),
  • Acid: 1-Benzyl-2-methyl-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 425.5 (M+H+).
    • Example 2 Benzyl-2-methyl-1H-indol-3-yl)-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)-methanone
  • Figure US20120040990A1-20120216-C00025
  • Amide coupling according to general procedure I:
  • Amine: 4-Phenyl-1,2,3,6-tetrahydro-pyridine (commercially available),
  • Acid: 1-Benzyl-2-methyl-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 407.5 (M+H+).
    • Example 3 Benzyl-2-methyl-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00026
  • Amide coupling according to general procedure I:
  • Amine: 4-(2-Methoxy-phenyl)-1,2,3,6-tetrahydro-pyridine (described in U.S. Pat. No. 6,326,381),
  • Acid: 1-Benzyl-2-methyl-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 437.6 (M+H+).
    • Example 4 (6-Chloro-1H-indol-3-yl)-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)-methanone
  • Figure US20120040990A1-20120216-C00027
  • Amide coupling according to general procedure I:
  • Amine: 4-Phenyl-1,2,3,6-tetrahydro-pyridine (commercially available),
    Acid: 6-chloro-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 337.4 (M+H+).
    • Example 5 (6-Chloro-1H-indol-3-yl)-[4-(4-fluoro-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00028
  • Amide coupling according to general procedure I:
  • Amine: 4-(4-Fluoro-phenyl)-1,2,3,6-tetrahydro-pyridine (commercially available),
    Acid: 6-chloro-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 355.4 (M+H+).
    • Example 6 (6-Chloro-1H-indol-3-yl)-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)-methanone
  • Figure US20120040990A1-20120216-C00029
  • Following general procedure I, the coupling of (commercially available) 4-phenyl-1,2,3,6-tetrahydro-pyridine, with 6-chloro-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 337.4 (M+H+).
    • Example 7 (6-Chloro-1H-indol-3-yl)-[4-(4-fluoro-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00030
  • Following general procedure I, the coupling of (commercially available) 4-(4-fluoro-phenyl)-1,2,3,6-tetrahydro-pyridine with 6-chloro-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 355.4 (M+H+).
    • Example 8 (6-Chloro-1H-indol-3-yl)-[4-(4-chloro-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00031
  • Following general procedure I, the coupling of (commercially available) 4-(4-chloro-phenyl)-1,2,3,6-tetrahydro-pyridine with 6-chloro-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 371.4 (M+H+).
    • Example 9 Benzyl-2-methyl-1H-indol-3-yl)-(5-methyl-4-phenyl-3,6-dihydro-2H-pyridin-1-yl)-methanone
  • Figure US20120040990A1-20120216-C00032
  • Following general procedure I, the coupling of (commercially available) 5-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine (described in WO 2005077912) with 1-benzyl-2-methyl-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 421.6 (M+H+).
    • Examples of Compounds of Formula I-b Example 10 (4-Benzyl-4-hydroxy-piperidin-1-yl)-(1-benzyl-2-methyl-1H-indol-3-yl)-methanone
  • Figure US20120040990A1-20120216-C00033
  • Amide coupling according to general procedure I:
  • Amine: 4-Benzyl-piperidin-4-ol (commercially available),
  • Acid: 1-Benzyl-2-methyl-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 439.5 (M+H+).
    • Example 11 (4-Benzyl-4-hydroxy-piperidin-1-yl)-[1-(2-chloro-benzyl)-2-methyl-1-indol-3-yl]-methanone
  • Figure US20120040990A1-20120216-C00034
    • (4-Benzyl-4-hydroxy-piperidin-1-yl)-(2-methyl-1H-indol-3-A-methanone
  • To a stirred solution of 0.1 g (0.57 mmol) 2-methyl-1H-indole-3-carboxylic acid in 10 ml CH2Cl2 were added 0.14 g (0.73 mmol) EDC, 0.10 g (0.73 mmol) HOBt, 90 μl (0.63 mmol) Et3N and 0.11 g (0.57 mmol) 4-benzyl-piperidin-4-ol. The mixture was stirred overnight at RT and then poured onto water and extracted with CH2Cl2. The combined organic phases were dried over Na2SO4 and concentrated in vacuo. Flash chromatography (ethyl acetate) afforded 0.15 g (75%) of (4-benzyl-4-hydroxy-piperidin-1-yl)-(2-methyl-1H-indol-3-yl)-methanone as a white solid.
  • ES-MS m/e (%): 349 (M+H+).
    • (4-Benzyl-4-hydroxy-piperidin-1-yl)-[1-(2-chloro-benzyl)-2-methyl-1H-indol-3-yl]-methanone
  • To a stirred solution of 40 mg (0.11 mmol) of (4-benzyl-4-hydroxy-piperidin-1-yl)-(2-methyl-1H-indol-3-yl)-methanone in 5 ml DMF were added 5 mg (0.11 mmol) NaH (60% in oil). The mixture was stirred at RT for 30 min. and then 28 mg (0.13 mmol) of 1-bromomethyl-2-chloro-benzene were added. The mixture was stirred an additional hour and then poured onto water and extracted with ethyl acetate. The combined organic phases were dried over Na2SO4 and concentrated in vacuo. Preparative HPLC (30% CH3CN/H2O) afforded 33 mg (61%) of (4-benzyl-4-hydroxy-piperidin-1-yl)-[1-(2-chloro-benzyl)-2-methyl-1H-indol-3-yl]-methanone as a white solid.
  • ES-MS m/e (%): 473.4 (M+H+).
    • Example 12 Benzyl-5-chloro-2-methyl-1H-indol-3-yl)-(4-benzyl-4-hydroxy-piperidin-1-yl)-methanone
  • Figure US20120040990A1-20120216-C00035
    • (4-benzyl-4-hydroxy-piperidin-1-yl)-(5-chloro-2-methyl-1H-indol-3-yl)-methanone
  • Using the procedure described for the preparation of (4-benzyl-4-hydroxy-piperidin-1-yl)-(2-methyl-1H-indol-3-yl)-methanone, from 40 mg (0.19 mmol) of 5-chloro-2-methyl-1H-indole-3-carboxylic acid and 40 mg (0.21 mmol) of 4-benzyl-piperidin-4-ol were prepared 45 mg (62%) of (4-benzyl-4-hydroxy-piperidin-1-yl)-(5-chloro-2-methyl-1H-indol-3-yl)-methanone as a white solid.
  • ES-MS m/e (%): 383 (M+H+).
    • (1-benzyl-5-chloro-2-methyl-1H-indol-3-yl)-(4-benzyl-4-hydroxy-piperidin-1-yl)-methanone
  • Using the procedure described for the preparation of (4-benzyl-4-hydroxy-piperidin-1-yl)-[1-(2-chloro-benzyl)-2-methyl-1H-indol-3-yl]-methanone, from 13 mg (0.034 mmol) of (4-benzyl-4-hydroxy-piperidin-1-yl)-(5-chloro-2-methyl-1H-indol-3-yl)-methanone and 5.8 mg (0.034 mmol) of benzyl bromide were prepared 14 mg (87%) of (1-benzyl-5-chloro-2-methyl-1H-indol-3-yl)-(4-benzyl-4-hydroxy-piperidin-1-yl)-methanone as a white solid.
  • ES-MS m/e (%): 473.3 (M+H+).
    • Example 13 (4-Benzyl-4-hydroxy-piperidin-1-yl)-[5-chloro-1-(3-methoxy-benzyl)-2-methyl-1H-indol-3-yl]-methanone
  • Figure US20120040990A1-20120216-C00036
  • Using the procedure described for the preparation of (4-benzyl-4-hydroxy-piperidin-1-yl)-[1-(2-chloro-benzyl)-2-methyl-1H-indol-3-yl]-methanone, from 13 mg (0.034 mmol) of (4-benzyl-4-hydroxy-piperidin-1-yl)-(5-chloro-2-methyl-1H-indol-3-yl)-methanone and 6.8 mg (0.034 mmol) of 1-bromomethyl-3-methoxy-benzene were prepared 11 mg (65%) of (4-benzyl-4-hydroxy-piperidin-1-yl)-[5-chloro-1-(3-methoxy-benzyl)-2-methyl-1H-indol-3-yl]-methanone as a white solid.
  • ES-MS m/e (%): 503.5 (M+H+).
    • Example 14 (4-Benzyl-4-hydroxy-piperidin-1-yl)-[1-(2-methoxy-benzyl)-2-methyl-1-indol-3-yl]-methanone
  • Figure US20120040990A1-20120216-C00037
  • Using the procedure described for the preparation of (4-benzyl-4-hydroxy-piperidin-1-yl)-[1-(2-chloro-benzyl)-2-methyl-1H-indol-3-yl]-methanone, from 28 mg (0.080 mmol) of (4-benzyl-4-hydroxy-piperidin-1-yl)-(2-methyl-1H-indol-3-yl)-methanone and 15 mg (0.096 mmol) of 1-chloromethyl-2-methoxy-benzene were prepared 29 mg (77%) of (4-benzyl-4-hydroxy-piperidin-1-yl)-[1-(2-methoxy-benzyl)-2-methyl-1H-indol-3-yl]-methanone as a white solid.
  • ES-MS m/e (%): 469.6 (M+H+).
    • Example 15 Benzyl-2-methyl-1H-indol-3-yl)-[4-(3-fluoro-phenoxy)-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00038
  • Amide coupling according to general procedure I:
  • Amine: 4-(3-Fluoro-phenoxy)-piperidine (described in US260294700),
    Acid: 1-Benzyl-2-methyl-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 443.6 (M+H+).
    • Example 16 Benzyl-2-methyl-1H-indol-3-yl)-[4-(4-chloro-phenyl)-4-hydroxy-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00039
  • Amide coupling according to general procedure I:
  • Amine: 4-(4-Chloro-phenyl)-piperidin-4-ol (commercially available),
    Acid: 1-Benzyl-2-methyl-1H-indole-3-carboxylic acid
  • ES-MS m/e (%): 459.5 (M+H+).
    • Example 17 Benzyl-2-methyl-1H-indol-3-yl)-[4-(4-bromo-phenyl)-4-hydroxy-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00040
  • Amide coupling according to general procedure I:
  • Amine: 4-(4-Bromo-phenyl)-piperidin-4-ol (commercially available),
    Acid: 1-Benzyl-2-methyl-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 505.5 (M+H+).
    • Example 18 Benzyl-2-methyl-1H-indol-3-yl)-(4-hydroxy-4-phenyl-piperidin-1-yl)-methanone
  • Figure US20120040990A1-20120216-C00041
  • Amide coupling according to general procedure I:
  • Amine: 4-Phenyl-piperidin-4-ol (commercially available),
    Acid: 1-Benzyl-2-methyl-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 425.6 (M+H+).
    • Example 19 Benzyl-2-methyl-1H-indol-3-yl)-[4-(4-fluoro-phenyl)-4-hydroxy-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00042
  • Amide coupling according to general procedure I:
  • Amine: 4-(4-Fluoro-phenyl)-piperidin-4-ol (commercially available),
    Acid: 1-Benzyl-2-methyl-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 443.6 (M+H+).
    • Example 20 Benzyl-2-methyl-1H-indol-3-yl)-[4-(4-chloro-3-trifluoromethyl-phenyl)-4-hydroxy-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00043
  • Amide coupling according to general procedure I:
  • Amine: 4-(4-Chloro-3-trifluoromethyl-phenyl)-piperidin-4-ol (commercially available),
    Acid: 1-Benzyl-2-methyl-1H-indole-3-carboxylic acid
  • ES-MS m/e (%): 527.5 (M+H+).
    • Example 21 (4-Benzo[1,3]dioxol-5-yl-4-hydroxy-piperidin-1-yl)-(1-benzyl-2-methyl-1H-indol-3-yl)-methanone
  • Figure US20120040990A1-20120216-C00044
  • Amide coupling according to general procedure I:
  • Amine: 4-Benzo[1,3]dioxol-5-yl-piperidin-4-ol (described in WO9709311),
    Acid: 1-Benzyl-2-methyl-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 469.6 (M+H+).
    • Example 22 Benzyl-2-methyl-1H-indol-3-yl)-(4-hydroxy-4-p-tolyl-piperidin-1-yl)-methanone
  • Figure US20120040990A1-20120216-C00045
  • Amide coupling according to general procedure I:
  • Amine: 4-p-Tolyl-piperidin-4-ol (described in EP445701),
    Acid: 1-Benzyl-2-methyl-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 439.6 (M+H+).
    • Example 23 Benzyl-2-methyl-1H-indol-3-yl)-[4-hydroxy-4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00046
  • Amide coupling according to general procedure I:
  • Amine: 4-(3-Trifluoromethyl-phenyl)-piperidin-4-ol (commercially available),
    Acid: 1-Benzyl-2-methyl-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 493.6 (M+H+).
    • Example 24 Benzyl-2-methyl-1H-indol-3-yl)-(4-phenyl-piperidin-1-yl)-methanone
  • Figure US20120040990A1-20120216-C00047
  • Amide coupling according to general procedure I:
  • Amine: 4-Phenyl-piperidine (commercially available),
    Acid: 1-Benzyl-2-methyl-1H-indole-3-carboxylic acid
  • ES-MS m/e (%): 409.5 (M+H+).
    • Example 25 (6-Chloro-1H-indol-3-yl)-(4-phenyl-piperidin-1-yl)-methanone
  • Figure US20120040990A1-20120216-C00048
  • Amide coupling according to general procedure I:
  • Amine: 4-Phenyl-piperidine (commercially available),
    Acid: 6-chloro-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 339.4 (M+H+).
    • Example 26 (6-Chloro-1H-indol-3-yl)-[4-hydroxy-4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-methanol
  • Figure US20120040990A1-20120216-C00049
  • Amide coupling according to general procedure I:
  • Amine: 4-(3-Trifluoromethyl-phenyl)-piperidin-4-ol (commercially available),
    Acid: 6-chloro-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 423.4 (M+H+).
    • Example 27 1-(6-Chloro-1H-indole-3-carbonyl)-4-phenyl-piperidine-4-carbonitrile
  • Figure US20120040990A1-20120216-C00050
  • Amide coupling according to general procedure I:
  • Amine: 4-Phenyl-piperidine-4-carbonitrile (commercially available),
    Acid: 6-chloro-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 364.4 (M+H+).
    • Example 28 (6-Chloro-1H-indol-3-yl)-(4-hydroxy-4-p-tolyl-piperidin-1-yl)-methanone
  • Figure US20120040990A1-20120216-C00051
  • Amide coupling according to general procedure I:
  • Amine: 4-p-Tolyl-piperidin-4-ol (described in EP445701),
    Acid: 6-chloro-1H-indole-3-carboxylic acid
  • ES-MS m/e (%): 369.4 (M+H+).
    • Example 29 (6-Chloro-1H-indol-3-yl)-[4-(4-chloro-phenyl)-4-hydroxy-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00052
  • Amide coupling according to general procedure I:
  • Amine: 4-(4-Chloro-phenyl)-piperidin-4-ol (commercially available),
    Acid: 6-chloro-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 389.4 (M+).
    • Example 30 (6-Chloro-1H-indol-3-yl)-[4-(4-chloro-3-trifluoromethyl-phenyl)-4-hydroxy-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00053
  • Amide coupling according to general procedure I:
  • Amine: 4-(4-Chloro-3-trifluoromethyl-phenyl)-piperidin-4-ol (commercially available),
    Acid: 6-chloro-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 457.4 (M+).
    • Example 31 (4-Benzo[1,3]dioxol-5-yl-4-hydroxy-piperidin-1-yl)-(6-chloro-1H-indol-3-yl)-methanone
  • Figure US20120040990A1-20120216-C00054
  • Amide coupling according to general procedure I:
  • Amine: 4-Benzo[1,3]dioxol-5-yl-piperidin-4-ol (described in WO9709311),
    Acid: 6-chloro-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 399.4 (M+H+).
    • Example 32 [4-(4-Bromo-phenyl)-4-hydroxy-piperidin-1-yl]-(6-chloro-1H-indol-3-yl)-methanone
  • Figure US20120040990A1-20120216-C00055
  • Amide coupling according to general procedure I:
  • Amine: 4-(4-Bromo-phenyl)-piperidin-4-ol (commercially available),
    Acid: 6-chloro-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 435.3 (M+).
    • Example 33 [1-(6-chloro-1H-indole-3-carbonyl)-piperidin-4-yl]-carbamic acid tert-butyl ester
  • Figure US20120040990A1-20120216-C00056
  • Amide coupling according to general procedure I:
  • Amine: Piperidin-4-yl-carbamic acid tert-butyl ester (commercially available),
    Acid: 6-chloro-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 378.3 (M+H+).
    • Example 34 N-[1-(6-Chloro-1H-indole-3-carbonyl)-piperidin-4-yl]-2-fluoro-benzamide
  • Figure US20120040990A1-20120216-C00057
    • (4-Amino-piperidin-1-yl)-(6-chloro-1H-indol-3-yl)-methanone
  • To a stirred solution of 0.50 g (1.32 mmol) of [1-(6-chloro-1H-indole-3-carbonyl)-piperidin-4-yl]-carbamic acid tert-butyl ester (the preparation of which has been described in example 31) in CH2Cl2 (10 ml), were added 2 ml of TFA. The mixture was stirred 2 hours, then poured onto an aqueous solution of sat. NaHCO3 and then extracted with ethyl acetate. The combined organic phases were dried over Na2SO4 and concentrated in vacuo, to afford 0.25 g (68%) of (4-amino-piperidin-1-yl)-(6-chloro-1H-indol-3-yl)-methanone as a light brown solid.
  • ES-MS m/e (%): 78.1 (M+H+).
    • N-[1-(6-Chloro-1H-indole-3-carbonyl)-piperidin-4-yl]-2-fluoro-benzamide
  • To a stirred solution of 50 mg (0.36 mmol) 2-fluoro-benzoic acid in 5 ml CH2Cl2 were added 90 mg (0.47 mmol) EDC, 63 mg (0.47 mmol) HOBt, 60 μl (0.47 mmol) Et3N and 100 mg (0.36 mmol) (4-amino-piperidin-1-yl)-(6-chloro-1H-indol-3-yl)-methanone. The mixture was stirred overnight at RT and then poured onto water and extracted with CH2Cl2. The combined organic phases were dried over Na2SO4 and concentrated in vacuo. Flash chromatography (ethyl acetate) afforded 82 mg (57%) N-[1-(6-Chloro-1H-indole-3-carbonyl)-piperidin-4-yl]-2-fluoro-benzamide of as a white solid.
  • ES-MS m/e (%): 400.3 (M+H+).
    • Example 35 1-[1-(1-Cyclohexylmethyl-1H-indole-3-carbonyl)-piperidin-4-yl]-1,3-dihydro-benzoimidazol-2-one
  • Figure US20120040990A1-20120216-C00058
  • Following general procedure I, the coupling of (commercially available) 4-(4-fluoro-phenyl)-piperidine with 1-benzyl-2-methyl-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 427.6 (M+H+).
    • Example 36 (6-Chloro-1H-indol-3-yl)-[4-(4-chloro-phenyl)-4-hydroxy-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00059
  • Following general procedure I, the coupling of (commercially available) 4-(4-chloro-phenyl)-piperidin-4-ol with 6-chloro-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 389.4 (M+H+).
    • Example 37 (6-Chloro-1H-indol-3-yl)-[4-(4-nitro-phenyl)-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00060
  • Following general procedure I, the coupling of (commercially available) 4-(4-nitro-phenyl)-piperidine with 6-chloro-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 384.4 (M+H+).
    • Example 38 (6-Chloro-1H-indol-3-yl)-[4-(3-chloro-phenyl)-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00061
  • Following general procedure I, the coupling of (commercially available) 4-(3-chloro-phenyl)-piperidine with 6-chloro-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 373.3 (M+H+).
    • Example 39 (6-Chloro-1H-indol-3-yl)-[4-(2-hydroxy-phenyl)-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00062
  • Following general procedure I, the coupling of (commercially available) 2-piperidin-4-yl-phenol with 6-chloro-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 355.4 (M+H+).
    • Example 40 (6-Chloro-1H-indol-3-yl)-[4-(2,6-dimethoxy-phenyl)-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00063
  • Following general procedure I, the coupling of (commercially available) 4-(2,6-dimethoxy-phenyl)-piperidine with 6-chloro-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 399.2 (M+H+).
    • Example 41 (6-Chloro-1H-indol-3-yl)-[4-(4-fluoro-phenyl)-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00064
  • Following general procedure I, the coupling of (commercially available) 4-(4-fluoro-phenyl)-piperidine with 6-chloro-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 357.4 (M+H+).
    • Example 42 (6-Chloro-1H-indol-3-yl)-(4-methoxy-4-phenyl-piperidin-1-yl)-methanone
  • Figure US20120040990A1-20120216-C00065
  • Following general procedure I, the coupling of 4-methoxy-4-phenyl-piperidine (described in WO 9800400) with 6-chloro-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 369.4 (M+H+).
    • Example 43 2-{6-Chloro-3-[4-(2,6-dimethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide
  • Figure US20120040990A1-20120216-C00066
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2,6-dimethoxy-phenyl)-piperidin-1-yl]-methanone (preparation described herein), with commercially available 2-chloro-N,N-dimethyl-acetamide gave the title compound.
  • ES-MS m/e (%): 484.3 (M+H+).
    • Example 44 2-{6-Chloro-3-[4-(2,6-dimethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-1-pyridin-2-yl-ethanone
  • Figure US20120040990A1-20120216-C00067
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2,6-dimethoxy-phenyl)-piperidin-1-yl]-methanone (preparation described herein), with commercially available 2-chloro-1-pyridin-2-yl-ethanone gave the title compound.
  • ES-MS m/e (%): 518.4 (M+H+).
    • Example 45 (6-Chloro-1-pyridin-4-ylmethyl-1H-indol-3-yl)-[4-(2,6-dim ethoxy-phenyl)-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00068
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2,6-dimethoxy-phenyl)-piperidin-1-yl]-methanone (preparation described herein), with commercially available 4-chloromethyl-pyridine gave the title compound.
  • ES-MS m/e (%): 490.3 (M+H+).
    • Example 46 (6-Chloro-1-pyridin-3-ylmethyl-1H-indol-3-yl)-[4-(2,6-dim ethoxy-phenyl)-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00069
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2,6-dimethoxy-phenyl)-piperidin-1-yl]-methanone (preparation described herein), with commercially available 3-chloromethyl-pyridine gave the title compound.
  • ES-MS m/e (%): 490.3 (M+H+).
    • Example 47 (6-Chloro-1-pyridin-2-ylmethyl-1H-indol-3-yl)-[4-(2,6-dim ethoxy-phenyl)-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00070
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2,6-dimethoxy-phenyl)-piperidin-1-yl]-methanone (preparation described herein), with methanesulfonic acid pyridin-2-ylmethyl ester (described in WO 9955318) gave the title compound.
  • ES-MS m/e (%): 490.3 (M+H+).
    • Example 48 [6-Chloro-1-(6-chloro-pyridin-3-ylmethyl)-1H-indol-3-yl]-[4-(2,6-dimethoxy-phenyl)-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00071
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2,6-dimethoxy-phenyl)-piperidin-1-yl]-methanone (preparation described herein), with methanesulfonic acid 6-chloro-pyridin-3-ylmethyl ester (described in Journal of Organic Chemistry (1999), 64(23), 8576-8581) gave the title compound.
  • ES-MS m/e (%): 524.2 (M+H+).
    • Example 49 {6-Chloro-3-[4-(2,6-dimethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid tert-butyl ester
  • Figure US20120040990A1-20120216-C00072
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2,6-dimethoxy-phenyl)-piperidin-1-yl]-methanone (preparation described herein), with (commercially available) bromo-acetic acid tert-butyl ester gave the title compound.
  • ES-MS m/e (%): 513.3 (M+H+).
    • Example 50 6-Chloro-1-pyrazin-2-ylmethyl-1H-indol-3-yl)-[4-(2,6-dimethoxy-phenyl)-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00073
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2,6-dimethoxy-phenyl)-piperidin-1-yl]-methanone (preparation described herein), with methanesulfonic acid pyrazin-2-ylmethyl ester (described in WO 2002064574) gave the title compound.
  • ES-MS m/e (%): 491.1 (M+H+).
    • Example 51 [6-Chloro-1-(3,5-difluoro-benzyl)-1H-indol-3-yl]-[4-(2,6-dimethoxy-phenyl)-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00074
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2,6-dimethoxy-phenyl)-piperidin-1-yl]-methanone (preparation described herein), with (commercially available) 1-chloromethyl-3,5-difluoro-benzene gave the title compound.
  • ES-MS m/e (%): 525.3 (M+H+).
    • Example 52 [6-Chloro-1-(2-dimethylamino-ethyl)-1H-indol-3-yl]-[4-(2,6-dimethoxy-phenyl)-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00075
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2,6-dimethoxy-phenyl)-piperidin-1-yl]-methanone (preparation described herein), with (commercially available) (2-chloro-ethyl)-dimethyl-amine gave the title compound.
  • ES-MS m/e (%): 470.5 (M+H+).
    • Example 53 (6-Chloro-1H-indol-3-yl)-[4-(2-isopropoxy-phenyl)-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00076
  • Following general procedure I, the coupling of 4-(2-isopropoxy-phenyl)-piperidine (described in Journal of Medicinal Chemistry (1998), 41(12), 1997-2009) with 6-chloro-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 397.1 (M+H+).
    • Example 54 (6-Chloro-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00077
  • Following general procedure I, the coupling of (commercially available) 4-(2-methoxy-phenyl)-piperidine with 6-chloro-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 367.0 (M+H+).
    • Example 55 2-{6-Chloro-3-[4-(2,6-dimethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-1-(4-methyl-piperazin-1-yl)-ethanone
  • Figure US20120040990A1-20120216-C00078
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2,6-dimethoxy-phenyl)-piperidin-1-yl]-methanone (preparation described herein), with (commercially available) 2-chloro-1-(4-methyl-piperazin-1-yl)-ethanone gave the title compound.
  • ES-MS m/e (%): 539.6 (M+H+).
    • Example 56 [6-Chloro-1-(3,5-difluoro-benzyl)-1H-indol-3-yl]-[4-(2-methoxy-phenyl)-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00079
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-piperidin-1-yl]-methanone (preparation described herein), with (commercially available) 1-chloromethyl-3,5-difluoro-benzene gave the title compound.
  • ES-MS m/e (%): 495.2 (M+H+).
    • Example 57 2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide
  • Figure US20120040990A1-20120216-C00080
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-piperidin-1-yl]-methanone (preparation described herein), with (commercially available) 2-chloro-N,N-dimethyl-acetamide gave the title compound.
  • ES-MS m/e (%): 454.3 (M+H+).
    • Example 58 2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-1-(4-methyl-piperazin-1-yl)-ethanone
  • Figure US20120040990A1-20120216-C00081
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-piperidin-1-yl]-methanone (preparation described herein), with (commercially available) 2-chloro-1-(4-methyl-piperazin-1-yl)-ethanone gave the title compound.
  • ES-MS m/e (%): 509.3 (M+H+).
    • Example 59 {6-Chloro-3-[4-(2-methoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid tert-butyl ester
  • Figure US20120040990A1-20120216-C00082
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-piperidin-1-yl]-methanone (preparation described herein), with (commercially available) bromo-acetic acid tert-butyl ester gave the title compound.
  • ES-MS m/e (%): 483.3 (M+H+).
    • Example 60 2-{6-Chloro-3-[4-cyano-4-(2-methoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide
  • Figure US20120040990A1-20120216-C00083
  • Amide coupling according to general procedure I:
  • Amine: 4-(2-Methoxy-phenyl)-piperidine-4-carbonitrile (described in WO2003053361),
    Acid: 6-Chloro-1-dimethylcarbamoylmethyl-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 479.1 (M+H+).
    • Example 61 2-{6-Chloro-3-[4-cyano-4-(2-fluoro-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide
  • Figure US20120040990A1-20120216-C00084
  • Amide coupling according to general procedure I:
  • Amine: 4-(2-Fluoro-phenyl)-piperidine-4-carbonitrile (described in Tetrahedron 2004, 4875),
    Acid: 6-Chloro-1-dimethylcarbamoylmethyl-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 467.1 (M+H+).
    • Example 62 2-{3-[4-(2,6-Dimethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide
  • Figure US20120040990A1-20120216-C00085
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2,6-dimethoxy-phenyl)-piperidin-1-yl]-methanone (preparation described herein), with (commercially available) 2-chloro-N,N-dimethyl-acetamide gave the title compound.
  • ES-MS m/e (%): 450.6 (M+H+).
    • Example 63 [6-Chloro-1-(2-methyl-pyridin-4-ylmethyl)-1H-indol-3-yl]-[4-(2,6-dimethoxy-phenyl)-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00086
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2,6-dimethoxy-phenyl)-piperidin-1-yl]-methanone (preparation described herein), with methanesulfonic acid 2-methyl-pyridin-4-ylmethyl ester (prepared by mesylation of the commercially available (2-methyl-pyridin-4-yl)-methanol) gave the title compound.
  • ES-MS m/e (%): 504.1 (M+H+).
    • Example 64 2-{3-[4-(2,6-Dimethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-1-(4-methyl-piperazin-1-yl)-ethanone
  • Figure US20120040990A1-20120216-C00087
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2,6-dimethoxy-phenyl)-piperidin-1-yl]-methanone (preparation described herein), with (commercially available) 2-chloro-1-(4-methyl-piperazin-1-yl)-ethanone gave the title compound.
  • ES-MS m/e (%): 505.4 (M+H+).
    • Example 65 2-{6-Chloro-3-[4-(2,6-dimethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N-(2-dimethylamino-ethyl)-acetamide {6-Chloro-3-[4-(2,6-dimethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2,6-dimethoxy-phenyl)-piperidin-1-yl]-methanone (preparation described herein), with (commercially available) bromo-acetic acid gave the title compound.
  • ES-MS m/e (%): 457.5 (M+H+).
    • 2-{6-Chloro-3-[4-(2,6-dimethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N-(2-dimethylamino-ethyl)-acetamide
  • Figure US20120040990A1-20120216-C00088
  • Analogous to general procedure I, the coupling of {6-chloro-3-[4-(2,6-dimethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid with (commercially available) N1,N1-dimethyl-ethane-1,2-diamine gave the title compound.
  • ES-MS m/e (%): 527.3 (M+H+).
    • Example 66 2-{6-Chloro-3-[4-(2-isopropoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide
  • Figure US20120040990A1-20120216-C00089
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-isopropoxy-phenyl)-piperidin-1-yl]-methanone (preparation described herein), with (commercially available) 2-chloro-N,N-dimethyl-acetamide gave the title compound.
  • ES-MS m/e (%): 482.6 (M+H+).
    • Example 67 2-{6-Chloro-3-[4-(2-isopropoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-1-(4-methyl-piperazin-1-yl)-ethanone
  • Figure US20120040990A1-20120216-C00090
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-isopropoxy-phenyl)-piperidin-1-yl]-methanone (preparation described herein), with (commercially available) 2-chloro-1-(4-methyl-piperazin-1-yl)-ethanone gave the title compound.
  • ES-MS m/e (%): 537.6 (M+H+).
    • Example 68 2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-1-piperazin-1-yl-ethanone {6-Chloro-3-[4-(2-methoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-piperidin-1-yl]-methanone (preparation described herein), with (commercially available) bromo-acetic acid gave the title compound.
  • ES-MS m/e (%): 427.5 (M+H+).
    • 2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-1-piperazin-1-yl-ethanone
  • Figure US20120040990A1-20120216-C00091
  • Analogous to general procedure I, the coupling of {6-chloro-3-[4-(2-methoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid with (commercially available) piperazine-1-carboxylic acid tert-butyl ester gave, after treatment with TFA and neutralisation, the title compound.
  • ES-MS m/e (%): 495.5 (M+H+).
    • Example 69 2-{6-Chloro-3-[4-(2,6-dimethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-1-piperazin-1-yl-ethanone
  • Figure US20120040990A1-20120216-C00092
  • Analogous to general procedure I, the coupling of {6-chloro-3-[4-(2,6-dimethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid (prepared herein) with (commercially available) piperazine-1-carboxylic acid tert-butyl ester gave, after treatment with TFA and neutralisation, the title compound.
  • ES-MS m/e (%): 525.5 (M+H+).
    • Example 70 (6-Chloro-1H-indol-3-yl)-[4-(2,3-dihydro-benzofuran-7-yl)-piperidin-1-yl]-methanone 4-(5-Bromo-2,3-dihydro-benzofuran-7-yl)-pyridine
  • 4-Bromopyridine or hydrochloride salt thereof was dissolved in DME under argon and Pd(Ph3P)4 (3 mol %) was added. The mixture was stirred for 10 min at 50° C. To this solution was added (commercially available) 5-bromo-2,3-dihydrobenzo[b]furan-7-boronic acid dissolved in a minimum amount of EtOH/DME 1:2 followed by 2N Na2CO3. The reaction mixture was refluxed (110° C.) under stirring for 2 h. The flask was cooled to RT, the mixture was treated with sat. aq. NH4Cl solution and extracted with CHCl3. Evaporation and purification by SiO2 gel chromatography (hexane/ethyl acetate: 4/1) gave the title compound in 76% yield.
  • ES-MS m/e (%): 275.9 (M+H+).
    • 1-Benzyl-4-(5-bromo-2,3-dihydro-benzofuran-7-yl)-1,2,3,6-tetrahydro-pyridine
  • To a solution of 4-(5-bromo-2,3-dihydro-benzofuran-7-yl)-pyridine in toluene was added benzyl bromide (1 eq.) and the reaction mixture was stirred under reflux for 14 h. Reaction was monitored by TLC (CH2Cl2/MeOH 95:5) and revealed total conversion to an intermediate. Complete evaporation of the solvent gave a white solid. The solid was dissolved in MeOH under argon and cooled down to 0° C., NaBH4 (2.05 eq.) was added portion-wise (exothermic reaction) and the reaction mixture was stirred for 3 h at RT. Evaporation of MeOH, redissolution in CH2Cl2 and sequential washing with 1N NaHCO3 and brine, followed by purification by SiO2 gel chromatography (CH2Cl2/MeOH: 98/2) gave 71% yield of the title compound.
  • ES-MS m/e (%): 370.0 (M+H+).
    • 4-(2,3-Dihydro-benzofuran-7-yl)-piperidine
  • To a solution of 1-benzyl-4-(5-bromo-2,3-dihydro-benzofuran-7-yl)-1,2,3,6-tetrahydro-pyridine in EtOH and 4N HCl was added 40 wt % of 10% Pd/C catalyst. The reaction flask was charged with H2 (3.5 bar) and then stirred overnight at 50° C. The reaction mixture was filtered over Celite under argon. The solvents were evaporated and the product was partitioned between CH2Cl2 and aq. K2CO3. The organic phase was dried over Na2SO4 and evaporated to give the title compound in 81% yield.
  • ES-MS m/e (%): 204.3 (M+H+).
    • (6-Chloro-1H-indol-3-yl)-[4-(2,3-dihydro-benzofuran-7-yl)-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00093
  • Following general procedure I, the coupling of 4-(2,3-dihydro-benzofuran-7-yl)-piperidine (described herein below) with 6-chloro-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 381.1 (M+H+).
    • Example 71 2-{6-Chloro-3-[4-(2,3-dihydro-benzofuran-7-yl)-piperidine-1-carbonyl]-indol-1-yl}-1-(4-methyl-piperazin-1-yl)-ethanone
  • Figure US20120040990A1-20120216-C00094
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2,3-dihydro-benzofuran-7-yl)-piperidin-1-yl]-methanone (preparation described herein), with (commercially available) 2-chloro-1-(4-methyl-piperazin-1-yl)-ethanone gave the title compound.
  • ES-MS m/e (%): 521.6 (M+H+).
    • Example 72 2-{6-Chloro-3-[4-(2,3-dihydro-benzofuran-7-yl)-piperidine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide
  • Figure US20120040990A1-20120216-C00095
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2,3-dihydro-benzofuran-7-yl)-piperidin-1-yl]-methanone (preparation described herein), with (commercially available) 2-chloro-N,N-dimethyl-acetamide gave the title compound.
  • ES-MS m/e (%): 466.6 (M+H+).
    • Example 73 2-{6-Chloro-3-[4-(2,3-dihydro-benzofuran-7-yl)-piperidine-1-carbonyl]-indol-1-yl}-N-(2-dimethylamino-ethyl)-acetamide {6-Chloro-3-[4-(2,3-dihydro-benzofuran-7-yl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2,3-dihydro-benzofuran-7-yl)-piperidin-1-yl]-methanone (preparation described herein), with (commercially available) bromo-acetic acid gave the title compound.
  • ES-MS m/e (%): 437.1 (M−H+).
    • 2-{6-Chloro-3-[4-(2,3-dihydro-benzofuran-7-yl)-piperidine-1-carbonyl]-indol-1-yl}-N-(2-dimethylamino-ethyl)-acetamide
  • Figure US20120040990A1-20120216-C00096
  • Analogous to general procedure I, the coupling of {6-chloro-3-[4-(2,3-dihydro-benzofuran-7-yl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid with (commercially available) N1,N1-dimethyl-ethane-1,2-diamine gave the title compound.
  • ES-MS m/e (%): 509.6 (M+H+).
    • Example 74 2-{6-Chloro-3-[4-(2,3-dihydro-benzofuran-7-yl)-piperidine-1-carbonyl]-indol-1-yl}-1-piperazin-1-yl-ethanone
  • Figure US20120040990A1-20120216-C00097
  • Analogous to general procedure I, the coupling of {6-chloro-3-[4-(2,3-dihydro-benzofuran-7-yl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid (prepared described herein) with (commercially available) piperazine-1-carboxylic acid tert-butyl ester gave, after treatment with TFA and neutralisation, the title compound.
  • ES-MS m/e (%): 507.0 (M+H+).
    • Example 75 2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperidine-1-carbonyl]-5-methyl-indol-1-yl}-N,N-dimethyl-acetamide
  • Figure US20120040990A1-20120216-C00098
  • Amide coupling according to general procedure I:
  • Amine: 4-(2-Methoxy-phenyl)-piperidine (commercially available),
    Acid: 6-Chloro-1-dimethylcarbamoylmethyl-5-methyl-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 468.3 (M+H+).
    • Example 76 2-{6-Chloro-3-[4-(2,3-dihydro-benzofuran-7-yl)-piperidine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide
  • Figure US20120040990A1-20120216-C00099
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2,3-dihydro-benzofuran-7-yl)-piperidin-1-yl]-methanone (preparation described herein), with (commercially available) 2-chloro-N-methyl-acetamide gave the title compound.
  • ES-MS m/e (%): 451.7 (M+H+).
    • Example 77 N-(2-Amino-ethyl)-2-{6-chloro-3-[4-(2,3-dihydro-benzofuran-7-yl)-piperidine-1-carbonyl]-indol-1-yl}-acetamide
  • Figure US20120040990A1-20120216-C00100
  • Analogous to general procedure I, the coupling of {6-chloro-3-[4-(2,3-dihydro-benzofuran-7-yl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid (prepared herein) with (commercially available) (2-amino-ethyl)-carbamic acid tert-butyl ester gave, after treatment with HCl and neutralisation, the title compound.
  • ES-MS m/e (%): 481.3 (M+H+).
    • Example 78 2-{6-Chloro-3-[4-(2,3-dihydro-benzofuran-7-yl)-piperidine-1-carbonyl]-indol-1-yl}-acetamide
  • Figure US20120040990A1-20120216-C00101
  • Analogous to general procedure I, the coupling of {6-chloro-3-[4-(2,3-dihydro-benzofuran-7-yl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid (prepared herein) with (commercially available) ammonia in THF, gave the title compound.
  • ES-MS m/e (%): 438.2 (M+H+).
    • Example 79 2-{6-Chloro-3-[4-(2,3-dihydro-benzofuran-7-yl)-piperidine-1-carbonyl]-indol-1-yl}-N-(2-methylamino-ethyl)-acetamide
  • Figure US20120040990A1-20120216-C00102
  • Analogous to general procedure I, the coupling of {6-chloro-3-[4-(2,3-dihydro-benzofuran-7-yl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid (prepared herein) with (commercially available) (2-amino-ethyl)-methyl-carbamic acid tert-butyl ester gave, after treatment with TFA and neutralisation, the title compound.
  • ES-MS m/e (%): 495.5 (M+H+).
    • Example 80 2-{5,6-Dichloro-3-[4-(2-methoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide
  • Figure US20120040990A1-20120216-C00103
  • Amide coupling according to general procedure I:
  • Amine: 4-(2-Methoxy-phenyl)-piperidine (commercially available),
    Acid: 5,6-Dichloro-1-dimethylcarbamoylmethyl-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 488.5 (M+H+).
    • Example 81 2-{6-Chloro-3-[4-(2,6-dimethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetamide
  • Figure US20120040990A1-20120216-C00104
  • Analogous to general procedure I, the coupling of {6-chloro-3-[4-(2,6-dimethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid (prepared herein) with (commercially available) ammonia in THF gave the title compound.
  • ES-MS m/e (%): 456.2 (M+H+).
    • Example 82 2-{6-Chloro-3-[4-(2,6-dimethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide
  • Figure US20120040990A1-20120216-C00105
  • Analogous to general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2,6-dimethoxy-phenyl)-piperidin-1-yl]-methanone (prepared herein) with (commercially available) 2-chloro-N-methyl-acetamide gave the title compound.
  • ES-MS m/e (%): 470.2 (M+H+).
    • Example 83 2-{6-Chloro-3-[4-(2,6-dimethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N-(2-methylamino-ethyl)-acetamide
  • Figure US20120040990A1-20120216-C00106
  • Analogous to general procedure I, the coupling of {6-chloro-3-[4-(2,6-dimethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid (prepared herein) with (commercially available) (2-amino-ethyl)-methyl-carbamic acid tert-butyl ester gave, after treatment with TFA and neutralisation, the title compound.
  • ES-MS m/e (%): 513.5 (M+H+).
    • Example 84 N-(2-Amino-ethyl)-2-{6-chloro-3-[4-(2,6-dimethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetamide
  • Figure US20120040990A1-20120216-C00107
  • Analogous to general procedure I, the coupling of {6-chloro-3-[4-(2,6-dimethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid (prepared herein) with (commercially available) (2-amino-ethyl)-carbamic acid tert-butyl ester gave, after treatment with HCl and neutralisation, the title compound.
  • ES-MS m/e (%): 499.5 (M+H+).
    • Example 85 (6-Chloro-1H-indol-3-yl)-[4-(2-trifluoromethoxy-phenyl)-piperidin-1-yl]-methanone 4-(2-Trifluoromethoxy-phenyl)-pyridine
  • To a solution of (commercially available) (1-bromo-2-trifluoromethoxy-benzene) in DME (first degased with argon) under argon was added 3 mol % Pd(PPh3)4, pyridyl-4-boronic acid and 2N Na2CO3, the resulting reaction mixture was vigorously stirred under reflux. After 5 h at reflux, reaction as monitored by TLC showed completion. Two phases were separated, evaporation of most of the DME, redissolution of the residue in EtOAc and washing with aq. NaOH followed by evaporation gave a yellow oil. Flash Chromatography on SiO2 gel with a mixture of CH2Cl2/MeOH gave the title compound in 51% yield.
  • ES-MS m/e (%): 239.9 (M+H+).
    • 1-Benzyl-4-(2-trifluoromethoxy-phenyl)-1,2,3,6-tetrahydro-pyridine
  • To a solution of 4-(2-trifluoromethoxy-phenyl)-pyridine in toluene was added (1 eq.) benzyl bromide, and reaction mixture was stirred under reflux for 2 h. Reaction was monitored by TLC (CH2Cl2/MeOH 95:5) and revealed total conversion to the first intermediate. Complete evaporation of solvent gave a white solid which was pure enough to carry out the next step. The white solid was dissolved in MeOH under argon and cooled down to 0° C., (4 eq.) NaBH4 was added portion-wise (exothermic reaction). The reaction mixture was then stirred for 3 h at RT, reaction again monitored by TLC (CH2Cl2/MeOH 95:5) and revealed total conversion. Evaporation of MeOH, redissolution in CH2Cl2, and washing with 1N NaHCO3 then brine, and evaporation, followed by SiO2 gel chromatography (CH2Cl2/MeOH) gave the title compound in 61% yield.
  • ES-MS m/e (%): 334.3 (M+H+).
    • 4-(2-Trifluoromethoxy-phenyl)-piperidine
  • To a solution of 1-benzyl-4-(2-trifluoromethoxy-phenyl)-1,2,3,6-tetrahydro-pyridine
  • (described herein below) in EtOH was added (0.2 wt %) 10% Pd/C, followed by (5 eq.) TFA in a sealed tube. The reaction mixture was stirred at 50° C. under 3.0 bar of H2 for 12 h. The reaction mixture was filtered over Celite and the filtrate evaporated down to dryness. Redissolution in EtOAc, washing with 1N NaHCO3 and concentration gave the crude product which was directly used for the next step.
  • ES-MS m/e (%): 246.6 (M+H+).
    • (6-Chloro-1H-indol-3-yl)-[4-(2-trifluoromethoxy-phenyl)-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00108
  • Following general procedure I, the coupling of 4-(2-trifluoromethoxy-phenyl)-piperidine with 6-chloro-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 423.3 (M+H+).
    • Example 86 (6-Chloro-1H-indol-3-yl)-[4-(2-trifluoromethyl-phenyl)-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00109
  • Following general procedure I, the coupling of (commercially available) 4-(2-trifluoromethyl-phenyl)-piperidine (described herein) with 6-chloro-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 407.1 (M+H+).
    • Example 87 [6-Chloro-1-(2-dimethylamino-ethyl)-1H-indol-3-yl]-[4-(2,3-dihydro-benzofuran-7-yl)-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00110
  • Analogous to general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2,3-dihydro-benzofuran-7-yl)-piperidin-1-yl]-methanone (prepared herein) with (commercially available) (2-chloro-ethyl)-dimethyl-amine gave the title compound.
  • ES-MS m/e (%): 452.2 (M+H+).
    • Example 88 2-{6-Chloro-3-[4-(2-trifluoromethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-1-(4-methyl-piperazin-1-yl)-ethanone
  • Figure US20120040990A1-20120216-C00111
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-trifluoromethoxy-phenyl)-piperidin-1-yl]-methanone (preparation described herein), with (commercially available) 2-chloro-1-(4-methyl-piperazin-1-yl)-ethanone gave the title compound.
  • ES-MS m/e (%): 563.3 (M+H+).
    • Example 89 2-{6-Chloro-3-[4-(2-trifluoromethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N-(2-dimethylamino-ethyl)-acetamide {6-Chloro-3-[4-(2-trifluoromethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-trifluoromethoxy-phenyl)-piperidin-1-yl]-methanone (preparation described herein), with (commercially available) bromo-acetic acid gave the title compound.
  • ES-MS m/e (%): 481.3 (M+H+).
    • 2-{6-Chloro-3-[4-(2-trifluoromethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N-(2-dimethylamino-ethyl)-acetamide
  • Figure US20120040990A1-20120216-C00112
  • Analogous to general procedure I, the coupling of {6-chloro-3-[4-(2-trifluoromethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid (prepared herein) with (commercially available) N1,N1-dimethyl-ethane-1,2-diamine gave the title compound.
  • ES-MS m/e (%): 551.5 (M+H+).
    • Example 90 2-{6-Chloro-3-[4-(2-trifluoromethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide
  • Figure US20120040990A1-20120216-C00113
  • Analogous to general procedure I, the coupling of (6-chloro-1H-indol-3-yl)-[4-(2-trifluoromethoxy-phenyl)-piperidin-1-yl]-methanone (prepared herein) with (commercially available) 2-chloro-N-methyl-acetamide gave the title compound.
  • ES-MS m/e (%): 494.5 (M+H+).
    • Example 91 2-{6-Chloro-3-[4-(2-trifluoromethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetamide
  • Figure US20120040990A1-20120216-C00114
  • Analogous to general procedure I, the coupling of {6-chloro-3-[4-(2-trifluoromethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid (prepared herein) with (commercially available) ammonia in THF, gave the title compound.
  • ES-MS m/e (%): 480.3 (M+H+).
    • Example 92 2-{6-Chloro-3-[4-(2-trifluoromethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-1-piperazin-1-yl-ethanone
  • Figure US20120040990A1-20120216-C00115
  • Analogous to general procedure I, the coupling of {6-chloro-3-[4-(2-trifluoromethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid (prepared described herein) with (commercially available) piperazine-1-carboxylic acid tert-butyl ester gave, after treatment with TFA and neutralisation, the title compound.
  • ES-MS m/e (%): 548.7 (M+H+).
    • Example 93 2-{6-Chloro-3-[4-(2-trifluoromethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N-(2-methylamino-ethyl)-acetamide
  • Figure US20120040990A1-20120216-C00116
  • Analogous to general procedure I, the coupling of {6-chloro-3-[4-(2-trifluoromethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid (prepared described herein) with (commercially available) (2-amino-ethyl)-methyl-carbamic acid tert-butyl ester gave, after treatment with TFA and neutralisation, the title compound.
  • ES-MS m/e (%): 536.7 (M+H+).
    • Example 94 N-(2-Amino-ethyl)-2-{6-chloro-3-[4-(2-trifluoromethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetamide
  • Figure US20120040990A1-20120216-C00117
  • Analogous to general procedure I, the coupling of {6-chloro-3-[4-(2-trifluoromethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid (prepared described herein) with (commercially available) (2-amino-ethyl)-carbamic acid tert-butyl ester gave, after treatment with HCl and neutralisation, the title compound.
  • ES-MS m/e (%): 522.7 (M+H+).
    • Example 95 2-{6-Chloro-3-[4-(2-trifluoromethoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide
  • Figure US20120040990A1-20120216-C00118
  • Analogous to general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-trifluoromethoxy-phenyl)-piperidin-1-yl]-methanone (prepared herein) with (commercially available) 2-chloro-N,N-dimethyl-acetamide gave the title compound.
  • ES-MS m/e (%): 508.4 (M+H+).
    • Example 96 2-{6-Chloro-3-[4-(2-trifluoromethyl-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide
  • Figure US20120040990A1-20120216-C00119
  • Analogous to general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-trifluoromethyl-phenyl)-piperidin-1-yl]-methanone (prepared herein) with (commercially available) 2-chloro-N-methyl-acetamide gave the title compound.
  • ES-MS m/e (%): 477.7 (M+H+).
    • Example 97 2-{6-Chloro-3-[4-(2-trifluoromethyl-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-1-(4-methyl-piperazin-1-yl)-ethanone
  • Figure US20120040990A1-20120216-C00120
  • Analogous to general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-trifluoromethyl-phenyl)-piperidin-1-yl]-methanone (prepared herein) with (commercially available) 2-chloro-1-(4-methyl-piperazin-1-yl)-ethanone gave the title compound.
  • ES-MS m/e (%): 546.8 (M+H+).
    • Example 98 2-{6-Chloro-3-[4-(2-trifluoromethyl-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetamide {6-Chloro-3-[4-(2-trifluoromethyl-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-trifluoromethyl-phenyl)-piperidin-1-yl]-methanone (preparation described herein), with (commercially available) bromo-acetic acid gave the title compound.
  • ES-MS m/e (%): 481.3 (M+H+).
    • 2-{6-Chloro-3-[4-(2-trifluoromethyl-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetamide
  • Figure US20120040990A1-20120216-C00121
  • Analogous to general procedure I, the coupling of {6-chloro-3-[4-(2-trifluoromethyl-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid with (commercially available) ammonia in THF, gave the title compound.
  • ES-MS m/e (%): 464.6 (M+H+).
    • Example 99 2-{6-Chloro-3-[4-(2-trifluoromethyl-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-1-piperazin-1-yl-ethanone hydrochloride
  • Figure US20120040990A1-20120216-C00122
  • Analogous to general procedure I, the coupling of {6-chloro-3-[4-(2-trifluoromethyl-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid (prepared herein) with (commercially available) piperazine-1-carboxylic acid tert-butyl ester gave, after treatment with HCl, the title compound.
  • ES-MS m/e (%): 532.7 (M+H+).
    • Example 100 2-{6-Chloro-3-[4-(2-trifluoromethyl-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N-(2-methylamino-ethyl)-acetamide hydrochloride
  • Figure US20120040990A1-20120216-C00123
  • Analogous to general procedure I, the coupling of {6-chloro-3-[4-(2-trifluoromethyl-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid (prepared herein) with (commercially available) (2-amino-ethyl)-methyl-carbamic acid tert-butyl ester gave, after treatment with HCl the title compound.
  • ES-MS m/e (%): 521.3 (M+H+).
    • Example 101 N-(2-Amino-ethyl)-2-{6-chloro-3-[4-(2-trifluoromethyl-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetamide hydrochloride
  • Figure US20120040990A1-20120216-C00124
  • Analogous to general procedure I, the coupling of {6-chloro-3-[4-(2-trifluoromethyl-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid (prepared herein) with (commercially available) (2-amino-ethyl)-carbamic acid tert-butyl ester gave, after treatment with HCl, the title compound.
  • ES-MS m/e (%): 507.3 (M+H+).
    • Example 102 2-{6-Chloro-3-[4-(2-trifluoromethyl-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide
  • Figure US20120040990A1-20120216-C00125
  • Analogous to general procedure I, the coupling of (6-chloro-1H-indol-3-yl)-[4-(2-trifluoromethyl-phenyl)-piperidin-1-yl]-methanone (prepared herein) with (commercially available) 2-chloro-N,N-dimethyl-acetamide gave the title compound.
  • ES-MS m/e (%): 491.7 (M+H+).
    • Example 103 N-(2-Amino-ethyl)-2-{6-chloro-3-[4-(2-trifluoromethyl-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetamide hydrochloride
  • Figure US20120040990A1-20120216-C00126
  • Analogous to general procedure I, the coupling of {6-chloro-3-[4-(2-trifluoromethyl-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid (prepared herein) with (commercially available) N1,N1-dimethyl-ethane-1,2-diamine, gave the title compound.
  • ES-MS m/e (%): 534.8 (M+H+).
    • Example 104 [1-(2-Amino-ethyl)-6-chloro-1H-indol-3-yl]-[4-(2,3-dihydro-benzofuran-7-yl)-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00127
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2,3-dihydro-benzofuran-7-yl)-piperidin-1-yl]-methanone (preparation described herein), with (commercially available) 2-chloro-ethylamine gave the title compound.
  • ES-MS m/e (%): 424.5 (M+H+).
    • Example 105 [1-(2-Amino-ethyl)-6-chloro-1H-indol-3-yl]-[4-(2-trifluoromethoxy-phenyl)-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00128
  • Analogous to general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-trifluoromethoxy-phenyl)-piperidin-1-yl]-methanone (prepared herein) with (commercially available) 2-chloro-ethylamine gave the title compound.
  • ES-MS m/e (%): 466.4 (M+H+).
    • Example 106 2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide
  • Figure US20120040990A1-20120216-C00129
  • Following general procedure II, the alkylation of (6-Chloro-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-piperidin-1-yl]-methanone (preparation described herein), with (commercially available) 2-chloro-N-methyl-acetamide gave the title compound.
  • ES-MS m/e (%): 440.4 (M+H+).
    • Example 107 [6-Chloro-1-(2-methylamino-ethyl)-1H-indol-3-yl]-[4-(2,3-dihydro-benzofuran-7-yl)-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00130
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2,3-dihydro-benzofuran-7-yl)-piperidin-1-yl]-methanone (preparation described herein), with (commercially available) (2-chloro-ethyl)-methyl-amine gave the title compound.
  • ES-MS m/e (%): 438.4 (M+H+).
    • Example 108 [6-Chloro-1-(2-dimethylamino-ethyl)-1H-indol-3-yl]-[4-(2-methoxy-phenyl)-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00131
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-piperidin-1-yl]-methanone (preparation described herein), with (commercially available) (2-chloro-ethyl)-dimethyl-amine gave the title compound.
  • ES-MS m/e (%): 440.3 (M+H+).
    • Example 109 [6-Chloro-1-(2-methylamino-ethyl)-1H-indol-3-yl]-[4-(2-methoxy-phenyl)-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00132
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-piperidin-1-yl]-methanone (preparation described herein), with (commercially available) (2-chloro-ethyl)-methyl-amine gave the title compound.
  • ES-MS m/e (%): 426.3 (M+H+).
    • Example 110 [1-(2-Amino-ethyl)-6-chloro-1H-indol-3-yl]-[4-(2-methoxy-phenyl)-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00133
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-piperidin-1-yl]-methanone (preparation described herein), with (commercially available) 2-chloro-ethylamine gave the title compound.
  • ES-MS m/e (%): 412.3 (M+H+).
    • Example 111 2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide (6-Chloro-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperidin-1-yl]-methanone
  • Following general procedure I, the coupling of (commercially available) 4-(2-fluoro-phenyl)-piperidine (described herein below) with 6-chloro-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 357.3 (M+H+).
    • 2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide
  • Figure US20120040990A1-20120216-C00134
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperidin-1-yl]-methanone, with (commercially available) 2-chloro-N-methyl-acetamide gave the title compound.
  • ES-MS m/e (%): 428.2 (M+H+).
    • Example 112 [1-(2-Amino-ethyl)-6-chloro-1H-indol-3-yl]-[4-(2-fluoro-phenyl)-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00135
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperidin-1-yl]-methanone (preparation described herein), with (commercially available) 2-chloro-ethylamine gave the title compound.
  • ES-MS m/e (%): 400.1 (M+H+).
    • Example 113 2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetamide {6-Chloro-3-[4-(2-fluoro-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperidin-1-yl]-methanone (preparation described herein), with (commercially available) bromo-acetic acid gave the title compound.
  • ES-MS m/e (%): 413.0 (M−H+).
    • 2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetamide
  • Figure US20120040990A1-20120216-C00136
  • Following general procedure I, the coupling of {6-chloro-3-[4-(2-fluoro-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid, with (commercially available) ammonia in THF gave the title compound.
  • ES-MS m/e (%): 414.2 (M+H+).
    • Example 114 2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide
  • Figure US20120040990A1-20120216-C00137
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperidin-1-yl]-methanone (preparation described herein below), with (commercially available) 2-chloro-N,N-dimethyl-acetamide gave the title compound.
  • ES-MS m/e (%): 442.3 (M+H+).
    • Example 115 [6-Chloro-1-(2-dimethylamino-ethyl)-1H-indol-3-yl]-[4-(2-fluoro-phenyl)-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00138
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperidin-1-yl]-methanone (preparation described herein), with (commercially available) (2-chloro-ethyl)-dimethyl-amine gave the title compound.
  • ES-MS m/e (%): 428.2 (M+H+).
    • Example 116 2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-1-(4-methyl-piperazin-1-yl)-ethanone
  • Figure US20120040990A1-20120216-C00139
  • Following general procedure I, the coupling of {6-chloro-3-[4-(2-fluoro-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid (preparation described herein), with (commercially available) N1,N1-dimethyl-ethane-1,2-diamine gave the title compound.
  • ES-MS m/e (%): 485.2 (M+H+).
    • Example 117 2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-1-(4-methyl-piperazin-1-yl)-ethanone
  • Figure US20120040990A1-20120216-C00140
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperidin-1-yl]-methanone (preparation described herein), with (commercially available) 2-chloro-1-(4-methyl-piperazin-1-yl)-ethanone gave the title compound.
  • ES-MS m/e (%): 497.2 (M+H+).
    • Example 118 2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-1-piperazin-1-yl-ethanone hydrochloride
  • Figure US20120040990A1-20120216-C00141
  • Following general procedure I, the coupling of {6-chloro-3-[4-(2-fluoro-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid (preparation described herein), with (commercially available) piperazine-1-carboxylic acid tert-butyl ester gave, after treatment with HCl, gave the title compound.
  • ES-MS m/e (%): 483.2 (M+H+).
    • Example 119 2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-N-(2-methylamino-ethyl)-acetamide hydrochloride
  • Figure US20120040990A1-20120216-C00142
  • Following general procedure I, the coupling of {6-chloro-3-[4-(2-fluoro-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid (preparation described herein), with (commercially available) (2-amino-ethyl)-methyl-carbamic acid tert-butyl ester gave, after treatment with HCl, the title compound.
  • ES-MS m/e (%): 471.2 (M+H+).
    • Example 120 N-(2-Amino-ethyl)-2-{6-chloro-3-[4-(2-fluoro-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetamide hydrochloride
  • Figure US20120040990A1-20120216-C00143
  • Following general procedure I, the coupling of {6-chloro-3-[4-(2-fluoro-phenyl)-piperidine-1-carbonyl]-indol-1-yl}-acetic acid (preparation described herein), with (commercially available) (2-amino-ethyl)-carbamic acid tert-butyl ester gave, after treatment with HCl the title compound.
  • ES-MS m/e (%): 457.2 (M+H+).
    • Example 121 (6-Chloro-1H-indol-3-yl)-(3,4,5,6-tetrahydro-2H-[4,4]bipyridinyl-1-yl)-methanone
  • Figure US20120040990A1-20120216-C00144
  • Following general procedure I, the coupling of (commercially available) 1,2,3,4,5,6-hexahydro-[4,4′]bipyridinyl with 6-chloro-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 340.1 (M+H+).
    • Example 122 2-[6-Chloro-3-(3,4,5,6-tetrahydro-2H-[4,4]bipyridinyl-1-carbonyl)-indol-1-yl]-N,N-dimethyl-acetamide
  • Figure US20120040990A1-20120216-C00145
  • Following general procedure I, the coupling of (commercially available) 2-piperazin-1-yl-nicotinonitrile with 6-chloro-1-dimethylcarbamoylmethyl-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 425.2 (M+H+).
    • Example 123 (6-Chloro-2-methyl-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00146
  • To a solution of 0.040 g (0.19 mmol) 6-chloro-2-methyl-1H-indole-3-carboxylic acid, 0.069 ml (0.40 mmol) N,N-diisopropylethylamine and 0.061 g (0.19 mmol) 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate in 1 ml dry N,N-dimethylformamide were added 0.038 g (0.20 mmol) 4-(2-methoxy-phenyl)-piperidine at room temperature. After stirring for 1 h the reaction mixture was quenched with 0.5 M aqueous sodium hydroxide solution (20 ml) and extracted with ethyl acetate (2×30 ml). The combined organic layers were washed with water (2×30 ml) and brine (1×30 ml), dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography (n-heptane/ethyl acetate) to give the title compound (0.050 g; 69%) as a white solid.
  • MS m/e (%): 381 (M−H+, 100).
    • Example 124 (6-Chloro-1-methanesulfonyl-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-piperidin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00147
  • To a solution of 0.035 g (0.09 mmol) (6-chloro-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-piperidin-1-yl]-methanone in 2 ml N,N-dimethylformamide were added 0.005 g (0.10 mmol) sodium hydride (50% in oil). After 45′, 0.008 ml (0.10 mmol) methanesulfonyl chloride were added. The reaction mixture was quenched with water after 3 h and extracted with ethyl acetate (2×50 ml). The combined organic layers were washed with water (2×30 ml) and brine (1×30), dried over sodium sulfate and concentrated to dryness. The residue was chromatographed (loaded as a solution in toluene; Flashpac 5 g; n-heptane/ethyl acetate 100:0->75:25) to give the title compound (0.007 g; 17%) as a light yellow solid.
  • MS m/e (%): 447 (M+H+, 100).
    • Example 125 2-{6-Chloro-3-[4-(5-fluoro-benzo[d] isoxazol-3-yl)-piperidine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide
  • Figure US20120040990A1-20120216-C00148
  • Following general procedure I, the coupling of (commercially available) 5-fluoro-3-piperidin-4-yl-benzo[d]isoxazole with 6-chloro-1-methylcarbamoylmethyl-1H-indole-3-carboxylic acid (prepared as described herein) gave the title compound.
  • ES-MS m/e (%): 469.1 (M+H+).
    • Example 126 2-{6-Chloro-3-[4-(2-fluoro-phenyl)-4-hydroxy-piperidine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide
  • Figure US20120040990A1-20120216-C00149
  • Following general procedure I, the coupling of 4-(2-fluoro-phenyl)-piperidin-4-ol (described in WO 2005118587) with 6-chloro-1-methylcarbamoylmethyl-1H-indole-3-carboxylic acid (prepared as described herein) gave the title compound.
  • ES-MS m/e (%): 444.1 (M+H+).
    • Example 127 2-[6-Chloro-3-(3,4,5,6-tetrahydro-2H-[4,4]bipyridinyl-1-carbonyl)-indol-1-yl]-N-methyl-acetamide
  • Figure US20120040990A1-20120216-C00150
  • Following general procedure I, the coupling of (commercially available) 2-piperazin-1-yl-nicotinonitrile with 6-chloro-1-methylcarbamoylmethyl-1H-indole-3-carboxylic acid (prepared as described herein) gave the title compound.
  • ES-MS m/e (%): 411.2 (M+H+).
    • Example 128 10-[4-(2-M ethoxy-phenyl)-piperidine-1-carbonyl]-3,4-dihydro-1H-pyrazino[1,2-a]indole-2-carboxylic acid tert-butyl ester
  • Figure US20120040990A1-20120216-C00151
  • To a solution of 0.10 g (0.32 mmol) 3,4-dihydro-1H-pyrazino[1,2-a]indole-2,10-dicarboxylic acid 2-tert-butyl ester, 0.067 g (0.35 mmol) 4-(2-methoxyphenyl)-piperidine and 0.051 g (0.38 mmol) 1-hydroxybenzotriazole in 3.5 ml N,N-dimethylformamide were added 0.073 g (0.38 mmol) N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride at room temperature. After stirring for 3 h the reaction mixture was diluted with saturated aqueous ammonium chloride solution and extracted with tert-butyl methyl ether (2×50 ml). The combined organic layers were washed with 1 M sodium hydroxide solution (1×30 ml) and water (1×30 ml), dried over sodium sulfate, concentrated in vacuo and purified by flash-chromatography (aminopropyl-modified silica gel, n-heptane/ethyl acetate) to give the title compound (0.087 g, 56%) as a light yellow solid.
  • MS m/e (%): 490 (M+H+, 47).
    • Example 129 [4-(2-M ethoxy-phenyl)-piperidin-1-yl]-(1,2,3,4-tetrahydro-pyrazino[1,2-a]indol-10-yl)-methanone hydrochloride
  • Figure US20120040990A1-20120216-C00152
  • A mixture of 0.085 g (0.17 mmol) 10-[4-(2-methoxy-phenyl)-piperidine-1-carbonyl]-3,4-dihydro-1H-pyrazino[1,2-a]indole-2-carboxylic acid tert-butyl ester and 1.4 ml of a 1.25 M solution of hydrochloric acid (1.7 mmol) in methanol was stirred for 15 min at 50° C. The reaction mixture was concentrated in vacuo to give the title compound (0.072 g, 97%) as a light yellow solid.
  • MS m/e (%): 390 (M+H+, 100).
    • Example 130 [4-(2-M ethoxy-phenyl)-piperidin-1-yl]-(2-methyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indol-10-yl)-methanone
  • Figure US20120040990A1-20120216-C00153
  • A solution of 0.040 g (0.094 mmol) [4-(2-methoxy-phenyl)-piperidin-1-yl]-(1,2,3,4-tetrahydro-pyrazino[1,2-a]indol-10-yl)-methanone hydrochloride, 0.026 ml (0.19 mmol) triethylamine and 0.023 g (0.77 mmol) paraformaldehyde in 2 ml methanol was heated at reflux for 1 h. The reaction mixture was cooled to 0° C. on an ice-water bath and treated with 0.0089 g (0.14 mmol) sodium cyanoborohydride. After completed addition the mixture was allowed to warm to room temperature and stirred for 2 h. Quenching with water and dilution with 2 M aqueous sodium carbonate solution was followed by extraction with dichloromethane (2×50 ml). The combined organic layers were dried over sodium sulfate, concentrated in vacuo and purified by flash-chromatography (aminopropyl-modified silica gel, n-heptane/ethyl acetate) to give the title compound (0.031 g, 82%) as an off-white solid.
  • MS m/e (%): 404 (M+H+, 100).
    • Examples of Compounds of Formula I-c Example 131 Benzyl-2-methyl-1H-indol-3-yl)-(4-phenyl-piperazin-1-yl)-methanone
  • Figure US20120040990A1-20120216-C00154
  • Amide coupling according to general procedure I:
  • Amine: 1-Phenyl-piperazine (commercially available),
    Acid: 1-Benzyl-2-methyl-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 410.6 (M+H+).
    • Example 132 Benzyl-2-methyl-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00155
  • Amide coupling according to general procedure I:
  • Amine: 1-(2-Methoxy-phenyl)-piperazine (commercially available),
    Acid: 1-Benzyl-2-methyl-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 440.6 (M+H+).
    • Example 133 Benzyl-2-methyl-1H-indol-3-yl)-[4-(4-methoxy-phenyl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00156
  • Amide coupling according to general procedure I:
  • Amine: 1-(4-Methoxy-phenyl)-piperazine (commercially available),
    Acid: 1-Benzyl-2-methyl-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 440.6 (M+H+).
    • Example 134
  • Benzyl-2-methyl-1H-indol-3-yl)-[4-(2-chloro-phenyl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00157
  • Amide coupling according to general procedure I:
  • Amine: 1-(2-Chloro-phenyl)-piperazine (commercially available),
    Acid: 1-Benzyl-2-methyl-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 444.5 (M+H+).
    • Example 135 Benzyl-2-methyl-1H-indol-3-yl)-[4-(4-chloro-phenyl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00158
  • Amide coupling according to general procedure I:
  • Amine: 1-(4-Chloro-phenyl)-piperazine (commercially available),
    Acid: 1-Benzyl-2-methyl-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 444.5 (M+H+).
    • Example 136 (6-Chloro-1H-indol-3-yl)-(4-phenyl-piperazin-1-yl)-methanone
  • Figure US20120040990A1-20120216-C00159
  • Amide coupling according to general procedure I:
  • Amine: 1-Phenyl-piperazine (commercially available),
    Acid: 6-chloro-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 340.4 (M+H+).
    • Example 137 (6-Chloro-1H-indol-3-yl)-[4-(2-chloro-6-nitro-phenyl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00160
  • Following general procedure I, the coupling of (commercially available) 1-(2-chloro-6-nitro-phenyl)-piperazine with 6-chloro-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 419.4 (M+H+).
    • Example 138 (6-Chloro-1H-indol-3-yl)-[4-(2,6-dichloro-phenyl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00161
  • Following general procedure I, the coupling of (commercially available) 1-(2,6-dichloro-phenyl)-piperazine with 6-chloro-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 408.4 (M+H+).
    • Example 139 (6-Chloro-1H-indol-3-yl)-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00162
  • Following general procedure I, the coupling of (commercially available) 1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazine with 6-chloro-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 398.4 (M+H+).
    • Example 140 (6-Chloro-1H-indol-3-yl)-[4-(2-nitro-4-trifluoromethyl-phenyl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00163
  • Following general procedure I, the coupling of (commercially available) 1-(2-nitro-4-trifluoromethyl-phenyl)-piperazine with 6-chloro-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 453.4 (M+H+).
    • Example 141 (6-Chloro-1H-indol-3-yl)-[4-(2-chloro-phenyl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00164
  • Following general procedure I, the coupling of (commercially available) 1-(2-chloro-phenyl)-piperazine, with 6-chloro-1H-indole-3-carboxylic acid gave the title compound
  • ES-MS m/e (%): 374.4 (M+H+).
    • Example 142 [4-(2-Amino-6-chloro-phenyl)-piperazin-1-yl]-(6-chloro-1H-indol-3-yl)-methanone
  • Figure US20120040990A1-20120216-C00165
  • Following general procedure I, the coupling of 3-chloro-2-piperazin-1-yl-phenylamine (described in Tetrahedron Letters (2001), 42(9), 1645-1646), with 6-chloro-1H-indole-3-carboxylic acid gave the title compound
  • ES-MS m/e (%): 389.4 (M+H+).
    • Example 143 (6-Chloro-1H-indol-3-yl)-[4-(4-methoxy-phenyl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00166
  • Following general procedure I, the coupling of (commercially available) 1-(4-methoxy-phenyl)-piperazine with 6-chloro-1H-indole-3-carboxylic acid gave the title compound
  • ES-MS m/e (%): 370.4 (M+H+).
    • Example 144 (6-Chloro-1H-indol-3-yl)-[4-(3-methoxy-phenyl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00167
  • Following general procedure I, the coupling of (commercially available) 1-(3-methoxy-phenyl)-piperazine with 6-chloro-1H-indole-3-carboxylic acid gave the title compound
  • ES-MS m/e (%): 370.4 (M+H+).
    • Example 145 (6-Chloro-1H-indol-3-yl)-[4-(2-nitro-phenyl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00168
  • Following general procedure I, the coupling of (commercially available) 1-(2-nitro-phenyl)-piperazine with 6-chloro-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 385.4 (M+H+).
    • Example 146 (6-Chloro-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00169
  • Following general procedure I, the coupling of (commercially available) 1-(2-methoxy-phenyl)-piperazine with 6-chloro-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 370.4 (M+H+).
    • Example 147 (6-Chloro-1H-indol-3-yl)-[4-(4-fluoro-phenyl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00170
  • Following general procedure I, the coupling of (commercially available) 1-(4-fluoro-phenyl)-piperazine with 6-chloro-1H-indole-3-carboxylic acid gave the title compound
  • ES-MS m/e (%): 358.4 (M+H+).
    • Example 148 (6-Chloro-1H-indol-3-yl)-[4-(3-fluoro-phenyl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00171
  • Following general procedure I, the coupling of (commercially available) 1-(3-fluoro-phenyl)-piperazine with 6-chloro-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 358.4 (M+H+).
    • Example 149
  • Chloro-4-[4-(6-chloro-1H-indole-3-carbonyl)-piperazin-1-yl]-benzonitrile
  • Figure US20120040990A1-20120216-C00172
  • Following general procedure I, the coupling of (commercially available) 3-chloro-4-piperazin-1-yl-benzonitrile with 6-chloro-1H-indole-3-carboxylic acid gave the title compound
  • ES-MS m/e (%): 399.4 (M+H+).
    • Example 150 (6-Chloro-1H-indol-3-yl)-[4-(2-ethoxy-phenyl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00173
  • Amide coupling according to general procedure I:
  • Amine: 1-(2-Ethoxy-phenyl)-piperazine (commercially available),
    Acid: 6-Chloro-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 384.0 (M+H+).
    • Example 151 2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide
  • Figure US20120040990A1-20120216-C00174
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-piperazin-1-yl]-methanone (preparation described herein), with (commercially available) 2-chloro-N,N-dimethyl-acetamide gave the title compound.
  • ES-MS m/e (%): 455.2 (M+H+).
    • Example 152 2-{6-Chloro-3-[4-(2-ethoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide
  • Figure US20120040990A1-20120216-C00175
  • Amide coupling according to general procedure I:
  • Amine: 1-(2-Ethoxy-phenyl)-piperazine (commercially available),
    Acid: 6-Chloro-1-dimethylcarbamoylmethyl-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 469.1 (M+H+).
    • Example 153 2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-1-(4-methyl-piperazin-1-yl)-ethanone
  • Figure US20120040990A1-20120216-C00176
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-piperazin-1-yl]-methanone (preparation described herein), with (commercially available) 2-chloro-1-(4-methyl-piperazin-1-yl)-ethanone gave the title compound.
  • ES-MS m/e (%): 510.6 (M+H+).
    • Example 154 2-{6-Chloro-3-[4-(2-ethoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-1-(4-methyl-piperazin-1-yl)-ethanone
  • Figure US20120040990A1-20120216-C00177
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-ethoxy-phenyl)-piperazin-1-yl]-methanone (preparation described herein), with (commercially available) 2-chloro-1-(4-methyl-piperazin-1-yl)-ethanone gave the title compound.
  • ES-MS m/e (%): 524.6 (M+H+).
    • Example 155 2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-(2-dimethylamino-ethyl)-acetamide
  • Figure US20120040990A1-20120216-C00178
  • Analogous to general procedure I, the coupling of {6-chloro-3-[4-(2-methoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-acetic acid (prepared herein) with (commercially available) N1,N1-dimethyl-ethane-1,2-diamine gave the title compound.
  • ES-MS m/e (%): 499.6 (M+H+).
    • Example 156 2-{6-Chloro-3-[4-(2-ethoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-(2-dimethylamino-ethyl)-acetamide
  • Figure US20120040990A1-20120216-C00179
  • Analogous to general procedure I, the coupling of {6-chloro-3-[4-(2-ethoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-acetic acid (prepared herein) with (commercially available) N1,N1-dimethyl-ethane-1,2-diamine gave the title compound.
  • ES-MS m/e (%): 512.6 (M+H+).
    • Example 157 2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-acetamide
  • Figure US20120040990A1-20120216-C00180
  • Analogous to general procedure I, the coupling of {6-chloro-3-[4-(2-methoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-acetic acid (prepared described herein) with (commercially available) ammonia in THF, gave the title compound.
  • ES-MS m/e (%): 427.5 (M+H+).
    • Example 158 2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperidine-1-carbonyl]-5-methyl-indol-1-yl}-N,N-dimethyl-acetamide
  • Figure US20120040990A1-20120216-C00181
  • Amide coupling according to general procedure I:
  • Amine: 1-(2-Methoxy-phenyl)-piperazine (commercially available),
    Acid: 6-Chloro-1-dimethylcarbamoylmethyl-5-methyl-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 469.3 (M+H+).
    • Example 159 2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-1-piperazin-1-yl-ethanone hydrochloride
  • Figure US20120040990A1-20120216-C00182
  • Analogous to general procedure I, the coupling of {6-chloro-3-[4-(2-methoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-acetic acid (prepared described herein) with (commercially available)) piperazine-1-carboxylic acid tert-butyl ester gave, after treatment with HCl, the title compound.
  • ES-MS m/e (%): 496.5 (M+H+).
    • Example 160 2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-(2-methylamino-ethyl)-acetamide hydrochloride
  • Figure US20120040990A1-20120216-C00183
  • Analogous to general procedure I, the coupling of {6-chloro-3-[4-(2-methoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-acetic acid (prepared herein) with (commercially available) (2-amino-ethyl)-methyl-carbamic acid tert-butyl ester gave, after treatment with HCl, the title compound.
  • ES-MS m/e (%): 484.5 (M+H+).
    • Example 161 N-(2-Amino-ethyl)-2-{6-chloro-3-[4-(2-methoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-acetamide hydrochloride {6-Chloro-3-[4-(2-methoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-acetic acid
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-piperazin-1-yl]-methanone (preparation described herein), with (commercially available) bromo-acetic acid gave the title compound.
  • ES-MS m/e (%): 428.5 (M+H+).
    • N-(2-Amino-ethyl)-2-{6-chloro-3-[4-(2-methoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-acetamide hydrochloride
  • Figure US20120040990A1-20120216-C00184
  • Analogous to general procedure I, the coupling of {6-chloro-3-[4-(2-methoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-acetic acid with (commercially available) (2-amino-ethyl)-carbamic acid tert-butyl ester gave, after treatment with HCl, the title compound.
  • ES-MS m/e (%): 470.6 (M+H+).
    • Example 162 2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide
  • Figure US20120040990A1-20120216-C00185
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-piperazin-1-yl]-methanone (preparation described herein), with (commercially available) 2-chloro-N-methyl-acetamide gave the title compound.
  • ES-MS m/e (%): 441.5 (M+H+).
    • Example 163 [6-Chloro-1-(2-dimethylamino-ethyl)-1H-indol-3-yl]-[4-(2-methoxy-phenyl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00186
  • Analogous to general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-piperazin-1-yl]-methanone (prepared herein) with (commercially available) (2-chloro-ethyl)-dimethyl-amine gave the title compound.
  • ES-MS m/e (%): 441.5 (M+H+).
    • Example 164 [1-(2-Amino-ethyl)-6-chloro-1H-indol-3-yl]-[4-(2-methoxy-phenyl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00187
  • Analogous to general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-piperazin-1-yl]-methanone (prepared herein) with (commercially available) 2-chloro-ethylamine gave the title compound.
  • ES-MS m/e (%): 413.4 (M+H+).
    • Example 165 [6-Chloro-1-(2-methylamino-ethyl)-1H-indol-3-yl]-[4-(2-methoxy-phenyl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00188
  • Analogous to general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-piperazin-1-yl]-methanone (prepared herein) with (commercially available) (2-chloro-ethyl)-methyl-amine gave the title compound.
  • ES-MS m/e (%): 427.5 (M+H+).
    • Example 166 [6-Chloro-1-(2-methylamino-ethyl)-1H-indol-3-yl]-[4-(2-ethoxy-phenyl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00189
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-ethoxy-phenyl)-piperazin-1-yl]-methanone (preparation described herein), with (commercially available) (2-chloro-ethyl)-methyl-amine gave the title compound.
  • ES-MS m/e (%): 441.5 (M+H+).
    • Example 167 2-{6-Chloro-3-[4-(2-ethoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-(2-methylamino-ethyl)-acetamide {6-Chloro-3-[4-(2-ethoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-acetic acid
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-ethoxy-phenyl)-piperazin-1-yl]-methanone (preparation described herein), with (commercially available) bromo-acetic acid gave the title compound.
  • ES-MS m/e (%): 440.0 (M+H+).
    • 2-{6-Chloro-3-[4-(2-ethoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-(2-methylamino-ethyl)-acetamide
  • Figure US20120040990A1-20120216-C00190
  • Analogous to general procedure I, the coupling of {6-chloro-3-[4-(2-ethoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-acetic acid with (commercially available) (2-amino-ethyl)-methyl-carbamic acid tert-butyl ester gave, after treatment with HCl and neutralisation, the title compound.
  • ES-MS m/e (%): 498.5 (M+H+).
    • Example 168 [6-Chloro-1-(2-dimethylamino-ethyl)-1H-indol-3-yl]-[4-(2-ethoxy-phenyl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00191
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-ethoxy-phenyl)-piperazin-1-yl]-methanone (preparation described herein), with (commercially available) (2-chloro-ethyl)-dimethyl-amine gave the title compound.
  • ES-MS m/e (%): 455.3 (M+H+).
    • Example 169 (6-Chloro-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00192
  • Following general procedure I, the coupling of (commercially available) 1-(2-fluoro-phenyl)-piperazine (described herein) with 6-chloro-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 358.0 (M+H+).
    • Example 170 [1-(2-Amino-ethyl)-6-chloro-1H-indol-3-yl]-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00193
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone (preparation described herein), with (commercially available) 2-chloro-ethylamine gave the title compound.
  • ES-MS m/e (%): 401.2 (M+H+).
    • Example 171 [6-Chloro-1-(2-dimethylamino-ethyl)-1H-indol-3-yl]-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00194
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone (preparation described herein), with (commercially available) (2-chloro-ethyl)-dimethyl-amine gave the title compound.
  • ES-MS m/e (%): 429.3 (M+H+).
    • Example 172 2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-1-(4-methyl-piperazin-1-yl)-ethanone
  • Figure US20120040990A1-20120216-C00195
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone (preparation described herein), with (commercially available) 2-chloro-1-(4-methyl-piperazin-1-yl)-ethanone gave the title compound.
  • ES-MS m/e (%): 498.3 (M+H+).
    • Example 173 2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-(2-dimethylamino-ethyl)-acetamide
  • Figure US20120040990A1-20120216-C00196
  • Following general procedure I, the coupling of {6-chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-acetic acid, with (commercially available) N1,N1-dimethyl-ethane-1,2-diamine gave the title compound.
  • ES-MS m/e (%): 486.3 (M+H+).
    • Example 174 2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide
  • Figure US20120040990A1-20120216-C00197
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone (preparation described herein), with (commercially available) 2-chloro-N,N-dimethyl-acetamide gave the title compound.
  • ES-MS m/e (%): 443.2 (M+H+).
    • Example 175 2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-acetamide
  • Figure US20120040990A1-20120216-C00198
  • Following general procedure I, the coupling of {6-chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-acetic acid (preparation described herein), with (commercially available) ammonia in THF gave the title compound.
  • ES-MS m/e (%): 415.2 (M+H+).
    • Example 176 2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide
  • Figure US20120040990A1-20120216-C00199
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone (preparation described herein), with (commercially available) 2-chloro-N-methyl-acetamide gave the title compound.
  • ES-MS m/e (%): 429.2 (M+H+).
    • Example 177 2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-1-piperazin-1-yl-ethanone {6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-acetic acid
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone (preparation described herein), with (commercially available) bromo-acetic acid gave the title compound.
  • ES-MS m/e (%): 414.0 (M−H+).
    • 2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-1-piperazin-1-yl-ethanone
  • Figure US20120040990A1-20120216-C00200
  • Following general procedure I, the coupling of {6-chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-acetic acid, with (commercially available) piperazine-1-carboxylic acid tert-butyl ester gave, after treatment with HCl and neutralisation, gave the title compound.
  • ES-MS m/e (%): 484.2 (M+H+).
    • Example 178 2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-(2-methylamino-ethyl)-acetamide
  • Figure US20120040990A1-20120216-C00201
  • Following general procedure II, the alkylation of {6-chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-acetic acid (preparation described herein), with (commercially available) (2-amino-ethyl)-methyl-carbamic acid tert-butyl ester gave, after treatment with HCl and neutralisation, the title compound.
  • ES-MS m/e (%): 472.2 (M+H+).
    • Example 179 N-(2-Amino-ethyl)-2-{6-chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-acetamide
  • Figure US20120040990A1-20120216-C00202
  • Following general procedure I, the coupling of {6-chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-acetic acid (preparation described herein), with (commercially available) (2-amino-ethyl)-carbamic acid tert-butyl ester gave, after treatment with HCl and neutralisation, the title compound.
  • ES-MS m/e (%): 458.2 (M+H+).
    • Example 180 2-{6-Chloro-3-[4-(2-methoxymethyl-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-(2-dimethylamino-ethyl)-acetamide 4-(2-Methoxymethyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester
  • A solution of (commercially available) 4-(2-hydroxymethyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester and (1 eq) MeI dissolved in THF was treated with NaH (2 eq) and stirred at RT for 2 h. After work-up, the crude solid was purified by SiO2 chromatography (Ethyl acetate-Heptane 1:4) to give the title compound.
  • ES-MS m/e (%): 307.5 (M+H+).
    • 1-(2-Methoxymethyl-phenyl)-piperazine
  • A solution of 4-(2-methoxymethyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (prepared as described herein below) in dioxan was treated with 4 eq. of 4M HCl in dioxane and stirred at RT for 16 h. After neutralization, the mixture was completely evaporated to give the crude title compound.
  • ES-MS m/e (%): 207.1 (M+H+).
    • 2-{6-Chloro-3-[4-(2-methoxymethyl-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-(2-dimethylamino-ethyl)-acetamide
  • Figure US20120040990A1-20120216-C00203
  • Following general procedure I, the coupling of 1-(2-methoxymethyl-phenyl)-piperazine, with 6-chloro-1-[(2-dimethylamino-ethylcarbamoyl)-methyl]-1H-indole-3-carboxylic acid (preparation described herein) gave the title compound.
  • ES-MS m/e (%): 512.3 (M+H+).
    • Example 181 2-{6-Chloro-3-[4-(2-trifluoromethyl-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-(2-dimethylamino-ethyl)-acetamide
  • Figure US20120040990A1-20120216-C00204
  • Following general procedure I, the coupling of (commercially available) 1-(2-trifluoromethyl-phenyl)-piperazine, with 6-chloro-1-[(2-dimethylamino-ethylcarbamoyl)-methyl]-1H-indole-3-carboxylic acid (preparation described herein) gave the title compound.
  • ES-MS m/e (%): 536.2 (M+H+).
    • Example 182 2-[6-Chloro-3-(4-pyridin-2-yl-piperazine-1-carbonyl)-indol-1-yl]-N-(2-dimethylamino-ethyl)-acetamide
  • Figure US20120040990A1-20120216-C00205
  • Following general procedure I, the coupling of (commercially available) 1-pyridin-2-yl-piperazine, with 6-chloro-1-[(2-dimethylamino-ethylcarbamoyl)-methyl]-1H-indole-3-carboxylic acid (preparation described herein) gave the title compound.
  • ES-MS m/e (%): 469.2 (M+H+).
    • Example 183 2-[6-Chloro-3-(4-pyridin-2-yl-piperazine-1-carbonyl)-indol-1-yl]-N-(2-dimethylamino-ethyl)-acetamide
  • Figure US20120040990A1-20120216-C00206
  • Following general procedure I, the coupling of (commercially available) 1-(2,4-difluoro-phenyl)-piperazine with 6-chloro-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 376.1 (M+H+).
    • Example 184 (6-Chloro-1H-indol-3-yl)-[4-(3-methyl-pyridin-2-yl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00207
  • Following general procedure I, the coupling of (commercially available) 1-(3-methyl-pyridin-2-yl)-piperazine with 6-chloro-1H-indole-3-carboxylic acid gave the title compound. ES-MS m/e (%): 355.1 (M+H+).
    • Example 185 (6-Chloro-1H-indol-3-yl)-[4-(3,5-dichloro-pyridin-4-yl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00208
  • Following general procedure I, the coupling of (commercially available) 1-(3,5-dichloro-pyridin-4-yl)-piperazine with 6-chloro-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 409.0 (M+H+).
    • Example 186 (6-Chloro-1H-indol-3-yl)-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00209
  • Following general procedure I, the coupling of (commercially available) 1-(3-trifluoromethyl-pyridin-2-yl)-piperazine with 6-chloro-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 409.1 (M+H+).
    • Example 187 2-[4-(6-Chloro-1H-indole-3-carbonyl)-piperazin-1-yl]-nicotinonitrile
  • Figure US20120040990A1-20120216-C00210
  • Following general procedure I, the coupling of (commercially available) 2-piperazin-1-yl-nicotinonitrile with 6-chloro-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 366.1 (M+H+).
    • Example 188 (6-Chloro-1H-indol-3-yl)-(4-pyridin-2-yl-piperazin-1-yl)-methanone
  • Figure US20120040990A1-20120216-C00211
  • Following general procedure I, the coupling of (commercially available) 1-pyridin-2-yl-piperazine with 6-chloro-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 341.1 (M+H+).
    • Example 189 (6-Chloro-1H-indol-3-yl)-(4-thiazol-2-yl-piperazin-1-yl)-methanone
  • Figure US20120040990A1-20120216-C00212
  • Following general procedure I, the coupling of (commercially available) 1-thiazol-2-yl-piperazine with 6-chloro-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 347.0 (M+H+).
    • Example 190 2-{6-Chloro-3-[4-(2,4-difluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide
  • Figure US20120040990A1-20120216-C00213
  • Following general procedure I, the coupling of (commercially available) 1-(2,4-difluoro-phenyl)-piperazine, with 6-chloro-1-methylcarbamoylmethyl-1H-indole-3-carboxylic acid (prepared as described herein below) gave the title compound.
  • ES-MS m/e (%): 447.1 (M+H+).
    • Example 191 2-[6-Chloro-3-(2,3,5,6-tetrahydro-[1,2]bipyrazinyl-4-carbonyl)-indol-1-yl]-N-methyl-acetamide
  • Figure US20120040990A1-20120216-C00214
  • Following general procedure I, the coupling of (commercially available) 3,4,5,6-tetrahydro-2H-[1,2]bipyrazinyl, with 6-chloro-1-methylcarbamoylmethyl-1H-indole-3-carboxylic acid (prepared as described herein) gave the title compound.
  • ES-MS m/e (%): 413.1 (M+H+).
    • Example 192 2-{6-Chloro-3-[4-(3-methyl-pyridin-2-yl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide
  • Figure US20120040990A1-20120216-C00215
  • Following general procedure I, the coupling of (commercially available) 1-(3-methyl-pyridin-2-yl)-piperazine with 6-chloro-1-methylcarbamoylmethyl-1H-indole-3-carboxylic acid (prepared as described herein) gave the title compound.
  • ES-MS m/e (%): 426.2 (M+H+).
    • Example 193 2-{6-Chloro-3-[4-(3,5-dichloro-pyridin-4-yl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide
  • Figure US20120040990A1-20120216-C00216
  • Following general procedure I, the coupling of (commercially available) 1-(3,5-dichloro-pyridin-4-yl)-piperazine with 6-chloro-1-methylcarbamoylmethyl-1H-indole-3-carboxylic acid (prepared as described herein) gave the title compound.
  • ES-MS m/e (%): 480.1 (M+H+).
    • Example 194 2-[6-Chloro-3-(4-pyridin-2-yl-piperazine-1-carbonyl)-indol-1-yl]-N-methyl-acetamide
  • Figure US20120040990A1-20120216-C00217
  • Following general procedure I, the coupling of (commercially available) 1-pyridin-2-yl-piperazine with 6-chloro-1-methylcarbamoylmethyl-1H-indole-3-carboxylic acid (prepared as described herein) gave the title compound.
  • ES-MS m/e (%): 412.1 (M+H+).
    • Example 195 2-[6-Chloro-3-(4-thiazol-2-yl-piperazine-1-carbonyl)-indol-1-yl]-N-methyl-acetamide
  • Figure US20120040990A1-20120216-C00218
  • Following general procedure I, the coupling of (commercially available) 1-thiazol-2-yl-piperazine with 6-chloro-1-methylcarbamoylmethyl-1H-indole-3-carboxylic acid (prepared as described herein) gave the title compound.
  • ES-MS m/e (%): 418.1 (M+H+).
    • Example 196 2-{6-Chloro-3-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide
  • Figure US20120040990A1-20120216-C00219
  • Following general procedure I, the coupling of (commercially available) 1-(3-trifluoromethyl-pyridin-2-yl)-piperazine with 6-chloro-1-methylcarbamoylmethyl-1H-indole-3-carboxylic acid (prepared as described herein) gave the title compound.
  • ES-MS m/e (%): 480.1 (M+H+).
    • Example 197 2-{6-Chloro-3-[4-(3-cyano-pyridin-2-yl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide
  • Figure US20120040990A1-20120216-C00220
  • Following general procedure I, the coupling of (commercially available) 2-piperazin-1-yl-nicotinonitrile with 6-chloro-1-methylcarbamoylmethyl-1H-indole-3-carboxylic acid (prepared as described herein) gave the title compound.
  • ES-MS m/e (%): 437.1 (M+H+).
    • Example 198 [1-((S)-2-Amino-propyl)-6-chloro-1H-indol-3-yl]-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00221
  • Following general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone (preparation described herein), with methanesulfonic acid (S)-2-tert-butoxycarbonylamino-propyl ester (described in WO 2005100321) gave, after treatment with TFA and subsequent neutralization, the title compound.
  • ES-MS m/e (%): 415.2 (M+H+).
    • Example 199 (6-Chloro-1-(S)-1-piperidin-3-ylmethyl-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00222
  • In analogy to the reaction conditions used in general procedure II, the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone (preparation described herein), with methanesulfonic acid (S)-3-methanesulfonyloxymethyl-piperidine-1-carboxylic acid tert-butyl ester (described in JP 2001278872), followed by treatment with TFA and subsequent neutralisation, gave the title compound in 56% yield.
  • ES-MS m/e (%): 455.3 (M+H+).
    • Example 200 (6-Chloro-1-(S)-1-pyrrolidin-2-ylmethyl-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00223
  • In analogy to the preparation of (6-chloro-1-(S)-1-piperidin-3-ylmethyl-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone (described herein), the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone (preparation described herein), with (S)-2-methanesulfonyloxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester (described in Tetrahedron: Asymmetry (1997), 8(13), 2209-2213), followed by treatment with TFA and subsequent neutralisation, gave the title compound in 55% yield.
  • ES-MS m/e (%): 441.3 (M+H+).
    • Example 201 (6-Chloro-1-(RS)-1-pyrrolidin-3-ylmethyl-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00224
  • In analogy to the preparation of (6-chloro-1-(S)-1-piperidin-3-ylmethyl-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone (described herein), the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone (preparation described herein), with (RS)-3-methanesulfonyloxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester (described in WO 9742189), followed by treatment with TFA and subsequent neutralisation, gave the title compound in 51% yield.
  • ES-MS m/e (%): 441.3 (M+H+).
    • Example 202 [6-Chloro-1-((S)-1-methyl-piperidin-3-ylmethyl)-1H-indol-3-yl]-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00225
  • A solution of (6-chloro-1-(S)-1-piperidin-3-ylmethyl-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone (preparation described herein below) in MeOH was treated with aq. H2CO (1.5 eq) and AcOH (1.1 eq) and stirred for 15 min at RT, then treated with NaCNBH3 (1.1 eq) and stirred at RT for 1 h. Concentration and purification by prep HPLC gave the desired product. in 71% yield.
  • ES-MS m/e (%): 469.3 (M+H+).
    • Example 203 [6-Chloro-1-((S)-1-methyl-pyrrolidin-2-ylmethyl)-1H-indol-3-yl]-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00226
  • (6-Chloro-1-(S)-1-pyrrolidin-2-ylmethyl-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone (preparation described herein), was treated with a 37% aq. solution of formaldehyde (1.05 eq.), acetic acid (1.05 eq.) and sodium cyanoborohydride (1.0 eq.) in MeOH at RT for 2 h to give after purification by prep. HPLC the title compound in 62% yield.
  • ES-MS m/e (%): 455.3 (M+H+).
    • Example 204 [6-Chloro-1-((RS)-1-methyl-pyrrolidin-3-ylmethyl)-1H-indol-3-yl]-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00227
  • Following the procedure described in the preparation of (6-chloro-1-(S)-1-pyrrolidin-2-ylmethyl-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone (described herein), the alkylation of (6-chloro-1-(RS)-1-pyrrolidin-3-ylmethyl-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone (preparation described herein) gave the title compound in 64% yield.
  • ES-MS m/e (%): 455.3 (M+H+).
    • Example 205 2-{6-Chloro-3-[4-(2,4-difluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide
  • Figure US20120040990A1-20120216-C00228
  • Following general procedure I, the coupling of (commercially available) 1-(2,4-difluoro-phenyl)-piperazine, with 6-chloro-1-dimethylcarbamoylmethyl-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 461.2 (M+H+).
    • Example 206 2-[6-Chloro-3-(2,3,5,6-tetrahydro-[1,2]bipyrazinyl-4-carbonyl)-indol-1-yl]-N,N-dimethyl-acetamide
  • Figure US20120040990A1-20120216-C00229
  • Following general procedure I, the coupling of (commercially available) 3,4,5,6-tetrahydro-2H-[1,2]bipyrazinyl, with 6-chloro-1-dimethylcarbamoylmethyl-1H-indole-3-carboxylic acid (prepared as described herein) gave the title compound.
  • ES-MS m/e (%): 427.2 (M+H+).
    • Example 207 2-{6-Chloro-3-[4-(3-methyl-pyridin-2-yl)-piperazine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide
  • Figure US20120040990A1-20120216-C00230
  • Following general procedure I, the coupling of (commercially available) 1-(3-methyl-pyridin-2-yl)-piperazine with 6-chloro-1-dimethylcarbamoylmethyl-1H-indole-3-carboxylic acid (prepared as described herein) gave the title compound.
  • ES-MS m/e (%): 440.2 (M+H+).
    • Example 208 2-{6-Chloro-3-[4-(3,5-dichloro-pyridin-4-yl)-piperazine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide
  • Figure US20120040990A1-20120216-C00231
  • Following general procedure I, the coupling of (commercially available) 1-(3,5-dichloro-pyridin-4-yl)-piperazine with 6-chloro-1-dimethylcarbamoylmethyl-1H-indole-3-carboxylic acid (prepared as described herein) gave the title compound.
  • ES-MS m/e (%): 494.1 (M+H+).
    • Example 209 2-[6-Chloro-3-(4-pyridin-2-yl-piperazine-1-carbonyl)-indol-1-yl]-N-methyl-acetamide
  • Figure US20120040990A1-20120216-C00232
  • Following general procedure I, the coupling of (commercially available) 1-pyridin-2-yl-piperazine with 6-chloro-1-dimethylcarbamoylmethyl-1H-indole-3-carboxylic acid (prepared as described herein) gave the title compound.
  • ES-MS m/e (%): 426.2 (M+H+).
    • Example 210 2-[6-Chloro-3-(4-thiazol-2-yl-piperazine-1-carbonyl)-indol-1-yl]-N,N-dimethyl-acetamide
  • Figure US20120040990A1-20120216-C00233
  • Following general procedure I, the coupling of (commercially available) 1-thiazol-2-yl-piperazine with 6-chloro-1-dimethylcarbamoylmethyl-1H-indole-3-carboxylic acid (prepared as described herein) gave the title compound.
  • ES-MS m/e (%): 432.2 (M+H+).
    • Example 211 2-{6-Chloro-3-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide
  • Figure US20120040990A1-20120216-C00234
  • Following general procedure I, the coupling of (commercially available) 1-(3-trifluoromethyl-pyridin-2-yl)-piperazine with 6-chloro-1-dimethylcarbamoylmethyl-1H-indole-3-carboxylic acid gave the title compound. ES-MS m/e (%): 494.2 (M+H+).
    • Example 212 2-{6-Chloro-3-[4-(3-cyano-pyridin-2-yl)-piperazine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide
  • Figure US20120040990A1-20120216-C00235
  • Following general procedure I, the coupling of (commercially available) 2-piperazin-1-yl-nicotinonitrile with 6-chloro-1-dimethylcarbamoylmethyl-1H-indole-3-carboxylic acid (prepared as described herein) gave the title compound.
  • ES-MS m/e (%): 451.2 (M+H+).
    • Example 213 2-[6-Chloro-3-(4-pyrimidin-2-yl-piperazine-1-carbonyl)-indol-1-yl]-N,N-dimethyl-acetamide
  • Figure US20120040990A1-20120216-C00236
  • Following general procedure I, the coupling of (commercially available) 2-piperidin-4-yl-pyrimidine with 6-chloro-1-dimethylcarbamoylmethyl-1H-indole-3-carboxylic acid (prepared as described herein) gave the title compound.
  • ES-MS m/e (%): 427.2 (M+H+).
    • Example 214 (6-Chloro-1-(R)-1-pyrrolidin-2-ylmethyl-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00237
  • In analogy to the preparation of (6-chloro-1-(S)-1-piperidin-3-ylmethyl-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone (described herein), the alkylation of (6-chloro-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone (preparation described herein), with (R)-2-methanesulfonyloxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester (described in Tetrahedron: Asymmetry (1997), 8(13), 2209-2213), followed by treatment with TFA and subsequent neutralisation, gave the title compound in 26% yield.
  • ES-MS m/e (%): 441.3 (M+H+).
    • Example 215 [6-Chloro-1-((R)-1-methyl-pyrrolidin-2-ylmethyl)-1H-indol-3-yl]-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00238
  • Following the procedure described in the preparation of [6-chloro-1-((S)-1-methyl-pyrrolidin-2-ylmethyl)-1H-indol-3-yl]-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone, the alkylation of (6-chloro-1-(R)-1-pyrrolidin-2-ylmethyl-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone (preparation described herein) gave the title compound.
  • ES-MS m/e (%): 455.3 (M+H+)
    • Example 216 (6-Chloro-2-methyl-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00239
  • The title compound was obtained as a white solid in 16% yield according to the procedure described for the preparation of (6-chloro-2-methyl-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-piperidin-1-yl]-methanone using 1-(2-methoxy-phenyl)-piperazine instead of 4-(2-methoxy-phenyl)-piperidine.
  • MS m/e (%): 382 (M−H+, 100).
    • Example 217 N-(2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-ethyl)-acetamide [1-(2-Amino-ethyl)-6-chloro-1H-indol-3-yl]-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone
  • To a solution of (6-chloro-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone in dry DMF under argon at 0° C. was added (1.1 eq) NaH. The reaction mixture was stirred for 1 h at 0° C. 2,2-Dioxo-2λ6-[1,2,3]oxathiazolidine-3-carboxylic acid tert-butyl ester (1.1 eq) (described in WO 2003037327) was added, and the reaction mixture was stirred for 2 h at RT. After evaporation of DMF, redissolution in dioxan, addition of 5 eq. of HCl (4.0M solution in dioxane) and a few drops of water, the reaction mixture was stirred for 2 h at 50° C.; LC-MS showed complete conversion to the crude product.
  • Concentration in vacuo, redissolution in EtOAc, and washing with 1N NaHCO3, gave after concentration, the crude product which was purified by SiO2 gel chromatography with CH2Cl2/MeOH to give the title compound in 55% yield.
  • ES-MS m/e (%): 401.2 (M+H+).
    • N-(2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-ethyl)-acetamide
  • Figure US20120040990A1-20120216-C00240
  • [1-(2-Amino-ethyl)-6-chloro-1H-indol-3-yl]-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone, was treated with acetylchloride (1.05 eq) and triethylamine (1.05 eq) in CH2Cl2 under argon at RT for 2 h to give after purification by prep. HPLC the title compound.
  • ES-MS m/e (%): 443.2 (M+H+).
    • Example 218 N-(2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-ethyl)-methanesulfonamide
  • Figure US20120040990A1-20120216-C00241
  • [1-(2-Amino-ethyl)-6-chloro-1H-indol-3-yl]-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone (preparation described herein), was treated with mesylchloride (1.05 eq) and triethylamine (1.05 eq) in CH2Cl2 under argon at RT. to give after purification by prep. HPLC the title compound.
  • ES-MS m/e (%): 479.1 (M+H+).
    • Example 219 N-(2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-ethyl)-N-methyl-acetamide
  • Figure US20120040990A1-20120216-C00242
  • N-(2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-ethyl)-acetamide (preparation described herein) was treated with NaH (1.05 eq), MeI (1.05 eq) in dry DMF under argon at RT for 2 h to give after purification by prep. HPLC the title compound.
  • ES-MS m/e (%): 457.1 (M+H+).
    • Example 220 N-(2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-ethyl)-N-methyl-acetamide
  • Figure US20120040990A1-20120216-C00243
  • N-(2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-ethyl)-methanesulfonamide (preparation described herein), was treated with NaH (1.05 eq), MeI (1.05 eq) in dry DMF under argon at RT for 2 h to give after purification by prep. HPLC the title compound.
  • ES-MS m/e (%): 493.1 (M+H+).
    • Example 221 2-{6-Chloro-3-[4-(6-chloro-pyridin-2-yl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide
  • Figure US20120040990A1-20120216-C00244
  • Following general procedure I, the coupling of (commercially available) 1-(6-chloro-pyridin-2-yl)-piperazine, with 6-chloro-1-methylcarbamoylmethyl-1H-indole-3-carboxylic acid (prepared as described herein) gave the title compound.
  • ES-MS m/e (%): 446.1 (M+H+).
    • Example 222 2-{6-Chloro-3-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide
  • Figure US20120040990A1-20120216-C00245
  • Following general procedure I, the coupling of (commercially available) 1-(5-trifluoromethyl-pyridin-2-yl)-piperazine, with 6-chloro-1-methylcarbamoylmethyl-1H-indole-3-carboxylic acid (prepared as described herein) gave the title compound.
  • ES-MS m/e (%): 480.1 (M+H+).
    • Example 223 2-[6-Chloro-3-(4-thieno[2,3-c]pyridin-7-yl-piperazine-1-carbonyl)-indol-1-yl]-N-methyl-acetamide
  • Figure US20120040990A1-20120216-C00246
  • Following general procedure I, the coupling of (commercially available) 7-piperazin-1-yl-thieno[2,3-c]pyridine, with 6-chloro-1-methylcarbamoylmethyl-1H-indole-3-carboxylic acid (prepared as described herein) gave the title compound.
  • ES-MS m/e (%): 468.1 (M+H+).
    • Example 224 2-[6-Chloro-3-(4-thieno[3,2-c]pyridin-4-yl-piperazine-1-carbonyl)-indol-1-yl]-N-methyl-acetamide
  • Figure US20120040990A1-20120216-C00247
  • Following general procedure I, the coupling of (commercially available) 4-piperazin-1-yl-thieno[3,2-c]pyridine with 6-chloro-1-methylcarbamoylmethyl-1H-indole-3-carboxylic acid (prepared as described herein) gave the title compound.
  • ES-MS m/e (%): 468.1 (M+H+).
    • Example 225 2-{6-Chloro-3-[4-(3-iodo-pyridin-2-yl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide
  • Figure US20120040990A1-20120216-C00248
  • Following general procedure I, the coupling of (commercially available) 1-(3-iodo-pyridin-2-yl)-piperazine with 6-chloro-1-methylcarbamoylmethyl-1H-indole-3-carboxylic acid gave the title compound.
  • ES-MS m/e (%): 538.0 (M+H+).
    • Example 226 2-{6-Chloro-3-[4-(3-chloro-5-trifluoromethyl-pyridin-2-yl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide
  • Figure US20120040990A1-20120216-C00249
  • Following general procedure I, the coupling of (commercially available) 1-(3-chloro-5-trifluoromethyl-pyridin-2-yl)-piperazine with 6-chloro-1-methylcarbamoylmethyl-1H-indole-3-carboxylic acid (prepared as described herein) gave the title compound.
  • ES-MS m/e (%): 514.1 (M+H+).
    • Example 227 2-[4-(6-Chloro-1-methylcarbamoylmethyl-1H-indole-3-carbonyl)-piperazin-1-yl]-nicotinic acid
  • Figure US20120040990A1-20120216-C00250
  • Following general procedure I, the coupling of (commercially available) 2-piperazin-1-yl-nicotinic acid with 6-chloro-1-methylcarbamoylmethyl-1H-indole-3-carboxylic acid (prepared as described herein) gave the title compound.
  • ES-MS m/e (%): 456.1 (M+H+).
    • Example 228 2-{6-Chloro-3-[4-(2,4-difluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-(2-dimethylamino-ethyl)-acetamide
  • Figure US20120040990A1-20120216-C00251
  • Following general procedure I, the coupling of (commercially available) 1-(2,4-difluoro-phenyl)-piperazine with 6-chloro-1-[(2-dimethylamino-ethylcarbamoyl)-methyl]-1H-indole-3-carboxylic acid (prepared as described herein) gave the title compound.
  • ES-MS m/e (%): 504.3 (M+H+).
    • Example 229 2-{6-Chloro-3-[4-(4-fluoro-2-methanesulfonyl-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide
  • Figure US20120040990A1-20120216-C00252
  • Following general procedure I, the coupling of (commercially available) 1-(4-fluoro-2-methanesulfonyl-phenyl)-piperazine with 6-chloro-1-methylcarbamoylmethyl-1H-indole-3-carboxylic acid (prepared as described herein) gave the title compound.
  • ES-MS m/e (%): 506.9 (M+H+).
    • Example of a Compound of Formula I-d Example 230 (6-Chloro-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-4-oxy-piperazin-1-yl]-methanone
  • Figure US20120040990A1-20120216-C00253
  • Amide coupling according to general procedure I:
  • Amine: 1-(2-Methoxy-phenyl)-piperazine 1-oxide (described in EP126480),
    Acid: 6-chloro-1H-indole-3-carboxylic acid,
  • ES-MS m/e (%): 386.4 (M+H+).

Claims (24)

1. A compound of formula I:
Figure US20120040990A1-20120216-C00254
wherein
R1 is H,
C1-6-alkyl substituted by CN, C1-6-alkoxy, OH, halo, or NRiRii,
C2-6-alkyl,
aryl, 5 or 6 membered heteroaryl or sulfonylaryl each of which is optionally substituted by one or more B,
—(CH2)m—Ra wherein Ra is:
CN,
ORi,
NRiRii, or
C3-6-cycloalkyl, 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl each of which is optionally substituted by one or more B,
or —(CH2)n—(CO)—Rb or —(CH2)n—(SO2)—Rb, wherein Rb is:
C1-6-alkyl,
C1-6-alkoxy,
C3-6-cycloalkyl,
—(CH2)m—NRiiiRiv,
NRiRii, or
C3-6-cycloalkyl, 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl each of which is optionally substituted by one or more B,
or R1 and R3 together with the indole ring to which they are attached form a 5 or 6 membered heterocycloalkyl which is optionally substituted by ═O, C(O)O—C1-6-alkyl or C1-6-alkyl;
there is one or more R2, wherein each R2 is the same or different,
R2 is one or more H, OH, halo, CN, nitro, C1-6-alkoxy, —O—CH2—C2-6-alkenyl, benzyloxy, C1-6-haloalkoxy, or C1-6-alkyl optionally substituted by —NRiiRv or halo,
or two R2 together with the indole ring to which they are attached form an oxo or dioxo bridge;
R3 is H,
F,
—(CO)—Rc, wherein Rc is:
C1-6-alkyl,
—(CH2)n—NRiRii,
—(CH2)n—NRiiiRiv, or
5 or 6 membered heterocycloalkyl optionally substituted by C1-6-alkyl,
or C1-6-alkyl which is optionally substituted by
halo,
NRiRii,
NRiiiRiv,
—O(CO)—C1-6-alkyl,
or —NH(CO)Rd, wherein Rd is C1-6-alkyl optionally substituted by halo or nitro, or Rd is aryl or a 5 or 6 membered heteroaryl, each of which is optionally substituted by halo, nitro, C1-6-alkyl or C1-6-haloalkyl;
wherein R1, R2, and R3 are not simultaneously H;
A is selected from the group consisting of (a), (a′), (b), (c) and (d):
Figure US20120040990A1-20120216-C00255
wherein
R4 is —NH(CO)Re, wherein Re is
C1-6-alkoxy or aryl optionally substituted by halo,
C1-6-alkoxy, or
CN,
or aryl, 5 or 6 membered heteroaryl, benzyl, aryloxy or a 9 or 10-membered bicyclic heteroaryl ring, each of which is optionally substituted by CN, halo, C1-6-alkyl, C1-6-alkoxy, C1-6-haloalkyl, nitro, hydroxyl, NRiRii, NRiiiRiv, C1-6-alkoxy-C1-6-alkylene, S(O)2—C1-6-alkyl, or C1-6-haloalkoxy, or by an oxo or dioxo bridge;
R6 is C2-6-alkyl,
—C(O)—Rf wherein Rf is an aryl group substituted by halo, C1-6-alkoxy, or CN,
aryl, 5 or 6 membered heteroaryl, or a 9 or 10-membered bicyclic heteroaryl ring each of which is optionally substituted by halo, C1-6-alkyl, C1-6-alkoxy, C1-6-haloalkyl, CN, nitro, NRiRii, NRiiiRiv, C1-6-alkoxy-C1-6-alkylene, COOH, S(O)2—C1-6-alkyl, hydroxyl, or C1-6-haloalkoxy, or by an oxo or dioxo bridge;
B is halo,
CN,
NRiRii,
C1-6-alkyl optionally substituted by CN, halo or C1-6-alkoxy,
C1-6-haloalkyl,
C1-6-alkoxy,
C1-6-haloalkoxy,
C3-6-cycloalkyl,
—C(O)O—C1-6-alkyl,
—C(O)NRiRii,
—C(O)—C1-6-alkyl,
—S(O)2—C1-6-alkyl,
—S(O)2—NRiRii, or
(CRiiiRiv)n-phenyl, or (CRiiiRiv)n-5 or 6 membered heteroaryl wherein the phenyl or 5 or 6 membered heteroaryl moiety is optionally substituted by one or more substituent(s) selected from the group consisting of:
halo, CN, NRiRii, C1-6-alkyl optionally substituted by CN or C1-6-alkoxy, C1-6-alkoxy, C1-6-haloalkoxy, C3-6-cycloalkyl, —C(O)O—C1-6-alkyl, —C(O)—NRiRii, —C(O)—C1-6-alkyl, —S(O)2—C1-6-alkyl, and —S(O)2—NRiRii;
Ri and Rii are each independently H, C1-6-alkyl, C1-6-alkyl-NRiiiRiv, —(CO)O—C1-6-alkyl, —C(O)—NRiiiRiv, —C(O)—C1-6-alkyl, —S(O)2—C1-6-alkyl or —S(O)2—NRiiiRiv;
Riii and Riv are each independently H or C1-6-alkyl;
m is 1 to 6; and
n is 0 to 4;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1,
wherein
R1 is H,
C1-6-alkyl optionally substituted by CN or C1-6-alkoxy,
aryl, 5 or 6 membered heteroaryl or sulfonylaryl each of which is optionally substituted by one or more B,
—(CH2)m—Ra wherein Ra is:
CN,
OR1,
NRiRii, or
C3-6-cycloalkyl, 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl each of which is optionally substituted by one or more B,
or —(CH2)n—(CO)—Rb or —(CH2)n—(SO2)—Rb, wherein Rb is:
C1-6-alkyl,
C1-6-alkoxy,
C3-6-cycloalkyl,
—(CH2)m—NRiiiRiv,
NRiRii, or
C3-6-cycloalkyl, 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl each of which is optionally substituted by one or more B,
or R1 and R3 together with the indole ring to which they are attached form a 5 or 6 membered heterocycloalkyl which is optionally substituted by (CO);
there is one or more R2, wherein each R2 is the same or different,
R2 is one or more H, OH, halo, CN, nitro, C1-6-alkyl optionally substituted by —NRiiiRiv, C1-6-alkoxy, —O—CH2—C2-6-alkenyl, or benzyloxy,
or two R2 together with the indole ring to which they are attached form an oxo or dioxo bridge;
R3 is H,
halo,
—(CO)—Rc, wherein Rc is:
C1-6-alkyl,
—(CH2)n—NRiRii,
—(CH2)n—NRiiiRiv, or
5 or 6 membered heterocycloalkyl optionally substituted by C1-6-alkyl,
or C1-6-alkyl or aryl, each of which is optionally substituted by
halo,
—O(CO)—C1-6-alkyl, or
—NH(CO)Rd, wherein Rd is C1-6-alkyl optionally substituted by halo or nitro, or Rd is aryl or a 5 or 6 membered heteroaryl, each of which is optionally substituted by halo, nitro, C1-6-alkyl or C1-6-haloalkyl;
wherein R1, R2, and R3 are not simultaneously H;
A is selected from the group consisting of (a), (b), (c) and (d):
Figure US20120040990A1-20120216-C00256
wherein
R4 is —NH(CO)Re, wherein Re is
C1-6-alkoxy or aryl optionally substituted by halo,
C1-6-alkoxy, or
CN,
or aryl, 5 or 6 membered heteroaryl, benzyl, aryloxy or a 9 or 10-membered bicyclic heteroaryl ring each of which is optionally substituted by CN, halo, C1-6-alkyl, C1-6-alkoxy, or C1-6-haloalkyl, or by a dioxo bridge;
R6 is C1-6-alkyl,
—C(O)—Rf wherein Rf is an aryl group optionally substituted by halo, C1-6-alkoxy, or CN,
or aryl, 5 or 6 membered heteroaryl, or a 9 or 10-membered bicyclic heteroaryl ring each of which is optionally substituted by halo, C1-6-alkyl, C1-6-alkoxy, C1-6-haloalkyl, or CN or by a dioxo bridge;
B is halo,
CN,
NRiRii,
C1-6-alkyl optionally substituted by CN, halo or C1-6-alkoxy,
C1-6-alkoxy,
C1-6-haloalkoxy,
C3-6-cycloalkyl,
—C(O)O—C1-6-alkyl,
—C(O)NRiRii
—C(O)—C1-6-alkyl,
—S(O)2—C1-6-alkyl,
—S(O)2—NRiRii, or
(CRiiiRiv)n-phenyl, or (CRiiiRiv)n-5 or 6 membered heteroaryl wherein the phenyl or 5 or 6 membered heteroaryl moiety is optionally substituted by one or more substituent(s) selected from the group consisting of:
halo, CN, NRiRii, C1-6-alkyl optionally substituted by CN or C1-6-alkoxy, C1-6-alkoxy, C1-6-haloalkoxy, C3-6-cycloalkyl, —C(O)O—C1-6-alkyl, —C(O)—NRiRii, —C(O)—C1-6-alkyl, —S(O)2—C1-6-alkyl, and —S(O)2—NRiRii;
Ri and Rii are each independently H, C1-6-alkyl, C1-6-alkyl-NRiiiRiv, —(CO)O—C1-6-alkyl, —C(O)—NRiiiRiv, —C(O)—C1-6-alkyl, —S(O)2—C1-6-alkyl or —S(O)2—NRiiiRiv;
Riii and Riv are each independently H or C1-6-alkyl;
m is 1 to 6; and
n is 0 to 4;
or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1, wherein
R1 is H,
C1-6-alkyl optionally substituted by CN or C1-6-alkoxy,
aryl,
5 or 6 membered heteroaryl,
sulfonylaryl,
—(CH2)m—Ra wherein Ra is C3-6-cycloalkyl, 5 or 6 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl each of which is optionally substituted by one or more substituents selected from the group consisting of:
halo, CN, C1-6-alkyl, C1-6-alkoxy, C1-6-haloalkoxy, —C(O)O—C1-6-alkyl, and phenyl optionally substituted by halo, C1-6-alkyl, C1-6-haloalkyl or C1-6-alkoxy,
—(CH2)m—NRiRii,
or —(CH2)n—(CO)—Rb, wherein Rb is aryl or 5 or 6 membered-heterocycloalkyl;
there is one or more R2, wherein each R2 is the same or different,
R2 is one or more H, halo, CN, nitro, C1-6-alkyl, C1-6-alkoxy, —O—CH2—C2-6-alkenyl, or benzyloxy, or
two R2 together with the indole ring to which they are attached form an oxo or dioxo bridge;
R3 is H,
halo,
—(CO)—Rc, wherein Rc is C1-6-alkyl, 5 or 6 membered heterocycloalkyl optionally substituted by C1-6-alkyl, or Rc is —(CH2)n—NRiRii,
or C1-6-alkyl or aryl, each of which is optionally substituted by
—O(CO)—C1-6-alkyl, or
—NH(CO)Rd, wherein Rd is C1-6-alkyl optionally substituted by halo or nitro, or Rd is aryl or a 5 or 6 membered heteroaryl, each of which is optionally substituted by halo, nitro, C1-6-alkyl or C1-6-haloalkyl;
Ri and Rii are each independently selected from H, C1-6-alkyl and —(CO)O—C1-6-alkyl;
m is 1 to 6;
n is 0 to 4;
wherein R1, R2, and R3 are not simultaneously H;
A is selected from the group consisting of (a), (b), (c) and (d):
Figure US20120040990A1-20120216-C00257
wherein
R4 is —NH(CO)Re, wherein Re is C1-6-alkoxy or aryl optionally substituted by halo,
or aryl, benzyl, aryloxy or a 9 or 10-membered bicyclic heteroaryl ring each of which is optionally substituted by halo, C1-6-alkyl, C1-6-alkoxy, or C1-6-haloalkyl, or by a dioxo bridge; and
R6 is C1-6-alkyl,
—C(O)—Rf wherein Rf is an aryl group optionally substituted by halo,
or aryl, or a 9 or 10-membered bicyclic heteroaryl ring each of which is optionally substituted by halo, C1-6-alkyl, C1-6-alkoxy, or C1-6-haloalkyl, or by a dioxo bridge;
or a pharmaceutically acceptable salt thereof.
4. The compound of claim 1, wherein:
R1 is H,
C1-6-alkyl substituted by NRiRii,
—(CH2)m—Ra wherein Ra is:
NRiRii, or
5 to 6 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl each of which is optionally substituted by one or more B,
or —(CH2)n—(CO)—Rb or —(CH2)n—(SO2)—Rb, wherein Rb is:
C1-6-alkyl,
C1-6-alkoxy,
NRiRii, or
5 to 6 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl each of which is optionally substituted by one or more B,
or R1 and R3 together with the indole ring to which they are attached form a 5 or 6 membered heterocycloalkyl which is optionally substituted by ═O, C(O)O—C1-6-alkyl or C1-6-alkyl;
there is one or more R2, wherein each R2 is the same or different,
R2 is one or more H, halo, or C1-6-alkyl;
R3 is H, or
C1-6-alkyl;
wherein R1, R2, and R3 are not simultaneously H;
A is selected from the group consisting of (a), (a′), (b), (c) and (d):
Figure US20120040990A1-20120216-C00258
wherein
R4 is —NH(CO)Re, wherein Re is C1-6-alkoxy, or aryl optionally substituted by halo,
or aryl, 5 or 6 membered heteroaryl, benzyl, aryloxy or a 9 or 10-membered bicyclic heteroaryl ring, each of which is optionally substituted by halo, C1-6-alkyl, C1-6-alkoxy, C1-6-haloalkyl, nitro, hydroxyl, or C1-6-haloalkoxy, or by an oxo or dioxo bridge;
R6 is aryl, 5 or 6 membered heteroaryl, or a 9 or 10-membered bicyclic heteroaryl ring each of which is optionally substituted by halo, C1-6-alkyl, C1-6-alkoxy, C1-6-haloalkyl, CN, nitro, NRiRii, NRiiiRiv, C1-6-alkoxy-C1-6-alkylene, COOH, or S(O)2—C1-6-alkyl, or by an oxo or dioxo bridge;
B is halo, C1-6-alkyl optionally substituted by CN, halo or C1-6-alkoxy, or C1-6-alkoxy;
Ri and Rii are each independently H, C1-6-alkyl, C1-6-alkyl-NRiiiRiv, —C(O)—C1-6-alkyl or —S(O)2—C1-6-alkyl;
Riii and Riv are each independently H or C1-6-alkyl;
m is 1 to 6; and
n is 0 to 4;
or a pharmaceutically acceptable salt thereof.
5. The compound of claim 1, wherein R4 is not
Figure US20120040990A1-20120216-C00259
optionally substituted by CN, halo, C1-6-alkyl, C1-6-alkoxy, C1-6-haloalkyl, nitro, hydroxyl, NRiRii, NRiiiRiv, C1-6-alkoxy-C1-6-alkylene, S(O)2—C1-6-alkyl, or C1-6-haloalkoxy, or by an oxo or dioxo bridge.
6. The compound of claim 1, having formula (I-a) or (I-a′):
Figure US20120040990A1-20120216-C00260
or a pharmaceutically acceptable salt thereof.
7. The compound of claim 6,
wherein
R1 is H or —(CH2)m—Ra wherein Ra is aryl and m is 1 to 6;
there is one or more R2, wherein each R2 is the same or different,
R2 is one or more H or halo;
R3 is H or C1-6-alkyl; and
wherein R1, R2, and R3 are not simultaneously H;
R4 is aryl which is optionally substituted by halo or C1-6-alkoxy;
or a pharmaceutically acceptable salt thereof.
8. The compound of claim 6, which is selected from the group consisting of:
(1-Benzyl-2-methyl-1H-indol-3-yl)-[4-(4-fluoro-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-methanone;
(1-Benzyl-2-methyl-1H-indol-3-yl)-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)-methanone;
(1-Benzyl-2-methyl-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-methanone;
(6-Chloro-1H-indol-3-yl)-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)-methanone;
(6-Chloro-1H-indol-3-yl)-[4-(4-fluoro-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-methanone;
(6-Chloro-1H-indol-3-yl)-[4-(4-chloro-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-methanone;
(6-Chloro-1H-indol-3-yl)-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)-methanone; and
(1-Benzyl-2-methyl-1H-indol-3-yl)-(5-methyl-4-phenyl-3,6-dihydro-2H-pyridin-1-yl)-methanone.
9. The compound of claim 1, having formula (I-c)
Figure US20120040990A1-20120216-C00261
or a pharmaceutically acceptable salt thereof.
10. The compound of claim 9, wherein
R1 is H or
C1-6-alkyl substituted by NRiRii,
—(CH2)m—Ra wherein Ra is:
NRiRii, or
5 to 6 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl each of which is optionally substituted by one or more C1-6-alkyl,
or —(CH2)n—(CO)—Rb, wherein Rb is:
NRiRii, or
5 to 7 membered-heterocycloalkyl which is optionally substituted by one or more C1-6-alkyl;
there is one or more R2, wherein each R2 is the same or different,
R2 is one or more H, halo or C1-6-alkyl;
R3 is H or C1-6-alkyl;
wherein R1, R2, and R3 are not simultaneously H;
R6 is aryl, 5 or 6 membered heteroaryl, or a 9 or 10-membered bicyclic heteroaryl ring each of which is optionally substituted by halo, C1-6-alkyl, C1-6-alkoxy, C1-6-haloalkyl, CN, nitro, NRiRii, NRiiiRiv, C1-6-alkoxy-C1-6-alkylene, COOH, or S(O)2—C1-6-alkyl, or by an oxo or dioxo bridge;
Ri and Rii are each independently H, C1-6-alkyl, C1-6-alkyl-NRiiiRiv, —C(O)—C1-6-alkyl, or —S(O)2—C1-6-alkyl;
Riii and Riv are each independently H or C1-6-alkyl;
m is 1 to 6; and
n is 0 to 4;
or a pharmaceutically acceptable salt thereof.
11. The compound of claim 9, which is selected from the group consisting of:
(1-Benzyl-2-methyl-1H-indol-3-yl)-(4-phenyl-piperazin-1-yl)-methanone;
(1-Benzyl-2-methyl-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-piperazin-1-yl]-methanone;
(1-Benzyl-2-methyl-1H-indol-3-yl)-[4-(4-methoxy-phenyl)-piperazin-1-yl]-methanone;
(1-Benzyl-2-methyl-1H-indol-3-yl)-[4-(2-chloro-phenyl)-piperazin-1-yl]-methanone;
(1-Benzyl-2-methyl-1H-indol-3-yl)-[4-(4-chloro-phenyl)-piperazin-1-yl]-methanone;
(6-Chloro-1H-indol-3-yl)-(4-phenyl-piperazin-1-yl)-methanone;
(6-Chloro-1H-indol-3-yl)-[4-(2-chloro-6-nitro-phenyl)-piperazin-1-yl]-methanone;
(6-Chloro-1H-indol-3-yl)-[4-(2,6-dichloro-phenyl)-piperazin-1-yl]-methanone;
(6-Chloro-1H-indol-3-yl)-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin-1-yl]-methanone; and
(6-Chloro-1H-indol-3-yl)-[4-(2-nitro-4-trifluoromethyl-phenyl)-piperazin-1-yl]-methanone.
12. The compound of claim 9, which is selected from the group consisting of:
(6-Chloro-1H-indol-3-yl)-[4-(2-chloro-phenyl)-piperazin-1-yl]-methanone;
[4-(2-Amino-6-chloro-phenyl)-piperazin-1-yl]-(6-chloro-1H-indol-3-yl)-methanone;
(6-Chloro-1H-indol-3-yl)-[4-(4-methoxy-phenyl)-piperazin-1-yl]-methanone;
(6-Chloro-1H-indol-3-yl)-[4-(3-methoxy-phenyl)-piperazin-1-yl]-methanone;
(6-Chloro-1H-indol-3-yl)-[4-(2-nitro-phenyl)-piperazin-1-yl]-methanone;
(6-Chloro-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-piperazin-1-yl]-methanone;
(6-Chloro-1H-indol-3-yl)-[4-(4-fluoro-phenyl)-piperazin-1-yl]-methanone;
(6-Chloro-1H-indol-3-yl)-[4-(3-fluoro-phenyl)-piperazin-1-yl]-methanone;
3-Chloro-4-[4-(6-chloro-1H-indole-3-carbonyl)-piperazin-1-yl]-benzonitrile; and
(6-Chloro-1H-indol-3-yl)-[4-(2-ethoxy-phenyl)-piperazin-1-yl]-methanone.
13. The compound of claim 9, which is selected from the group consisting of:
2-{6-Chloro-3-[4-(2-ethoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-1-(4-methyl-piperazin-1-yl)-ethanone;
2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-(2-dimethylamino-ethyl)-acetamide;
2-{6-Chloro-3-[4-(2-ethoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-(2-dimethylamino-ethyl)-acetamide;
2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-acetamide;
2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperazine-1-carbonyl]-5-methyl-indol-1-yl}-N,N-dimethyl-acetamide;
2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-1-piperazin-1-yl-ethanone or hydrochloride salt thereof;
2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-(2-methylamino-ethyl)-acetamide or hydrochloride salt thereof;
N-(2-Amino-ethyl)-2-{6-chloro-3-[4-(2-methoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-acetamide or hydrochloride salt thereof;
[1-(2-Amino-ethyl)-6-chloro-1H-indol-3-yl]-[4-(2-methoxy-phenyl)-piperazin-1-yl]-methanone; and
[6-Chloro-1-(2-methylamino-ethyl)-1H-indol-3-yl]-[4-(2-methoxy-phenyl)-piperazin-1-yl]-methanone.
14. The compound of claim 9, which is selected from the group consisting of:
[6-Chloro-1-(2-methylamino-ethyl)-1H-indol-3-yl]-[4-(2-ethoxy-phenyl)-piperazin-1-yl]-methanone;
2-{6-Chloro-3-[4-(2-ethoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-(2-methylamino-ethyl)-acetamide;
[6-Chloro-1-(2-dimethylamino-ethyl)-1H-indol-3-yl]-[4-(2-ethoxy-phenyl)-piperazin-1-yl]-methanone;
(6-Chloro-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone;
[1-(2-Amino-ethyl)-6-chloro-1H-indol-3-yl]-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone;
2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-(2-dimethylamino-ethyl)-acetamide;
2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-(2-methylamino-ethyl)-acetamide;
N-(2-Amino-ethyl)-2-{6-chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-acetamide;
2-{6-Chloro-3-[4-(2-methoxymethyl-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-(2-dimethylamino-ethyl)-acetamide;
2-{6-Chloro-3-[4-(2-trifluoromethyl-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-(2-dimethylamino-ethyl)-acetamide; and
2-[6-Chloro-3-(4-pyridin-2-yl-piperazine-1-carbonyl)-indol-1-yl]-N-(2-dimethylamino-ethyl)-acetamide.
15. The compound of claim 9, which is selected from the group consisting of:
(6-Chloro-1H-indol-3-yl)-[4-(2,4-difluoro-phenyl)-piperazin-1-yl]-methanone;
(6-Chloro-1H-indol-3-yl)-[4-(3-methyl-pyridin-2-yl)-piperazin-1-yl]-methanone;
(6-Chloro-1H-indol-3-yl)-[4-(3,5-dichloro-pyridin-4-yl)-piperazin-1-yl]-methanone;
(6-Chloro-1H-indol-3-yl)-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-methanone;
2-[4-(6-Chloro-1H-indole-3-carbonyl)-piperazin-1-yl]-nicotinonitrile;
(6-Chloro-1H-indol-3-yl)-(4-pyridin-2-yl-piperazin-1-yl)-methanone;
(6-Chloro-1H-indol-3-yl)-(4-thiazol-2-yl-piperazin-1-yl)-methanone;
2-[6-Chloro-3-(2,3,5,6-tetrahydro-[1,2]bipyrazinyl-4-carbonyl)-indol-1-yl]-N-methyl-acetamide;
2-{6-Chloro-3-[4-(3-methyl-pyridin-2-yl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide;
2-{6-Chloro-3-[4-(3,5-dichloro-pyridin-4-yl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide; and
2-[6-Chloro-3-(4-pyridin-2-yl-piperazine-1-carbonyl)-indol-1-yl]-N-methyl-acetamide.
16. The compound of claim 9, which is selected from the group consisting of:
2-[6-Chloro-3-(4-thiazol-2-yl-piperazine-1-carbonyl)-indol-1-yl]-N-methyl-acetamide;
2-{6-Chloro-3-[4-(3-cyano-pyridin-2-yl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide;
(6-Chloro-1-(S)-1-piperidin-3-ylmethyl-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone;
(6-Chloro-1-(RS)-1-pyrrolidin-3-ylmethyl-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone;
[6-Chloro-1-((S)-1-methyl-piperidin-3-ylmethyl)-1H-indol-3-yl]-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone;
[6-Chloro-1-((RS)-1-methyl-pyrrolidin-3-ylmethyl)-1H-indol-3-yl]-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone;
2-[6-Chloro-3-(2,3,5,6-tetrahydro-[1,2′]bipyrazinyl-4-carbonyl)-indol-1-yl]-N,N-dimethyl-acetamide;
2-{6-Chloro-3-[4-(3-methyl-pyridin-2-yl)-piperazine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide;
2-{6-Chloro-3-[4-(3,5-dichloro-pyridin-4-yl)-piperazine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide;
2-[6-Chloro-3-(4-pyridin-2-yl-piperazine-1-carbonyl)-indol-1-yl]-N,N-dimethyl-acetamide; and
2-[6-Chloro-3-(4-thiazol-2-yl-piperazine-1-carbonyl)-indol-1-yl]-N,N-dimethyl-acetamide.
17. The compound of claim 9, which is selected from the group consisting of:
2-{6-Chloro-3-[4-(3-cyano-pyridin-2-yl)-piperazine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide;
2-[6-Chloro-3-(4-pyrimidin-2-yl-piperazine-1-carbonyl)-indol-1-yl]-N,N-dimethyl-acetamide;
(6-Chloro-2-methyl-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-piperazin-1-yl]-methanone;
2-{6-Chloro-3-[4-(6-chloro-pyridin-2-yl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide;
2-{6-Chloro-3-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide;
2-[6-Chloro-3-(4-thieno[2,3-c]pyridin-7-yl-piperazine-1-carbonyl)-indol-1-yl]-N-methyl-acetamide;
2-{6-Chloro-3-[4-(3-chloro-5-trifluoromethyl-pyridin-2-yl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide;
2-[4-(6-Chloro-1-methylcarbamoylmethyl-1H-indole-3-carbonyl)-piperazin-1-yl]-nicotinic acid;
2-{6-Chloro-3-[4-(2,4-difluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-(2-dimethylamino-ethyl)-acetamide; and
2-{6-Chloro-3-[4-(4-fluoro-2-methanesulfonyl-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide.
18. The compound of claim 9, which is selected from the group consisting of:
2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide;
2-{6-Chloro-3-[4-(2-ethoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide;
2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-1-(4-methyl-piperazin-1-yl)-ethanone;
2-{6-Chloro-3-[4-(2-methoxy-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide;
[6-Chloro-1-(2-dimethylamino-ethyl)-1H-indol-3-yl]-[4-(2-methoxy-phenyl)-piperazin-1-yl]-methanone;
[6-Chloro-1-(2-dimethylamino-ethyl)-1H-indol-3-yl]-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone;
2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-1-(4-methyl-piperazin-1-yl)-ethanone;
2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide; and
2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-acetamide.
19. The compound of claim 9, which is selected from the group consisting of:
2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide;
2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-1-piperazin-1-yl-ethanone;
2-{6-Chloro-3-[4-(2,4-difluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide;
2-{6-Chloro-3-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide;
[1-((S)-2-Amino-propyl)-6-chloro-1H-indol-3-yl]-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone;
(6-Chloro-1-(S)-1-pyrrolidin-2-ylmethyl-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone;
[6-Chloro-1-((S)-1-methyl-pyrrolidin-2-ylmethyl)-1H-indol-3-yl]-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone;
2-{6-Chloro-3-[4-(2,4-difluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide; and
2-{6-Chloro-3-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-carbonyl]-indol-1-yl}-N,N-dimethyl-acetamide.
20. The compound of claim 9, which is selected from the group consisting of:
(6-Chloro-1-(R)-1-pyrrolidin-2-ylmethyl-1H-indol-3-yl)-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone;
[6-Chloro-1-((R)-1-methyl-pyrrolidin-2-ylmethyl)-1H-indol-3-yl]-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone;
N-(2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-ethyl)-acetamide;
N-(2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-ethyl)-methanesulfonamide;
N-(2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-ethyl)-N-methyl-acetamide;
N-(2-{6-Chloro-3-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-indol-1-yl}-ethyl)-N-methyl-methanesulfonamide;
2-[6-Chloro-3-(4-thieno[3,2-c]pyridin-4-yl-piperazine-1-carbonyl)-indol-1-yl]-N-methyl-acetamide; and
2-{6-Chloro-3-[4-(3-iodo-pyridin-2-yl)-piperazine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide.
21. The compound of claim 1, having formula (I-d)
Figure US20120040990A1-20120216-C00262
or a pharmaceutically acceptable salt thereof.
22. The compound of claim 21, wherein:
R1 is H;
R2 is one or more halo;
R3 is H; and
wherein R1, R2, and R3 are not simultaneously H;
R6 is aryl substituted by C1-6-alkoxy;
or a pharmaceutically acceptable salt thereof.
23. The compound of claim 21, which is
(6-Chloro-1H-indol-3-yl)-[4-(2-methoxy-phenyl)-4-oxy-piperazin-1-yl]-methanone.
24. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I
Figure US20120040990A1-20120216-C00263
wherein
R1 is H,
C1-6-alkyl substituted by CN, C1-6-alkoxy, OH, halo, or NRiRii,
C2-6-alkyl,
aryl, 5 or 6 membered heteroaryl or sulfonylaryl each of which is optionally substituted by one or more B,
—(CH2)m—Ra wherein Ra is:
CN,
ORi,
NRiRii, or
C3-6-cycloalkyl, 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl each of which is optionally substituted by one or more B,
or —(CH2)n—(CO)—Rb or —(CH2)n—(SO2)—Rb, wherein Rb is:
C1-6 alkyl,
C1-6-alkoxy,
C3-6-cycloalkyl,
—(CH2)m—NRiiiRiv,
NRiRii, or
C3-6-cycloalkyl, 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl each of which is optionally substituted by one or more B,
or R1 and R3 together with the indole ring to which they are attached form a 5 or 6 membered heterocycloalkyl which is optionally substituted by ═O, C(O)O—C1-6-alkyl or C1-6-alkyl;
there is one or more R2, wherein each R2 is the same or different,
R2 is one or more H, OH, halo, CN, nitro, C1-6-alkoxy, —O—CH2—C2-6-alkenyl, benzyloxy, C1-6-haloalkoxy, or C1-6-alkyl optionally substituted by —NRiiRv or halo,
or two R2 together with the indole ring to which they are attached form an oxo or dioxo bridge;
R3 is H,
F,
—(CO)—Rc, wherein Rc is:
C1-6-alkyl,
—(CH2)n—NRiRii,
—(CH2)n—NRiiiRiv, or
5 or 6 membered heterocycloalkyl optionally substituted by C1-6-alkyl,
or C1-6-alkyl which is optionally substituted by
halo,
NRiRii,
NRiiiRiv,
—O(CO)—C1-6-alkyl,
or —NH(CO)Rd, wherein Rd is C1-6-alkyl optionally substituted by halo or nitro, or Rd is aryl or a 5 or 6 membered heteroaryl, each of which is optionally substituted by halo, nitro, C1-6-alkyl or C1-6-haloalkyl;
wherein R1, R2, and R3 are not simultaneously H;
A is selected from the group consisting of (a), (a′), (b), (c) and (d):
Figure US20120040990A1-20120216-C00264
wherein
R4 is —NH(CO)Re, wherein Re is
C1-6-alkoxy or aryl optionally substituted by halo,
C1-6-alkoxy, or
CN,
or aryl, 5 or 6 membered heteroaryl, benzyl, aryloxy or a 9 or 10-membered bicyclic heteroaryl ring, each of which is optionally substituted by CN, halo, C1-6-alkyl, C1-6-alkoxy, C1-6-haloalkyl, nitro, hydroxyl, NRiRii, NRiiiRiv, C1-6-alkoxy-C1-6-alkylene, S(O)2—C1-6-alkyl, or C1-6-haloalkoxy, or by an oxo or dioxo bridge;
R6 is C2-6-alkyl,
—C(O)—Rf wherein Rf is an aryl group substituted by halo, C1-6-alkoxy, or CN,
aryl, 5 or 6 membered heteroaryl, or a 9 or 10-membered bicyclic heteroaryl ring each of which is optionally substituted by halo, C1-6-alkyl, C1-6-alkoxy, C1-6-haloalkyl, CN, nitro, NRiRii, NRiiiRiv, C1-6-alkoxy-C1-6-alkylene, COOH, S(O)2—C1-6-alkyl, hydroxyl, or C1-6-haloalkoxy, or by an oxo or dioxo bridge;
B is halo,
CN,
NRiRii,
C1-6-alkyl optionally substituted by CN, halo or C1-6-alkoxy,
C1-6-haloalkyl,
C1-6 alkoxy,
C1-6-haloalkoxy,
C3-6-cycloalkyl,
—C(O)O—C1-6-alkyl,
—C(O)NRiRii,
—C(O)—C1-6-alkyl,
—S(O)2—C1-6-alkyl,
—S(O)2—NRiRii, or
(CRiiiRiv)n-phenyl, or (CRiiiRiv)n-5 or 6 membered heteroaryl wherein the phenyl or 5 or 6 membered heteroaryl moiety is optionally substituted by one or more substituent(s) selected from the group consisting of:
halo, CN, NRiRii, C1-6-alkyl optionally substituted by CN or C1-6-alkoxy, C1-6-alkoxy, C1-6-haloalkoxy, C3-6-cycloalkyl, —C(O)O—C1-6-alkyl, —C(O)—NRiRii, —C(O)—C1-6, —S(O)2—C1-6-alkyl, and —S(O)2—NRiRii;
Ri and Rii are each independently H, C1-6-alkyl, C1-6-alkyl-NRiiiRiv, —(CO)O—C1-6-alkyl, —C(O)—NRiiiRiv, —S(O)2—C1-6-alkyl or —S(O)2—NRiiiRiv;
Riii and Riv are each independently H or C1-6-alkyl;
m is 1 to 6; and
n is 0 to 4;
or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
US13/282,520 2005-07-29 2011-10-27 Indol-3-y-carbonyl-piperidin and piperazin-derivatives Abandoned US20120040990A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/282,520 US20120040990A1 (en) 2005-07-29 2011-10-27 Indol-3-y-carbonyl-piperidin and piperazin-derivatives

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP05107044 2005-07-29
EP05107044.9 2005-07-29
EP05111072.4 2005-11-22
EP05111072 2005-11-22
US11/492,312 US7781436B2 (en) 2005-07-29 2006-07-25 Indol-3-y-carbonyl-piperidin and piperazin-derivatives
US12/779,099 US20100222357A1 (en) 2005-07-29 2010-05-13 Indol-3-y-carbonyl-piperidin and piperazin-derivatives
US13/282,520 US20120040990A1 (en) 2005-07-29 2011-10-27 Indol-3-y-carbonyl-piperidin and piperazin-derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/779,099 Continuation US20100222357A1 (en) 2005-07-29 2010-05-13 Indol-3-y-carbonyl-piperidin and piperazin-derivatives

Publications (1)

Publication Number Publication Date
US20120040990A1 true US20120040990A1 (en) 2012-02-16

Family

ID=37442112

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/492,312 Expired - Fee Related US7781436B2 (en) 2005-07-29 2006-07-25 Indol-3-y-carbonyl-piperidin and piperazin-derivatives
US12/779,099 Abandoned US20100222357A1 (en) 2005-07-29 2010-05-13 Indol-3-y-carbonyl-piperidin and piperazin-derivatives
US13/282,520 Abandoned US20120040990A1 (en) 2005-07-29 2011-10-27 Indol-3-y-carbonyl-piperidin and piperazin-derivatives

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US11/492,312 Expired - Fee Related US7781436B2 (en) 2005-07-29 2006-07-25 Indol-3-y-carbonyl-piperidin and piperazin-derivatives
US12/779,099 Abandoned US20100222357A1 (en) 2005-07-29 2010-05-13 Indol-3-y-carbonyl-piperidin and piperazin-derivatives

Country Status (15)

Country Link
US (3) US7781436B2 (en)
EP (2) EP1917255A2 (en)
JP (1) JP2009502859A (en)
KR (1) KR101020351B1 (en)
CN (1) CN102295636A (en)
AR (1) AR057086A1 (en)
AU (1) AU2006274884B2 (en)
BR (1) BRPI0614692A2 (en)
CA (1) CA2616937A1 (en)
IL (1) IL188928A0 (en)
MX (1) MX2008001292A (en)
NO (1) NO20080316L (en)
RU (1) RU2422442C2 (en)
TW (1) TWI314147B (en)
WO (1) WO2007014851A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5379000B2 (en) 2006-07-31 2013-12-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Urotensin II receptor antagonist
EP2102186B1 (en) * 2006-12-08 2011-10-05 F. Hoffmann-La Roche AG Indoles
PE20081401A1 (en) 2006-12-28 2008-10-24 Hoffmann La Roche INDOLE DERIVATIVES AS ANTAGONISTS OF VASOPRESSIN RECEPTORS
PA8782701A1 (en) * 2007-06-07 2009-01-23 Janssen Pharmaceutica Nv UROTENSIN II RECEIVER ANTAGONISTS
RU2387642C2 (en) 2007-10-31 2010-04-27 Общество С Ограниченной Ответственностью "Бинатех" 5-substituted indole-3-carboxylic acid derivatives, having antiviral activity, synthesis method thereof and use
WO2009095162A1 (en) * 2008-01-31 2009-08-06 Sanofi-Aventis Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals
ATE546448T1 (en) * 2008-08-02 2012-03-15 Janssen Pharmaceutica Nv UROTENSIN II RECEPTOR ANTAGONISTS
WO2011058766A1 (en) * 2009-11-16 2011-05-19 Raqualia Pharma Inc. Aryl carboxamide derivatives as ttx-s blockers
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
WO2014151936A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles, their preparation and use
ES2705247T3 (en) * 2013-03-14 2019-03-22 Univ Columbia 4-phenylpiperidines, their preparation and use
EP2968303B1 (en) 2013-03-14 2018-07-04 The Trustees of Columbia University in the City of New York Octahydrocyclopentapyrroles, their preparation and use
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
US9981942B2 (en) * 2013-12-20 2018-05-29 Laboratorios Del Dr. Esteve S.A. Piperidine derivatives having multimodal activity against pain
AU2015253232B2 (en) 2014-04-30 2020-10-01 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparation and use
TW201938171A (en) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 Tricyclic compounds as vasopressin V1a receptor antagonists
HU231206B1 (en) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepines
EP4377307A1 (en) * 2021-07-30 2024-06-05 Confo Therapeutics N.V. Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US543169A (en) * 1895-07-23 Self-measuring liquid-tank
US2694700A (en) 1950-01-21 1954-11-16 Peter L Shanta Process of suspension polymerization
GB1305458A (en) * 1969-02-26 1973-01-31
DE2557342A1 (en) 1975-12-19 1977-06-30 Hoechst Ag BASIC SUBSTITUTED INDOLDER DERIVATIVES AND THE PROCESS FOR THEIR PRODUCTION
US4443242A (en) 1981-01-21 1984-04-17 Reckitt & Colman Products Limited Foliar feed
US4544657A (en) 1983-05-19 1985-10-01 Hoffmann-La Roche Inc. Substituted isoquinolines
GB8827189D0 (en) * 1988-11-21 1988-12-29 Fujisawa Pharmaceutical Co 2(1h)-quinolinone compounds processes for preparation thereof & pharmaceutical composition comprising same
JPH03161470A (en) 1989-11-17 1991-07-11 Nisshin Flour Milling Co Ltd Indole derivative
US5149817A (en) 1990-03-05 1992-09-22 Shionogi & Co., Ltd. Teirahydropyridine derivatives
ES2027898A6 (en) * 1991-01-24 1992-06-16 Espanola Prod Quimicos 2-Methoxyphenylpiperazine derivatives.
FR2696177B1 (en) * 1992-09-28 1995-05-12 Synthelabo Piperidine derivatives, their preparation and their therapeutic application.
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5567711A (en) * 1995-04-19 1996-10-22 Abbott Laboratories Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists
IL123293A (en) 1995-09-07 2003-06-24 Hoffmann La Roche Piperidine derivatives, their preparation and pharmaceutical compositions containing them
GB9609374D0 (en) 1996-05-03 1996-07-10 Merck Sharp & Dohme Therapeutic agents
US6355642B1 (en) 1996-06-28 2002-03-12 Meiji Seika Kaisha, Ltd. Tetrahydrobenzindole compounds
WO1998006715A1 (en) * 1996-08-09 1998-02-19 Smithkline Beecham Corporation Novel piperazine containing compounds
ES2125206B1 (en) * 1997-07-21 1999-11-16 Esteve Labor Dr DERIVATIVES OF ACIL-PIPERAZINIL-PIRIMIDINAS, ITS PREPARATION AND ITS APPLICATION AS MEDICINES.
JP2002515891A (en) * 1997-12-19 2002-05-28 スミスクライン・ビーチャム・コーポレイション New piperidine-containing compounds
KR100327100B1 (en) 1998-04-29 2002-03-06 최현식 Dihydroxyphenyl derivatives for hepatoprotection and treatment of liver diseases
US6326381B1 (en) 1998-12-17 2001-12-04 American Home Products Corporation Arylpiperidine and aryl-1,2,5,6-tetrahydropyidine amide derivates
GB2355454A (en) * 1999-10-20 2001-04-25 Ferring Bv Antidiuretic agents
EP1243268A4 (en) 1999-12-14 2003-05-21 Nippon Shinyaku Co Ltd Medicinal composition
JP2001278872A (en) 2000-03-27 2001-10-10 Banyu Pharmaceut Co Ltd New aminothiazole derivatives
DE60200061T2 (en) 2001-01-18 2004-07-08 Alps Electric Co., Ltd. rotary connector
AU2002256995A1 (en) 2001-02-07 2002-08-28 Ortho-Mcneil Pharmaceutical, Inc. Pyridoarylphenyl oxazolidinone antibacterials, and related compositions and methods
WO2002070662A2 (en) * 2001-03-02 2002-09-12 Gpc Biotech Ag Three hybrid assay system
US6825201B2 (en) 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
US7115741B2 (en) * 2001-09-06 2006-10-03 Levy Daniel E 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds
US6861440B2 (en) 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
JPWO2003037862A1 (en) 2001-10-30 2005-02-17 日本新薬株式会社 Amide derivatives and pharmaceuticals
KR100960827B1 (en) 2001-12-20 2010-06-08 오에스아이 파마슈티컬스, 인코포레이티드 Pyrrolopyrimidine A₂ｂ Selective Antagonist, Synthesis Method and Use thereof
BR0311425A (en) * 2002-05-31 2005-03-15 Takeda Pharmaceutical Compound, prodrug, method for preparing the compound, optically active alcohol, and ically active amine, and for preventing and / or treating abnormalities or diseases, medicament, and use of the compound or a prodrug thereof
TW200402417A (en) * 2002-06-21 2004-02-16 Akzo Nobel Nv 1-[(Indol-3-yl)carbonyl]piperazine derivatives
PT1581492E (en) 2002-11-28 2008-09-19 Suven Life Sciences Ltd N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
EP1615698B1 (en) 2003-04-11 2010-09-29 High Point Pharmaceuticals, LLC New amide derivatives and pharmaceutical use thereof
US7745630B2 (en) * 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
EP1701959A1 (en) * 2003-12-22 2006-09-20 Pfizer Limited Triazole derivatives as vasopressin antagonists
GB0400700D0 (en) * 2004-01-13 2004-02-18 Pfizer Ltd Compounds useful in therapy
ES2564804T3 (en) 2004-02-12 2016-03-29 Mitsubishi Tanabe Pharma Corporation Indazole compound and pharmaceutical use thereof
AR048528A1 (en) 2004-04-07 2006-05-03 Millennium Pharm Inc COMPOUNDS DERIVED FROM QUINOLINA AS AN ANTAGONIST OF THE PGD2 RECEPTOR FOR THE TREATMENT OF INFLAMMATORY DISEASES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US20070254877A1 (en) 2004-06-02 2007-11-01 Takada Pharmaceutical Company Limited Indole Derivative and Use for Treatment of Cancer
MX2008000886A (en) * 2005-07-21 2008-03-18 Hoffmann La Roche Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives as v1a receptor antagonists.

Also Published As

Publication number Publication date
KR20080027897A (en) 2008-03-28
RU2008101962A (en) 2009-09-10
EP2392571A3 (en) 2012-03-14
EP2392571A2 (en) 2011-12-07
MX2008001292A (en) 2008-03-25
US20100222357A1 (en) 2010-09-02
CN102295636A (en) 2011-12-28
TW200740790A (en) 2007-11-01
WO2007014851A2 (en) 2007-02-08
EP1917255A2 (en) 2008-05-07
AR057086A1 (en) 2007-11-14
US7781436B2 (en) 2010-08-24
IL188928A0 (en) 2008-08-07
RU2422442C2 (en) 2011-06-27
US20070027163A1 (en) 2007-02-01
WO2007014851A3 (en) 2007-05-31
BRPI0614692A2 (en) 2009-05-19
AU2006274884A1 (en) 2007-02-08
NO20080316L (en) 2008-02-13
TWI314147B (en) 2009-09-01
CA2616937A1 (en) 2007-02-08
KR101020351B1 (en) 2011-03-08
JP2009502859A (en) 2009-01-29
AU2006274884B2 (en) 2012-04-05

Similar Documents

Publication Publication Date Title
US20120040990A1 (en) Indol-3-y-carbonyl-piperidin and piperazin-derivatives
US7629353B2 (en) Indol-3-yl-carbonyl-spiro-piperidine derivatives as V1a receptor antagonists
US7351706B2 (en) Indol-3-yl-carbonyl-spiro-piperidine derivatives
US8076360B2 (en) Indoles
US7799923B2 (en) Indoles
US8202993B2 (en) Spiro-piperidine derivatives
US8143281B2 (en) Indoles
CN101277945A (en) Indol-3-yl-carbonyl-piperidine and piperazine derivatives

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION